

# Leveraging dual-ligase recruitment to enhance degradation via a heterotrivalent PROTAC

**Authors:** Adam G. Bond,<sup>‡,1</sup> Miquel Muñoz i Ordoño,<sup>‡,2</sup> Celia M. Bisbach,<sup>‡,3</sup> Conner Craigon,<sup>1</sup> Nikolai Makukhin,<sup>1</sup> Elizabeth A. Caine,<sup>3</sup> Manjula Nagala,<sup>1</sup> Marjeta Urh,<sup>3</sup> Georg E. Winter,<sup>\*,2</sup> Kristin M. Riching,<sup>\*,3</sup> Alessio Ciulli<sup>\*,1</sup>

## Authors affiliations:

<sup>1</sup> Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, 1 James Lindsay Place, DD1 5JJ, Dundee, United Kingdom

<sup>2</sup> CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria

<sup>3</sup> Promega Corporation, 2800 Woods Hollow Road, Madison, WI U.S.A 53711.

<sup>‡</sup> These authors contributed equally as co-first author

\*Co-corresponding authors

## Abstract:

Proteolysis targeting chimera (PROTAC) degraders are typically bifunctional with one moiety of an E3 ligase ligand connected to one target protein ligand via a linker. While augmented valency has been shown with trivalent PROTACs targeting two binding sites within a given target protein, or used to recruit two different targets, the possibility of recruiting two different E3 ligases within the same compound has not been demonstrated. Here we present dual-ligase recruitment as a strategy to enhance targeted protein degradation. We designed heterotrivalent PROTACs composed of a CRBN, VHL and BET targeting ligand, separately tethered via a branched trifunctional linker. Structure-activity relationships of 12 analogues qualifies AB3067 as the most potent and fastest degrader of BET proteins, with minimal E3 ligase cross-degradation. Comparative kinetic analyses in wild-type and ligase single and double knockout cell lines revealed that protein ubiquitination and degradation induced by AB3067 was contributed by both CRBN and VHL in an additive fashion. We further expand the scope of the dual-ligase approach by developing a hetero-trivalent CRBN/VHL-based BromoTag degrader and a tetravalent PROTAC comprising of two BET ligand moieties. In summary, we provide proof-of-concept for dual-E3 ligase recruitment as a strategy to boost degradation fitness by recruiting two E3 ligases with a single degrader molecule. This approach could potentially delay the outset of resistance mechanisms involving loss of E3 ligase functionality.

## 1.0. Introduction

Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that bridge a target protein to a ubiquitin E3 ligase to allow for poly-ubiquitination and proteasomal degradation of the target.<sup>1-4</sup> This modality of pharmacology features catalytic sub-stoichiometric mode of action, which brings benefits including lower doses and more durable effects compared to occupancy-based inhibitors that must occupy a functional site on the target protein to block its function.<sup>5</sup> PROTACs typically consist of a ligand for a target protein, connected by a chemical linker, to another ligand for an E3 ligase. This enables simultaneous recruitment and formation of a 1:1:1 ternary complex of a single molecule of target protein, the PROTAC and a single molecule of E3 ligase component. Most often, the recruited E3 ligases are either cereblon (CRBN) or von Hippel-Lindau (VHL).<sup>6</sup> Despite the advantages and remarkable successes achieved, it can be challenging to design PROTACs efficiently, often requiring extensive chemical optimization for the degradation of the target protein.<sup>7-9</sup>


We and others became intrigued by the possibility that augmenting the valency of PROTACs might offer advantages by leveraging the principles and benefits of multi-targeting poly-pharmacology and/or avidity.<sup>10</sup> In a first foray of such approach, our group developed the concept of trivalent PROTACs and exemplified this with molecules embodying two ligands that can simultaneously bind to two sites/domains of the same target protein (rather than two different targets). Trivalent PROTAC SIM1 connected a single VHL ligand to two instances of a Bromo- and Extra-Terminal (BET) domain protein ligand, joined via a trifunctional linker.<sup>11</sup> SIM1 effectively and durably degrades BET proteins with picomolar degradation potency, without any detectable hook effect up to micromolar concentrations, due to the combined avidity of a simultaneous *cis*-engagement of both BET bromodomains, and the cooperativity of the VHL-BET bromodomain system.<sup>11</sup> Subsequently, others have developed multifunctional PROTACs capable of degrading, more than one target at the same time, through conjugation of ligands for two different target proteins to a single E3 ligase ligand.<sup>12</sup>

Based on the success of SIM1, we wanted to understand whether recruiting two different E3 ligases (e.g. CRBN and VHL) simultaneously to the same target protein would have a synergistic effect on target protein degradation. We reasoned that such an approach could maximize the probability and efficacy of target protein degradation attained by a single PROTAC molecule, and minimize dependency on a single E3 ligase, a known Achilles' heel of PROTAC's mode of action, leading to mechanisms of cellular resistance to targeted protein degradation.<sup>13-15</sup> We therefore envisaged trifunctional or multifunctional molecules composed of one ligand for VHL, one ligand for CRBN, and one or more instances of target protein binding ligands. Such "hetero-multivalent" PROTACs would combine the ubiquitination activity from each E3 ligase, circumventing potential limitations of using two heterobivalent PROTAC molecules which would instead compete for binding to the same target protein. Here we provide proof-of-concept of this strategy with hetero-multivalent molecules designed to simultaneously recruit VHL and CRBN to BET bromodomains.

## 2.0. Results and Discussion

### 2.1. Heterotrivalent PROTAC design rationale

When envisaging the heterotrivalent PROTACs, we kept several design criteria in mind. The linkage between the VHL ligand VH032 and the BET ligand JQ1 should allow for VHL-driven BET degradation; and similarly, the linkage between CRBN-binding thalidomide and JQ1 should allow for CRBN-driven BET degradation. In contrast, we intended for the linkage between VH032, and thalidomide minimize any cross-degradation between VHL and CRBN. To link VH032 with JQ1, we used the linker lengths of active VHL recruiting trivalent, SIM1,<sup>11</sup> and bivalent, MZ1<sup>16</sup> and MZ2<sup>16</sup> (which differ by one PEG unit in the linker) BET degraders as scaffolds, all of which have 15, 11 and 14 C/O atoms, respectively, between the terminal amide NH of VH032 and JQ1 (Figure 1A). To enable CRBN mediated degradation of BET proteins, we chose to use the scaffold of dBET54,<sup>17</sup> an active CRBN recruiting BET degrader comprising of a 20 C/O atom long linker between the ether O tether to thalidomide and the amide NH of JQ1. Lastly, to avoid E3 ligase cross-degradation, we opted to use the linker lengths of inactive/poor CRBN-VHL heterobifunctional-E3 ligase degraders, “Compounds 7a & 7b”,<sup>18</sup> ZXH-4-135,<sup>19</sup> CRBN-2-2-2-2-VHL,<sup>20</sup> and CRBN-2-2-2-5-VHL,<sup>20</sup> (14, 20, 15, 11 and 14 C/O/N atoms, respectively, between VH032 amide NH, and the aniline NH tether to thalidomide) (Figure 1A).




**Figure 1. Heterotrivalent PROTAC design rationale.** (A) Active VHL-driven BET trivalent PROTAC, **SIM1** (top), and bivalent PROTACs, **MZ1** and **MZ2** (middle right). Active CRBN-driven BET PROTAC, **dBET54** (bottom). Inactive CRBN-VHL Heterobifunctional-E3 Ligase PROTACs, “**Compounds 7a & 7b**”, **ZXH-4-135**, **CRBN-2-2-2-2-VHL** and **CRBN-2-2-2-5-VHL** (middle left). VHL ligand, VH032 (orange), BET ligand, JQ1 (blue), and CRBN ligand, thalidomide (green) are highlighted. Black arrows indicate potential vectors for linker tethering. (B) Overlaid chemical structures of **CRBN-2-2-2-2-VHL/CRBN-2-2-2-5-VHL** and **MZ1/MZ2** to show target hetero-trivalent scaffold. Bonds shared by each compound are highlighted in bold.

When overlaying the structures of CRBN-2-2-2-2-VHL or CRBN-2-2-2-5-VHL with either MZ1 or MZ2, we envisaged an optimal linker composition and length between thalidomide and JQ1 (15 – 21 C/O atoms) that would ensure both VHL and CRBN-driven degradation of BET proteins, while helping to avoid the degradation of either ligase (Figure 1B).

## 2.2. Initial heterotrivalent PROTACs


For “proof-of-concept”, we set out to synthesise initially two heterotrivalent compounds, MN666 (**1**) and MN675 (**2**) (Figure 2). The structure of **1** shares a scaffold much like that of SIM1, differing only by a JQ1 ligand being substituted by thalidomide via an aniline tether. **2** is a smaller analogue of **1**, with a PEG unit removed from both VH032-JQ1 and VH032-thalidomide sides to the linker.



**Figure 2. Chemical structures of first generation heterotrivalent PROTACs.** Chemical structures of MN666 (**1**) and MN675 (**2**).

Using a similar route described by Imaide et al. for the synthesis of SIM1,<sup>11</sup> alcohol **3** was first alkylated with allyl bromide in a solution of potassium hydroxide and tetrabutylammonium bromide (TBAB) in toluene and water to give allyl ether **4** (Scheme 1). The acetonide of **3** was hydrolysed with trifluoroacetic acid (TFA) in methanol and water to yield diol **5**. Next, diol **5** was di-deprotonated using 4 equivalents (4 eq.) of sodium hydride at 0°C in dimethylformamide (DMF), before the addition of azido mesylates **6** and **7** and heating to 60°C to yield dialkylated allyl ethers **8** and **9**, respectively. Next, alkenes **8** and **9** were oxidatively cleaved with sodium periodate, 2,6-lutidine and a catalytic amount of osmium tetroxide in dioxane and water to yield aldehydes **10** and **11**. Then, aldehydes **10** and **11** underwent a Pinnick oxidation by treating them with 2-methyl-2-butene, monobasic sodium phosphate and sodium chlorite in *tert*-butanol and water to yield carboxylic acids **12** and **13** (Scheme 1).

**Scheme 1. Synthesis of initial heterotrivalent PROTACs MN666 (1) and MN675 (2) <sup>a</sup>**




<sup>a</sup> Reaction conditions: (a) allyl bromide, KOH, TBAB, toluene, H<sub>2</sub>O, r.t., 16 h; (b) TFA, MeOH, H<sub>2</sub>O, r.t., 3 h; (c) i) NaH, DMF, 0°C, 30 min, ii) **6** or **7**, DMF, 60°C, 16 h; (d) OsO<sub>4</sub>, NaIO<sub>4</sub>, 2,6-lutidine, dioxane, H<sub>2</sub>O, r.t., 16 h; (e) 2-methyl-2-butene, NaH<sub>2</sub>PO<sub>4</sub>, NaClO<sub>2</sub>, *t*-BuOH, H<sub>2</sub>O, r.t., 16 h; (f) VH032-amine (**14**), HATU, DIPEA, DMF, r.t., 2 h; (g) PPh<sub>3</sub>, EtOAc, 1.0 M HCl (aq); (h) **19**, DIPEA, NMP, 100-120°C, 4 h; (i) i) H<sub>2</sub>, 10% Pd/C, MeOH, r.t., 16 h, ii) (+)-JQ1-acid (**22**), HATU, DIPEA, DMF, r.t., 2 h.

With the trifunctional linkers in hand, the next step was to couple acids **12** and **13** with the terminal amine of VHL ligand, VH032 (**14**, synthesised through literature procedures<sup>21,22</sup>) via standard amide coupling conditions with 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU) and diisopropylethylamine (DIPEA) in DMF to yield amides **15** and **16**. A Staudinger reduction was then employed to reduce a single azide of diazides **15** and **16** by slow addition with 1 eq. of triphenylphosphine in ethyl acetate and 1.0 M aqueous hydrochloric acid to yield mono-amines **17** and **18**. Next, amines **17** and **18** underwent nucleophilic aromatic substitution (S<sub>N</sub>Ar) with CRBN ligand, 4-fluorothalidomide (**19**), by heating with DIPEA in *N*-methyl-2-pyrrolidone (NMP) between 100-120°C to yield 4-substituted anilines **20** and **21**. Finally, the azides of **20** and **21** were reduced with a suspension of 10% palladium on carbon (Pd/C) in methanol, under an atmosphere of hydrogen gas. The intermediate amines were



immediately coupled to the acid of BET ligand, JQ1 (**22**) using HATU and DIPEA in DMF to yield the amides of heterotrivalent PROTACs MN666 (**1**) and MN675 (**2**) (Scheme 1).

With our initial heterotrivalent PROTACs **1** and **2** in hand, we moved to evaluate the BET degradation profiles in cells. To this end, we performed live cell kinetic degradation assays in previously established CRISPR-edited HEK293 cell lines in which the 11-amino acid peptide, HiBiT, is appended to the N-terminus of endogenous BRD2, BRD3, and BRD4, and which stably express the 18 kDa LgBiT protein to produce NanoBiT luminescence.<sup>23</sup> We treated HiBiT-tagged BRD2, BRD3 and BRD4 HEK293 cells with varying concentrations of **1** and **2** (Figure 3A). Both **1** and **2** induced degradation of BRD2, BRD3 and BRD4, with  $D_{\max 50}$ s of 84 and 156 nM, respectively for BRD2; 23 and 21 nM, respectively for BRD3; and 37 and 55 nM respectively for BRD4.



**Figure 3. Cellular evaluation of MN666 (**1**) and MN675 (**2**).** (A), (B) Degradation potency of **1** and **2** from live cell kinetic profiles in HiBiT-BRD CRISPR knock-in HEK293 cells plotted as fractional degradation at  $D_{\max}$  versus concentration of **1** (left) and **2** (right). Cells were treated with DMSO and a threefold serial dilution of **1** or **2** over a concentration range of 4 nM – 3  $\mu\text{M}$  without (A) or with (B) 20  $\mu\text{M}$  of either CRBN inhibitor pomalidomide, or VHL inhibitor VH298.  $D_{\max 50}$  is tabulated. Mean  $\pm$  S.D.;  $n = 3$  biological replicates (A) or  $n = 1$  biological replicates (B). (C) Cell viability assay in BET sensitive wild-type and CRBN/VHL knock-out RKO cell lines. Cell antiproliferation of MZ1 and dBET6 (top) compared to **1** and **2** (bottom) after 316 pM to 10  $\mu\text{M}$  treatment in WT, CRBN KO, VHL KO or CRBN/VHL dKO RKO cell lines. Mean  $\pm$  S.D.;  $n = 6$  biological replicates.  $EC_{50}$  values are tabulated below and in Supplementary Table 1 with 95% CI.

To assess whether each E3 ligase ligand of **1** and **2** was able to drive degradation, we ran a similar experiment by treating HiBiT-BRD4 HEK293 cells with **1** or **2**, with or without pre-treatment of either CRBN ligand pomalidomide,<sup>24</sup> or VHL inhibitor VH298 (Figure 3B).<sup>25</sup> When VHL binding is blocked by VH298, the degradation profiles of **1** and **2** are not drastically affected by the inability to recruit VHL when comparing

to the vehicle control, with  $D_{\max 50S}$  of 34 and 58 nM, vs 32 and 38 nM, respectively (Figure 3B). In contrast, when CRBN recruitment was outcompeted by pomalidomide binding, the degradation potency dropped by 5.3-fold in the case of **1** ( $D_{\max 50S}$  of 32 vs 166 nM), and by 3.6-fold in the case of **2** ( $D_{\max 50S}$  of 38 vs 138 nM). This data suggests that although both **1** and **2** can degrade BRD4 in the absence of either VHL or CRBN, there is a strong preference for CRBN mediated degradation over VHL. We further assessed the contributions of each ligase warhead of **1** and **2** by monitoring the compound's antiproliferative effect in the BET sensitive, poorly differentiated colon carcinoma cell line, RKO, for which we had generated both CRBN and VHL single knockouts (KO), and CRBN/VHL double knockouts (dKO) (Figure 3C & Supplementary Table 1).

For reference and benchmarking, we treated each RKO cell line with heterobivalent BET degraders MZ1<sup>16</sup> (VHL-dependent) and dBET6<sup>26</sup> (CRBN-dependent). When both VHL and CRBN are knocked out in the same cell line, neither MZ1 nor dBET6 can recruit an E3 ligase ( $EC_{50S} > 10 \mu M$ ), giving rise to >4-fold cell antiproliferation when compared to the wildtype cell line. Interestingly, even with both CRBN and VHL being absent, **1** and **2** have a similar antiproliferation profile to wild-type and CRBN or VHL KO RKO cells. This suggested that **1** and **2** lacked the desired window for BET degradation over and above BET inhibition (Figure 3C & Supplementary Table 1).

Taken together, the data shows that while **1** and **2** can induce degradation of BET proteins by engaging either ligase, the induced degradation activity was not comparably driven by each E3 ligase, and that there remained a strong non-degrading component to the compound's cellular antiproliferative activity. We therefore sought to develop a larger and more diverse set of heterotrivalent PROTACs to expand the chemical space, and to improve on the characteristics presented by **1** and **2**.


### 2.3. Second generation heterotrivalent PROTACs



A first strategy to help improve our initial compounds, **1** and **2**, was to switch from an amide linkage for JQ1 conjugation chemistry to an ester, a modification which we have previously shown to be beneficial when optimising JQ1-based BET degraders.<sup>27, 28</sup> Next, we chose to introduce diversity in the VHL binding ligand by adding a methyl group to the benzylic position of VH032, a modification that is known to enhance the binary binding affinity to VHL.<sup>27-29</sup> To gain a better understanding of the effects on linker length between each ligand, we decided to synthesise analogues which varied in the number of PEG units separating either JQ1 or thalidomide to the central quaternary carbon centre of the linker (Table 1). Finally, we wanted to vary the linker attachment vector and functionality to thalidomide. Additionally to the anilines tethered at the 4-C of the phthalimide, we sought to use another linkage vector at the 5-C, a tethering site which has been used successfully in other CRBN-recruiting PROTACs.<sup>30-33</sup> Alongside the linkage vector at the 5-C, we wanted to introduce a fluorine atom ortho to the aniline. A fluorine at the 5/6-position of the phthalimide of thalidomide has been shown to increase both binding affinity to CRBN and to help reduce off-target degradation of neo-substrates, Aiolos (IKZF3) and CK1 $\alpha$ .<sup>34</sup> Finally, we chose to make two compounds which would be attached to thalidomide via a piperazine at either the 4-C or 5-C of the phthalimide ring. This basic functionality is



commonly used to aid in solubility and has also been widely used in CRBN-recruiting degraders (Table 1).<sup>32</sup>  
33, 35-37


**Table 1. Second generation heterotrivalent PROTAC library (23 – 32).**



Compound	R <sup>1</sup>	R <sup>2</sup> Vector	R <sup>2</sup>	R <sup>3</sup>	n	m
AB3062 ( <b>23</b> )	H	4-C	-NH-	H	3	3
AB3066 ( <b>24</b> )	Me	4-C	-NH-	H	3	3
AB3064 ( <b>25</b> )	H	4-C	-NH-	H	3	2
AB3063 ( <b>26</b> )	H	5-C	-NH-	F	3	3
AB3067 ( <b>27</b> )	Me	5-C	-NH-	F	3	3
AB3065 ( <b>28</b> )	H	5-C	-NH-	F	3	2
AB3126 ( <b>29</b> )	H	5-C	-NH-	F	2	3
AB3125 ( <b>30</b> )	H	5-C	-NH-	F	2	2
AB3029 ( <b>31</b> )	H	4-C		H	3	3
AB3030 ( <b>32</b> )	H	5-C		F	3	3

To synthesise linkers which would enable orthogonal trifunctionality, we adapted the approach seen in Scheme 1 and previously reported to make the linker for SIM1.<sup>11</sup> The linker design consisted of the following functionalities: a carboxylic acid, to allow for facile amide coupling to VHL ligands; an amine masked as an azide, to enable future S<sub>N</sub>Ar attachment to thalidomide; an alcohol protected by an acid labile acetal, to allow for esterification to JQ1, and also to allow for mesylation and subsequent nucleophilic substitution of piperazine substituted derivatives of thalidomide (Scheme 2).

**Scheme 2. Synthesis of trifunctional linkers 53 – 57<sup>a</sup>**



<sup>a</sup> Reaction conditions: (a) MEMCl or MOMBr, DIPEA, DCM, r.t., 16 h; (b) MsCl, DIPEA, DCM, r.t., 3 h; (c) i) NaH, DMF, 0°C, 30 min, ii) **6** or **7**, DMF, 60°C, 16 h; (d) i) NaH, DMF, 0°C, 30 min, ii) **39** or **40**, DMF, 60°C, 16 h; (e) i) NaH, DMF, 0°C, 30 min, ii) **38**, DMF, 60°C, 16 h; (f) OsO<sub>4</sub>, NaIO<sub>4</sub>, 2,6-lutidine, dioxane, H<sub>2</sub>O, r.t., 16 h; (h) 2-methyl-2-butene, NaH<sub>2</sub>PO<sub>4</sub>, NaClO<sub>2</sub>, *t*-BuOH, H<sub>2</sub>O, r.t., 16 h. <sup>b</sup> Products **43** – **47** formed through step (f) then (g). <sup>c</sup> Product **47** formed directly from step (e).


To make linkers which would ultimately result in a primary alcohol required for later esterification to JQ1, acetal protecting groups, methoxyethoxymethyl (MEM) and methoxymethyl (MOM), were selected to mask the alcohol functionality. Firstly, triethylene (**33**) and diethylene (**34**) glycols were treated with either methoxyethoxymethyl chloride (MEMCl) or methoxymethyl bromide (MOMBr) in DIPEA and dichloromethane (DCM) to afford mono-MEM protected alcohols **35** and **36**, and mono-MOM protected alcohol **37**, respectively. Then, alcohols **35** – **37** were treated with methanesulfonyl chloride (MsCl) with DIPEA in DCM to yield mesylates **38** – **40** (Scheme 2).

To build the trifunctional scaffold, diol **5** was carefully deprotonated using 1.2 eq. of sodium hydride at 0°C in DMF, before addition of azido mesylates **6** and **7** with heating at 60°C to yield mono-alkylated products **41** and **42**, respectively. This alkylation step was repeated by deprotonation of the alcohols of **41** and **42**, using 1.5 eq. of sodium hydride at 0°C, before heating to 60°C with acetal-protected mesylates **40** and **39** to afford dialkylated allyl ethers **43** – **46**. Diol **5** was also subjected to di-deprotonation with 4 eq. of sodium hydride at 0°C before quenching with 4 eq. MEM-protected mesylate **38** and heating to 60°C to yield dialkylated allyl ether **47**. Next, the alkenes of **43** – **47** were oxidatively cleaved with sodium periodate, 2,6-lutidine and a catalytic amount of osmium tetroxide in dioxane and water to yield aldehydes **48** – **52**. Finally,

aldehydes **48** – **52** underwent a Pinnick oxidation by treating them with 2-methyl-2-butene, monobasic sodium phosphate and sodium chlorite in *tert*-butanol and water to yield carboxylic acids **53** – **57** (Scheme 2).

The final part of the synthesis involved attachment of the trifunctional linker to the respective VHL, CRBN and BET ligands (Scheme 3).

**Scheme 3. Synthesis of aniline tethered heterotrivalent PROTACs **23** – **30**<sup>a</sup>**




<sup>a</sup> Reaction conditions: (a) HATU, DIPEA, DMF, r.t., 2 h; (b) i) **59** – **64**, H<sub>2</sub>, 10% Pd/C, MeOH, r.t., 16 h, ii) **19** or **65**, DIPEA, DMSO, 90°C, 16 h; (c) SOCl<sub>2</sub>, DCM, r.t., 3 h; (d) i) 4N HCl in dioxane, MeOH, r.t., 3 h, ii) **22**\*, DIPEA, DCM, r.t., 16 h. <sup>b</sup> Product used further in Scheme 4.

Carboxylic acid **53** was coupled to both VH032-amine (**14**) and Me-VH032-amine (**58**, synthesised through literature procedures<sup>38</sup>) using HATU and DIPEA in DMF to yield amides **59** and **60**, respectively. The remaining acids **54** – **57** were coupled to VH032-amine (**14**) only using the same conditions to yield amides **61** – **64**. Next, the azides of **59** – **63** were reduced with a suspension of 10% Pd/C in methanol, under an atmosphere of hydrogen gas. The intermediate amines subsequently underwent an S<sub>N</sub>Ar reaction with 4-

fluoro **19** and 5,6-difluoro **65** derivatives of thalidomide, by heating with DIPEA in DMSO at 90°C to yield 4-substituted anilines **66** – **68** and 5-substituted-6-fluoro anilines **69** – **73**. Finally, MOM/MEM protecting groups of **66** – **73** were hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The subsequent primary alcohols were immediately conjugated to an intermediate acid chloride (**22\***), formed after treating (+)-JQ1-acid (**22**) with thionyl chloride in DCM, to afford the esters of aniline tethered heterotrivalent PROTACs **23** – **30** (Scheme 3).

To synthesise heterotrivalent PROTACs whose linkers are tethered via a piperazine to the CRBN ligand, thalidomide, we required two masked alcohols in the linker to allow for esterification to JQ1, and also for mesylation and subsequent amination with piperazine substituted thalidomide derivatives (Scheme 4).

#### Scheme 4. Synthesis of piperazinyl tethered heterotrivalent PROTACs **31** & **32**<sup>a</sup>




<sup>a</sup> Reaction conditions: (a) i) 4N HCl in dioxane, MeOH, r.t., 1 h, ii) **22\***, DIPEA, DCM, r.t., 16 h; (b) i) MsCl, DIPEA, DCM, 0°C, 20 min, ii) r.t., 1 h; (c) 1-Boc-piperazine, DIPEA, DMSO, 90°C, 16 h; (d) i) **76** or **77**, 4 N HCl in dioxane, DCM, r.t., 16 h, ii) **75**, DIPEA, DMF, 80°C, 16 h.

Firstly, both MEM groups of compound **64** (synthesised in Scheme 3), were hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The intermediate diol was reacted with sub-stoichiometric amounts (0.8 eq.) of the acid chloride **22\*** (synthesised in Scheme 3) to afford mono-ester **74**. The remaining primary alcohol of **74** was mesylated by careful addition of MsCl in DCM at 0°C to yield mesylate **75**. Careful addition is required due to the observed formation of a di-mesylated product, where another mesyl group is attached to the secondary alcohol present on the hydroxyproline of the VH032 ligand, a group usually inert in

other reactions. Next step was to functionalise thalidomide derivatives **19** and **65** by heating them at 90°C with 1-Boc-piperazine and DIPEA in DMSO to give Boc-protected 4-piperazinyl (**76**) and 5-piperazinyl-6-fluoro (**77**) substituted thalidomide. The Boc groups of **76** and **77** were then hydrolysed using 4 N hydrochloric acid in dioxane and DCM. The intermediate hydrogen chloride salts were then alkylated by heating to 80°C with mesylate **75** and DIPEA in DMSO to yield the tertiary amine present in piperazine tethered heterotrivalent PROTACs **31** and **32**.

#### 2.4. Cellular evaluation of second generation heterotrivalent PROTACs **23** – **32**

With the library of new heterotrivalent PROTACs in hand, we proceeded to evaluate the BET degradation profiles in cells after treatment of compounds **23** – **32**. We treated HEK293 cells with compounds **23** – **32** to monitor levels of on-target BET degradation, and off-target CRBN and VHL degradation (Figure 4A, Table 2).



**Figure 4. Western blot evaluation of heterotrivalent PROTACs 23 – 32 in HEK293 cells.** (A) Western blot data for BET, CRBN and VHL protein levels monitored from 1  $\mu\text{M}$  to 100 pM compound treatments over 6 h in HEK293 cells. Blots arranged with fluorinated compounds 23 – 25 and 31 on top, and nonfluorinated compounds 26 – 30 and 32 on bottom. Bands are normalised to tubulin and vehicle control (DMSO) to derive  $\text{DC}_{50}$  values that enable rank ordering of each PROTAC. (B) Degradation potency and (C) rate constants extracted from kinetic degradation profiles of HEK293 HiBiT-BRD2, HiBiT-BRD3, or HiBiT-BRD4 cells treated with 3  $\mu\text{M}$  - 4 nM compound. Compounds with Fluorine represented by open symbols, compounds with no Fluorine represented by closed symbols. Mean  $\pm$  S.D.;  $n = 2$  biological replicates (six technical replicates) (BRD4) or  $n = 1$  biological replicate (three technical replicates) (BRD2 and BRD3).  $\text{D}_{\text{max } 50}$  and  $\lambda_{\text{max}}$  values are tabulated in Supplementary Table 2 & Supplementary Table 3, respectively, with 95% CI.



**Table 2. Quantification of western-blot degradation profile with heterotrivalent PROTACs 23 – 32 against BET proteins and CRBN in HEK293 cells.**

Compound	DC <sub>50</sub> , nM <sup>a</sup>				
	BRD4 <sup>Long</sup>	BRD4 <sup>Short</sup>	BRD3	BRD2	CRBN
AB3062 (23)	2.5 ± 0.5	11 ± 3.7	11 ± 4.6	58 ± 16	200 ± 110
AB3066 (24)	6.8 ± 1.3	5.9 ± 2.3	8.9 ± 1.5	43 ± 1.1	81 ± 11
AB3064 (25)	12 ± 2.4	18 ± 3.3	28 ± 0.8	75 ± 20	480 ± 370
AB3029 (31)	14 ± 3.9	15 ± 2.4	14 ± 2.9	52 ± 9.4	580 ± 240
AB3063 (26)	0.76 ± 0.1	3.2 ± 0.9	4.8 ± 2.4	14 ± 4.6	200 ± 31
AB3067 (27)	2.3 ± 0.4	2.1 ± 0.3	1.6 ± 0.3	15 ± 2.1	75 ± 14
AB3065 (28)	10 ± 4.4	12 ± 5.8	14 ± 7.5	21 ± 5.4	310 ± 200
AB3126 (29)	5.0 ± 5.3 <sup>b</sup>	5.3 ± 5.5 <sup>b</sup>	6.6 ± 0.3 <sup>b</sup>	33 ± 34 <sup>b</sup>	150 ± 190 <sup>b</sup>
AB3125 (30)	4.0 ± 2.1 <sup>b</sup>	4.4 ± 2.4 <sup>b</sup>	6.4 ± 0.8 <sup>b</sup>	19 ± 7.2 <sup>b</sup>	900 ± 720 <sup>b</sup>
AB3030 (32)	7.3 ± 2.1	9.4 ± 1.9	6.4 ± 1.9	28 ± 7.3 <sup>b</sup>	730 ± 270

<sup>a</sup> Calculated as mean (± S.E.M) from three independent biological experiments. <sup>b</sup> Calculated as mean (± S.D.) from two independent biological repeats. Data is colour scaled for lowest (green), median (yellow), and highest (red) DC<sub>50</sub> values.

**Table 3. Quantification of live-cell degradation parameters D<sub>max 50</sub> and degradation rate (λ<sub>max</sub>) with heterotrivalent PROTACs 1, 2 and 23 – 32 against BET proteins in HiBiT-BRD knock-in HEK293 cells.**

Compound	D <sub>max 50</sub> , nM <sup>a</sup>			λ <sub>max</sub> , h <sup>-1</sup> <sup>b</sup>		
	BRD4	BRD3	BRD2	BRD4	BRD3	BRD2
MN666 (1)	37					
MN675 (2)	55					
AB3062 (23)	11	5.7	>3.8	1.40	2.06	1.12
AB3066 (24)	3.0	<1.4	7.3	2.16	2.66	2.04
AB3064 (25)	31	8.1	74	1.09	1.69	1.34
AB3029 (31)	15	6.2	>61	1.99	2.36	1.9
AB3063 (26)	3.0	1.5	4.7	1.98	2.54	1.72
AB3067 (27)	0.64	<0.43	2.0	2.68	3.31	2.37
AB3065 (28)	2.9	1.2	23	1.51	2.14	1.46
AB3126 (29)	4.0	1.9	18	1.69	2.62	2.35
AB3125 (30)	8.2	3.0	31	1.76	2.6	2.63
AB3030 (32)	7.4	1.7	25	2.19	2.97	2.04

<sup>a</sup> Data is colour scaled for lowest (green), median (yellow), and highest (red) D<sub>max 50</sub> values. In cases where the fit of the curve was not sufficient to enable calculation of a 95% CI for either the upper or lower bound, the D<sub>max 50</sub> value was reported as “greater than” or “less than” the CI bound which could be determined. <sup>b</sup> Data is colour scaled for highest (green), median (yellow), and lowest (red) λ<sub>max</sub>, h<sup>-1</sup> values.

Gratifyingly, all compounds were able to potently degrade all BET proteins, each showing a preference for BRD4 (long and short isoforms) and BRD3 over BRD2. There was no observed degradation of VHL, however, each compound displayed degradation of CRBN to varying extents at the top treatment concentration of 1  $\mu$ M, and in some cases also at 100 nM (Figure 4A). Strikingly, fluorinated compounds which were 5-C tethering to the phthalimide ring (**26** – **28** and **32**) were an average of 3-fold more potent at degrading each BET protein when compared to their nonfluorinated 4-C tethered matched pairs (**26** vs **23**, **27** vs **24**, **28** vs **25**, and **32** vs **31**, respectively, Figure 4A, Table 2).

Out of the entire series, compounds AB3063 (**26**) and AB3067 (**27**), were the most potent degraders of each BET protein, with  $DC_{50}$  values of 0.76 nM and 2.3 nM for BRD4<sup>Long</sup>; 3.2 nM and 2.1 nM for BRD4<sup>Short</sup>; 4.8 nM and 1.6 nM, for BRD3; and, 14 nM and 15 nM, for BRD2, respectively (Table 2). **26** and **27**, which have 5-C tethering, were an average of 3.4-fold more potent than their 4-C tethered counterparts AB3062 (**23**) and AB3066 (**24**), respectively. Interestingly, the additional methyl group on the benzylic position of the VHL ligand present in **27** and **24** had no significant effect on BET degradation when comparing to their non-methylated matched pairs **26** and **23** respectively. However, the modification did lead to an unfavourable ~2.6-fold increase in CRBN degradation.

Moreover, when investigating the changes in linker length between each of the three ligands, there is a slight preference for a longer linker between both E3 ligase ligands, and the BET ligand for BET degradation. In the case of BRD4<sup>Long</sup>, removing a PEG unit from each of the VH032-JQ1 and thalidomide-VH032 (and therefore, thalidomide-JQ1) linkers from **26** to form AB3125 (**30**), results in an unfavourable 5.3-fold decrease in degradation, while leading to a much minor ~1.3-fold decrease for the degradation of the other BET proteins (Table 2). The shorter linker of **30** however, showed a favourable 4.5-fold decrease in CRBN degradation vs **26**, making it also an attractive compound, meeting the criteria for dialling out potential E3 ligase degradation.

Finally, comparing the 4-C and 5-C piperazinyl tethering vectors of AB3029 (**31**) and AB3030 (**32**), respectively, with their closest aniline tethered matched pairs **23** and **26**, respectively, we see that the piperazinyl tethered compounds were on average ~3-fold weaker at degrading the BET proteins than their respective aniline tethered matched pairs. Encouragingly however, **31** and **32** did show a 2.9 to 3.7-fold weaker degradation of CRBN compared with **23** and **27**, respectively (Table 2). It is important to note that **31** and **32** have the longest thalidomide-VH032/JQ1 linkers of the entire series, differing to thalidomide-VH032/JQ1 linkers of **23** and **26** by just two methylene groups in length and may also be a contributing factor to the changes in observed degradation potency.


Next, we sought to use the same live cell kinetic degradation assay set up as described above to evaluate degradation potency ( $D_{max\ 50}$ ) and degradation rate (Rate Constant  $\lambda$ , hr<sup>-1</sup>) of compounds **23** – **32** in HiBiT-BRD2, HiBiT-BRD3, and HiBiT-BRD4 HEK293 cell lines. This provides an orthogonal degradation assay to western blot, enables quantification of degradation rate, and allows for comparison with the initial compounds **1** and **2** (Figure 4B, kinetic traces provided in Supplementary Figure 1). Reassuringly, the  $D_{max\ 50}$  values (Table 3 & Supplementary Table 2) correlated well with  $DC_{50}$  values (Table 2) from western blot

analysis. Compound **27** was shown to be the most potent degrader of BRD3 and BRD4 out of the series, giving a sub-nanomolar  $D_{\max 50}$  value of 85 pM for BRD3 and 640 pM for BRD4, whilst giving a low nanomolar  $D_{\max 50}$  value of 2 nM for BRD2 (Table 3). This directly correlates with **27** also having the greatest degradation rate of BRD3 and BRD4, with a  $\lambda_{\max}$  of 2.68 h<sup>-1</sup> for BRD4, 3.31 h<sup>-1</sup> for BRD3 (which was the highest degradation rate of any compound in the series) and 2.37 h<sup>-1</sup> for BRD2 (Table 3 & Supplementary Table 3).

Encouragingly, all second generation heterotrivalent PROTACs performed 1.3 to 63-fold, and 1.6 to 78-fold better at degrading BRD4 than **1** and **2**, respectively (Table 3). The benefit of the amide-to-ester switch in the linker attachment point to JQ1 is evident when comparing molecular matched pairs, amide **1** and ester **23**. Ester **23** gave a 3.4-fold increase in the degradation of BRD4 than amide **1** ( $D_{\max 50} = 11$  vs 37 nM, respectively) (Table 3). BRD4 degradation was increased by a further 3.7-fold when further switching from the 4-C tethering to thalidomide of **23** to the 5-C tethering of 6-fluorothalidomide in **26** ( $D_{\max 50} = 11$  vs 3.0 nM, respectively), showing that there is a positive combinatory effect of applying each modification to the parent **1**. A similar combinatory effect is seen when applying both amide-to-ester substitution and 5-C tethering of 6-fluorothalidomide to **2**, to give molecular matched pair **30**, a compound which degrades BRD4 6.7-fold more than **2** ( $D_{\max 50} = 8.2$  vs 55 nM, respectively).

## 2.5. Further biological evaluation of lead heterotrivalent PROTACs **26** & **27**.

To determine whether our heterotrivalent PROTACs could drive antiproliferative effects, we evaluated the cytotoxicity of compounds **23** – **32** in cell viability assays performed in three different cell lines: RKO, KBM7 and K562 (Supplementary Figure 2 & Supplementary Table 4). The results of this assay shows that the cytotoxicity of the compounds, as measured by their  $EC_{50}$  values, follows the same trends observed in the western blot and HiBiT data. This further indicates that degradation is the major driver of cytotoxicity for these compounds, and that most of the second generation heterotrivalent PROTACS are potent cytotoxic compounds, with **26** and **27** standing out as the most cytotoxic across cell lines (Supplementary Figure 2 & Supplementary Table 4). The degradation profiles from both western blot and live cell HiBiT assay and the cell viability data indicate that compounds **26** and **27** are the most potent BET degraders of the series. We therefore wanted to further discriminate between these two compounds by evaluating their cell antiproliferation activity in BET sensitive RKO wild-type (WT) and CRBN and/or VHL KO/dKO cell lines (Figure 5 & Supplementary Table 5).




**Figure 5.** Cell viability assay with **26** and **27** in BET sensitive WT and CRBN/VHL KO RKO cell lines. Effect on cellular proliferation of **26** (left) and **27** (right) after 316 pM to 10  $\mu$ M treatment in WT, CRBN KO, VHL KO or CRBN/VHL dKO RKO cell lines. Mean  $\pm$  S.D.;  $n = 3$  biological replicates. EC<sub>50</sub> values are tabulated below and in Supplementary Table 5 with 95% CI.

We treated each RKO cell line with varying concentrations of either **26** or **27**. Strikingly, **26** and **27** showed ~9-fold greater antiproliferation in RKO WT cells when compared to RKO dKO cells with EC<sub>50</sub> values of 260 nM and 111 nM, vs 2235 nM and 988 nM, respectively, with **27** giving the largest window between WT and dKO cells (Figure 5). Interestingly, **27** gave a greater antiproliferative effect in each cell line with a 2.3-fold greater effect in WT, VHL KO, and VHL/CRBN dKO cells, and a 6.2-fold greater effect in CRBN KO cells when compared to **26** (Figure 5 & Supplementary Table 5). Importantly, the antiproliferative effect of **27** in CRBN KO and VHL KO cells was comparable (within 2-fold) with WT cells (EC<sub>50</sub> = 133, 180 and 111 nM, respectively). **27** was less effective in VHL KO cells compared to CRBN KO, suggesting that degradation is more VHL-driven. Conversely, for **26**, there is more discrepancy in antiproliferation, especially in CRBN KO cell lines over WT cells (Figure 5 & Supplementary Table 5). Additionally, **26** gave 3.2-fold less antiproliferation in CRBN KO cells than in WT cells and 1.6-fold less than in VHL KO cells, suggesting that the mode-of-action of **26** is more CRBN-driven, contradictory to what we see for **27**. As **26** and **27** are molecular matched pairs in all ways except for the additional benzylic methyl group present in the VH032 ligand of **27**, this switch in selectivity is likely due to an increased binary binding affinity for VHL for **27** relative to **26**.

To investigate the differences in ternary complex formation induced by either **26** or **27** between BRD4 and VHL/CRBN, we monitored live cell ternary complex formation using NanoBRET (Figure 6).<sup>23</sup> In this assay, the endogenously tagged HiBiT-BRD4 complemented with LgBiT served as the energy donor and transiently expressed HaloTag-CRBN or HaloTag-VHL served as the energy acceptor. A NanoBRET signal is observed when the donor and acceptor are in close proximity, making it ideal to measure cellular ternary complex formation and stability.<sup>11, 23</sup> We treated HEK293 HiBiT-BRD4 (LgBiT stable) cells that were transiently expressing either HaloTag-VHL or HaloTag-CRBN with a pre-treatment of proteasome inhibitor,

MG132,<sup>39</sup> followed by varying concentrations of **26** and **27**, and monitored the NanoBRET signal over 3.5 h (Figure 6).




**Figure 6. Live cell ternary complex formation between VHL or CRBN with **26** or **27** and BRD4.** NanoBRET kinetic ternary complex formation in endogenous HiBiT-BRD4 HEK293 cells stably expressing LgBiT and transiently expressing (A) HaloTag-VHL or (B) HaloTag-CRBN. Cells were pre-treated with 1 μM of proteasome inhibitor MG132, and subsequently treated with 0.01, 0.1 and 1 μM **26**, **27** or DMSO control. Donor and acceptor signal was continuously monitored for 3.5 h after compound addition.  $N = 1$  biological replicate, data is presented as mean values with error bars representing the S.D. of technical triplicates.

Encouragingly, both **26** and **27** can engage and form ternary complexes between BRD4 and either VHL or CRBN, with each compound showing slightly faster association kinetics for CRBN, plateauing after just 30 min. Interestingly, **27** gave more robust dose-response with both VHL and CRBN than **26**, suggesting that **27** may form a more stable and/or more highly populated ternary complex. This is likely to be one of the reasons why **27** is a more rapid and potent BRD4 degrader, evidencing that increased ternary complex population and stability positively correlates with the amount of ubiquitination and subsequent degradation.<sup>23</sup>

To further understand whether these improvements may be attributed to enhanced intracellular availability of **27** relative to **26**, we assessed the binary target engagement of **26** and **27** to either CRBN or VHL using a lytic and live cell NanoBRET target engagement assay (Figure 7).<sup>23, 40</sup>





**Figure 7. NanoBRET lytic and live cell target engagement assay of 26 and 27.** (A) & (B) Competitive displacement profiles of HEK293 cells transiently transfected with NanoLuc-VHL, which are incubated with a VHL fluorescent tracer in the presence of serial dilutions of **26**, **27** or VH298 in cells lysed with digitonin (A) or in live cells for 2h (B). (C) & (D) Competitive displacement profiles of HEK293 cells transiently transfected with NanoLuc-CRBN which are incubated with a CRBN fluorescent tracer in the presence of serial dilutions of **26**, **27** or Lenalidomide in cells lysed with digitonin (C) or in live cells for 2h (D). Data are represented as NanoBRET ratios normalized to 0  $\mu\text{M}$  compound. Error bars are expressed as S.D. of the mean of  $n = 2$  biological replicates (each consisting of 3 technical replicates) (A) & (B) or  $n = 3$  biological replicates (each consisting of 3 technical replicates) (C) & (D). IC<sub>50</sub> values are tabulated below for indicated target, compound, and assay format.

Competitive displacement of the VHL tracer molecule by **26** and **27** in lytic format showed that engagement of VHL was >3-fold stronger by **27** than **26** (IC<sub>50</sub>s = 559 nM and 1.82  $\mu\text{M}$ , respectively) (Figure 7). **27** differs to **26** only by an extra methyl group at the benzylic position of its VHL ligand VH032, a modification known to give rise to >2-fold binding affinity to VHL.<sup>27-29</sup> When in live cell format, **26** and **27** are >5.5-fold and 4-fold weaker, respectively, at engaging VHL (IC<sub>50</sub>s = 2.3  $\mu\text{M}$  and >10  $\mu\text{M}$ , respectively), with **27** now showing >4.4-fold (vs. >3-fold in lytic format) stronger binding with respect to **26** (Figure 7). This increased difference in binding affinity to VHL of **27** relative to **26** when comparing the live cell to lytic cell data suggests that **27** has a higher cell permeability than **26**. Interestingly, although comprising of the same fluorothalidomide-based ligand, **27** was able to engage CRBN >2-fold more strongly than **26** (IC<sub>50</sub>s =




190 nM and 412 nM, respectively) in lytic cell format (Figure 7). In live cell format, **27** engages CRBN 2.5-fold more strongly over **26**, again indicated that **27** is more cell permeable than **26**.

Taken together, out of the data presented above for all second generation compounds qualified compounds **26** and **27** as most potent degraders, with **27** emerging as the fittest of the two.

## 2.6. Design, synthesis, and characterisation of a heterotetravalent PROTAC

With the encouraging results presented by the heterotrivalent PROTAC series, we wanted to further investigate the chemical space and synthesise a compound which would more closely resemble SIM1, aiming to retain the avidity and BET bivalency it displays,<sup>11</sup> but now adding the ability to recruit two E3 ligases instead of just one. The so-called “heterotetravalent PROTAC” would be a combination of heterotrivalent PROTAC AB3063 (**26**) and BET-bivalent, trivalent PROTAC SIM1. We therefore decided to functionalise from the methyl group of the central quaternary carbon present in the linker of SIM1 as a potential vector to recruit CRBN by adding another linker tethered to thalidomide. We chose to synthesise a linker which would again allow for: simple amide coupling to the VH032; future S<sub>N</sub>Ar to a fluorothalidomide derivative; and diesterification to JQ1 (Scheme 5).

**Scheme 5. Synthesis of heterotetravalent PROTAC AB3124 (**86**)<sup>a</sup>**




<sup>a</sup> Reaction conditions: (a) i) NaH, DMF, 0°C, 15 min, ii) allyl bromide, r.t., 16 h; (b) i) NaH, DMF, r.t., 30 min, ii) **7**, DMF, 60°C, 16 h; (c) i) NaH, DMF, r.t., 30 min, ii) **40**, DMF, 60°C, 16 h; (d) OsO<sub>4</sub>, NaIO<sub>4</sub>, 2,6-lutidine, dioxane, H<sub>2</sub>O, r.t., 16 h; (e) 2-methyl-2-butene, NaH<sub>2</sub>PO<sub>4</sub>, NaClO<sub>2</sub>, *t*-BuOH, H<sub>2</sub>O, r.t., 16 h; (f) **14**, HATU, DIPEA, DMF, r.t., 2 h; (g) i) H<sub>2</sub>, 10% Pd/C, MeOH, r.t., 16 h, ii) **65**, DIPEA, DMSO, 90°C, 16 h; (h) i) 4N HCl in dioxane, MeOH, r.t., 3 h, ii) **22\***, DIPEA, DCM, r.t., 16 h.

The synthesis follows a similar route to the one used for heterotrivalent PROTACs (Schemes 2 & 3). Firstly, the tetrafunctional, pentaerythritol (**78**) was mono-alkylated by first deprotonating with sodium hydride in DMF, followed by the addition of allyl bromide to yield the allyl ether triol **79**. Triol **79** was then carefully deprotonated with sodium hydride in DMF, before heating to 60°C with azido mesylate **7** to yield ether **80**. Di-deprotonation of diol **80** with excess sodium hydride in DMF at 0°C before subsequent addition of mesylate **40** and heating at 60°C yielded **81**. Subsequently, alkene **81** was oxidatively cleaved with sodium periodate, 2,6-lutidine and a catalytic amount of osmium tetroxide in dioxane and water to yield aldehyde **82**. Aldehyde **82** subsequently underwent a Pinnick oxidation by treating with 2-methyl-2-butene, monobasic sodium phosphate and sodium chlorite in *tert*-butanol and water to yield carboxylic acid **83** in quantitative yields. Next, acid **83** was coupled to VH032-amine (**14**) with HATU and DIPEA in DMF to yield amide **84**.

Then, the azide of **84** was reduced with a suspension of 10% Pd/C in methanol, under an atmosphere of hydrogen gas. The intermediate amine subsequently underwent an S<sub>N</sub>Ar reaction with 5,6-difluorothalidomide **65**, by heating with DIPEA in DMSO at 90°C to yield 5-substituted-6-fluoro aniline **85**. Finally, MOM protecting groups of **85** were hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The subsequent diol was immediately conjugated to an intermediate acid chloride (**22\***, synthesised in Scheme 3), formed after treating (+)-JQ1-acid (**22**) with thionyl chloride in DCM, to afford the di-ester of heterotetravalent PROTAC AB3124 (**86**) (Scheme 5).

We then moved to assess the degradation profile of **86** by western blot and live cell kinetics. Firstly, we treated HEK293 cells with varying concentrations of **86** and monitored intracellular levels of on-target BET, and off-target CRBN and VHL degradation (Figure 8A, Table 4).



**Figure 8. Cellular evaluation of heterotetravalent PROTAC AB3124 (**86**).** (A) Western blot data for BET, CRBN and VHL protein levels monitored after 1  $\mu$ M to 100 pM treatments of **86** over 6 h in HEK293 cells. Bands are normalised to tubulin and vehicle control (DMSO) to derive DC<sub>50</sub> values that enable rank order of each PROTAC. (B) Plots of D<sub>max</sub> expressed as fractional degradation versus concentration of **86** and **27** from live cell degradation kinetics in HiBiT-BRD4 CRISPR knock in HEK293 cells. Cells were treated with DMSO and a threefold serial dilution of **86** and **27** over a concentration range of 5 pM – 3  $\mu$ M in HiBiT-BRD4 knock in cells. Data points  $\geq$  333  $\mu$ M for **86** were excluded from the data fitting due to appeared onset of hook-effect. Mean  $\pm$  S.D.;  $n = 2$  biological replicates (each consisting of 3 technical replicates). (C) Cell viability assay with **86** and **27** in BET sensitive

WT and CRBN/VHL KO RKO cell lines. Cell antiproliferation of **86** (top) and **27** (bottom) after 316 pM to 10  $\mu$ M treatment in WT, CRBN KO, VHL KO or CRBN/VHL dKO RKO cell lines. Mean  $\pm$  S.D.;  $n = 3$  biological replicates. EC<sub>50</sub> values are tabulated below and in Supplementary Table 5 with 95% CI.

**Table 4. Quantification of the degradation profile of heterotetravalent PROTAC AB3124 (**86**) and heterotrivalent PROTACs AB3063 (**26**) and AB3067 (**27**) against BET proteins and CRBN in HEK293 cells.**

Compound	Western Blot DC <sub>50</sub> (nM) <sup>a</sup>					HiBiT D <sub>max 50</sub> (nM) <sup>b</sup>	
	BRD4 <sup>Long</sup>	BRD4 <sup>Short</sup>	BRD3	BRD2	CRBN	BRD4	95% CI
AB3124 ( <b>86</b> )	2.2 $\pm$ 0.1	2.9 $\pm$ 0.3	3.5 $\pm$ 0.3	1.0 $\pm$ 0.2	113 $\pm$ 3.2	1.1	0.91 to 1.4
AB3063 ( <b>26</b> )	0.76 $\pm$ 0.1	3.2 $\pm$ 0.9	4.8 $\pm$ 2.4	14 $\pm$ 4.6	200 $\pm$ 31	3.0	2.6 to 3.3
AB3067 ( <b>27</b> )	2.3 $\pm$ 0.4	2.1 $\pm$ 0.3	1.6 $\pm$ 0.3	15 $\pm$ 2.1	75 $\pm$ 14	0.64	0.50 to 0.80

<sup>a</sup> Calculated as mean ( $\pm$  S.E) from three independent biological experiments. <sup>b</sup> Calculated as mean from two independent biological experiments.

Compound **86** was able to potently degrade all BET proteins, with DC<sub>50</sub> values of 2.2 nM for BRD4<sup>Long</sup>; 2.9 nM for BRD4<sup>Short</sup>; 3.5 nM for BRD3; and 1 nM for BRD2. Similarly, to the heterotrivalent PROTAC series, **86** showed no observed degradation of VHL, whilst showing degradation of CRBN at high concentrations (DC<sub>50</sub> = 113 nM). In contrast with heterotrivalent PROTACs **23** – **32**, **86** showed potent and preferential degradation for BRD2, albeit incomplete (D<sub>max</sub> ~80%) and showing an earlier onset of the hook effect at 1  $\mu$ M (Figure 8A). This hook effect can also be seen to a weaker extent in BRD4<sup>Long</sup> blot (Figure 8A). The earlier onset of the hook effect is likely due to **86** inhibiting BRD2 and BRD4 more strongly due to its extra linkage to a second JQ1 molecule and potential BET bivalency. The switch in BET protein preference and increase in potency that **86** has for degrading BRD2 compared with the heterotrivalent compounds is likely due to the extra JQ1 “arm”. Trivalent PROTAC SIM1, also shows preferential degradation of BRD2 by simultaneously engaging both BD1 and BD2 of the same BRD2 protein with high avidity, forming a stable 1:1:1 (BRD2<sup>BD1-BD2</sup>:SIM1:VHL) ternary complex with VHL.<sup>11</sup> This is likely the reason for the observed switch in selectivity, especially when comparing heterotetravalent PROTAC **86** to its heterotrivalent matched pair **26** (Table 4).


In addition to the western blot analysis, we assessed the live cell kinetic degradation displayed by **86** in HiBiT-BRD4 HEK293 cells (Figure 8B, Table 4). Strikingly, **86** showed near equipotent degradation of BRD4 with the best heterotrivalent degrader **27**, with a D<sub>max 50</sub> value of 1.1 nM vs 0.6 nM. Interestingly, **86** was ~3-fold more potent than its trivalent counterpart **26**, with a D<sub>max 50</sub> value of 1.1 nM vs 3 nM (Table 4). Although **86** displayed potent degradation of BRD4 in this assay, the compound gave a final D<sub>max</sub> >10% less than for **26** and **27**, with an observable hook-effect at treatment concentrations  $\geq$  333 nM (Figure 8). Furthermore, BRD4 degradation mediated by **86** was remarkably slow compared to the rapid degradation mediated by **27** (Supplementary Figure 3), likely due to reduced cellular permeability.

Finally, we evaluated cell antiproliferation caused by **86** in BET sensitive RKO WT and CRBN and/or VHL KO/dKO cell lines. We treated cells with concentrations ranging from 316 pM to 10  $\mu$ M of **86** and

measured cell viability normalised to a DMSO control (Figure 8C & Supplementary Table 5). **86** displayed a potent cell antiproliferation in WT, CRBN KO and VHL KO RKO lines, with EC<sub>50</sub> values of 33, 62 and 34 nM, respectively, hence suggesting that both VHL and CRBN driven degradation occurred. When comparing the EC<sub>50</sub> values of **86** with that of the most cytotoxic heterotrivalent PROTAC, **27**, the antiproliferative effect of **86** was 3.4-fold greater in WT cells (EC<sub>50</sub> = 33 vs 111 nM); 2.1-fold greater in CRBN KO cells (EC<sub>50</sub> = 62 vs 133 nM); and 5.3-fold greater in VHL KO cells (EC<sub>50</sub> = 34 vs 180 nM); confirming the enhanced potency of the compound. Surprisingly, **86** also had a marked antiproliferative effect on VHL/CRBN dKO cells (EC<sub>50</sub> = 15 nM), which was found to be near equipotent to WT cells. This suggests that **86** is acting more as a potent bivalent BET inhibitor as there is no enhanced cytotoxic effect through BET degradation.

## 2.7. Further biological characterisation of AB3067 (**27**)

After profiling all heterotrivalent (**23** – **32**) and heterotetravalent (**86**) compounds in various biological assays, we established AB3067 (**27**) as the most suitable hetero-multivalent compound to take forward for further study. We wanted to further assess the relative contribution of both VHL and CRBN to degrade BET proteins with **27**. To this end, we investigated live cell kinetic degradation of endogenous HiBiT-BRD4 in the presence of either a VHL or CRBN KO (Figure 9).



**Figure 9. Degradation and ubiquitination profiles for 27 in HiBiT-BRD4 CRISPR knock-in HEK293 cells with/without CRBN or VHL knocked out.** Plots of (A)  $D_{max}$  expressed as fractional degradation and (B) rate constant  $\lambda$  ( $h^{-1}$ ) versus concentration



of **27** from live cell degradation kinetics in HiBiT-BRD4 CRISPR knock in HEK293 cells with normal E3 ligase expression or with a CRBN or VHL KO. Cells were treated with DMSO and a threefold serial dilution of **27** over a concentration range of 5 pM – 3  $\mu$ M.  $n = 2$  biological replicates, a single representative experiment is shown. Error bars in A represent S.D. of technical triplicates. (C) Ubiquitination plots of HiBiT-BRD4 parental (left), with CRBN KO (middle), and with VHL KO (right) CRISPR knock-in HEK293 cells. Cells were first transiently transfected with HaloTag-Ubiquitin and were then treated with DMSO and a threefold serial dilution of **27** over a concentration range of 12 nM – 3  $\mu$ M. The BRET signal was then measured at regular time points over 4 h.  $n = 3$  biological replicates, a single representative experiment is shown. Error bars in (C) represent S.D. of technical triplicates.


In each VHL and CRBN KO HiBiT-BRD4 cell line, the  $D_{\max 50}$  values for the degradation of BRD4 were 40 and 60-fold less, respectively, than in the parent HiBiT-BRD4 cells ( $D_{\max 50} = 23$  vs 0.6 nM, and 38 vs 0.6 nM, respectively, Figure 9A). This implies that **27** is almost equally reliant on VHL and CRBN to drive the degradation of BRD4, but performing slightly worse in CRBN KO cells than VHL KO or parental cells, and so showing a slight preferential reliance on CRBN. The rate of degradation ( $\lambda$ ) for both VHL and CRBN KO cells lines is 2-fold slower than in parental cells ( $\lambda_{\max} = 1.2$  and  $1.0 \text{ h}^{-1}$ , vs  $2.3 \text{ h}^{-1}$ , Figure 9B). Remarkably, the sum of the rate constants from **27** in both VHL and CRBN KO cells equal the rate constant in the parental cells, indicating that both VHL and CRBN are contributing to the degradation of BRD4 in an additive fashion.

Next, we wanted to compare how intracellular ubiquitination levels in parental, CRBN KO, and VHL KO HiBiT-BRD4 cells differed (Figure 9C). To this end, we adopted a NanoBRET ubiquitination assay similar to the ternary complex assay described previously. In the NanoBRET ubiquitination assay, parental, CRBN KO, or VHL KO HiBiT-BRD4 cell lines were transiently transfected with HaloTag-Ubiquitin and treated with a dilution series of **27**.<sup>11, 40</sup> Ubiquitination of BRD4 in parental cells treated with **27** occurs more rapidly than in either the CRBN KO or VHL KO cells, and the parental cells also exhibit a larger magnitude in BRET fold-change. Taken together, this indicates that each ligase is contributing to ubiquitination and therefore helping to drive the degradation of BRD4 when cells are treated with **27**.

Additionally, we sought to synthesise a series of control compounds which should complement the data in CRBN KO and or VHL KO cell lines and allow us to gain a better understanding of the contributions from each ligase. To this end, we synthesised control compounds *neg*-AB3067 (**93**), structurally identical to **27**, but with the glutarimide nitrogen of the CRBN ligand methylated, a modification well known to block CRBN binding;<sup>41</sup> *cis*-AB3067 (**94**), a diastereomer of **27** bearing the *cis*- instead of *trans*-hydroxyproline group to abrogate binding to VHL;<sup>16</sup> and *neg-cis*-AB3067 (**95**), a diastereomer of **93**, which has both the glutarimide methylated and the *cis*-hydroxyproline, to prevent both CRBN and VHL binding and provide a completely non-degrader control compound (Scheme 6).



**Scheme 6. Synthesis of AB3067 (27) control compounds, 93 – 95<sup>a</sup>**




<sup>a</sup> Reaction conditions: (a) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 0°C – r.t., 5.5 h; (b) HATU, DIPEA, DMF, r.t., 2 h; (b) i) H<sub>2</sub>, 10% Pd/C, MeOH, r.t., 16 h, ii) **87** or **65**, DIPEA, DMSO, 90°C, 16 h; (c) i) 4N HCl in dioxane, MeOH, r.t., 3 h, ii) **22\***, DIPEA, DCM, r.t., 16 h.

The synthetic route for the control compounds **93 – 95** was similar to that of **27** (Schemes 2 & 3). Firstly, glutarimide **65** was methylated after treatment with potassium carbonate and methyl iodide in DMF to yield methylated difluorothalidomide **87**. Next, carboxylic acid **53** was coupled to both Me-VH032-amine (**58**) and *cis*-Me-VH032-amine (**88**, synthesised according to literature procedures<sup>38</sup>) using HATU and DIPEA in DMF to yield amides **60** and **89**. Next, the azides of **60** and **89** were reduced with a suspension of 10% Pd/C in methanol, under an atmosphere of hydrogen gas. The intermediate amines subsequently underwent an S<sub>N</sub>Ar reaction with 5,6-difluorothalidomide derivatives **87** and **65**, by heating with DIPEA in DMSO at 90°C to give anilines **90 – 92**. Finally, the MOM protecting groups of **90 – 92** were hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The subsequent primary alcohols were immediately conjugated to an intermediate

acid chloride (**22\***, synthesised in Scheme 3), formed after treating (+)-JQ1-acid (**22**) with thionyl chloride in DCM, to afford the esters of control compounds **93** – **95** (Scheme 6).

With compounds **93** – **95** in hand, we validated their on-target BRD4 degradation activity in parental (WT VHL and CRBN expression), CRBN KO, and VHL KO cell lines all expressing endogenous HiBiT-BRD4 (Supplementary Figure 4). As expected, **95** showed no degradation of BRD4 in any of the cell lines, owing to its inability to engage either ligase, while **93** was inactive in VHL KO cells, and **94** was inactive in CRBN KO cells. While the potency of **93** was decreased relative to **27** in parental and CRBN KO cells, **94** exhibited an unexpected increase in degradation potency relative to **27** in both parental and VHL KO cells. To further explore the functional impact of degradation mediated by these control compounds, we next evaluated the cell antiproliferative effect of **93** – **95**, using the same cell viability assay described above, in BET sensitive RKO WT and CRBN and/or VHL KO/dKO cell lines. We again treated cells with ranging concentrations of compound and measured cell viability normalised to a DMSO control (Figure 10).



EC <sub>50</sub> (nM)	MZ1	<i>neg</i> -AB3067 ( <b>93</b> )	dBET6	<i>cis</i> -AB3067 ( <b>94</b> )	AB3067 ( <b>27</b> )	<i>neg</i> - <i>cis</i> -AB3067 ( <b>95</b> )
RKO WT	160	107	256	48	73	594
RKO CRBN KO	136	105	>10000	832	82	586
RKO VHL KO	>5000	391	291	48	110	522
RKO CRBN/VHL dKO	>5000	420	>10000	804	818	657


**Figure 10.** Cell viability assay with control compound **93** – **95** in BET sensitive wild-type and CRBN/VHL knock-out RKO cell lines compared with, MZ1, dBET6 and **27**. Cell antiproliferation of heterobivalent (MZ1 and dBET6) and heterotrivalent (**27**) BET degraders, and control compounds **93** – **95** after 500 pM to 10 μM treatment in wild-type, CRBN knock-out, VHL knock-out or CRBN/VHL double knock-out RKO cell lines. EC<sub>50</sub> values are tabulated below and in Supplementary Table 6 with 95% CI.

Expectedly, double negative control, *neg*-*cis*-AB3067 (**95**) gave a similar antiproliferative effect in each WT, KO and dKO cell line with EC<sub>50</sub>s between 522–657 nM, comparable with the dKO plot of AB3067 (**27**, EC<sub>50</sub> = 818 nM) (Figure 10 & Supplementary Table 6).

Encouragingly, *neg*-AB3067 (**93**, inactive CRBN ligand) displays the same antiproliferative effect in both WT and CRBN KO cells with  $EC_{50}$ s  $\sim$ 106 nM, again very comparable with the WT and CRBN KO plots of **27** ( $EC_{50}$  = 73 and 82 nM, respectively). This effect is 4-fold weaker in VHL KO cells which share the same antiproliferative effect as for VHL/CRBN dKO cells with  $EC_{50}$ s  $\sim$ 400 nM. Reassuringly, the antiproliferative profiles of **93** share the same trends as for heterobivalent PROTAC MZ1, which also has an enhanced antiproliferative effect in WT and CRBN KO cells ( $EC_{50}$ s = 160 and 136 nM, respectively), compared to VHL KO and VHL/CRBN dKO cells ( $EC_{50}$ s  $>$  5  $\mu$ M, Figure 10 & Supplementary Table 6). Interestingly, **93** displayed a slightly greater antiproliferative effect than MZ1 in WT ( $EC_{50}$  = 107 vs 160 nM, respectively) and CRBN KO ( $EC_{50}$  = 105 vs 136 nM, respectively) cell lines, while also giving a marked  $>$ 10-fold increased antiproliferative effect in both VHL KO and VHL/CRBN dKO cells compared to MZ1 ( $EC_{50}$   $\sim$ 400 vs  $>$ 5  $\mu$ M, respectively), the latter likely due to a stronger BET inhibitory potential relative to MZ1.

Furthermore, *cis*-AB3067 (**94**, inactive VHL ligand) displays the same antiproliferative effect in both WT and VHL KO cells with  $EC_{50}$ s of 48 nM, interestingly performing slightly better than **27** in both the WT and VHL KO cell lines ( $EC_{50}$  = 73 and 110 nM, respectively). This effect is 15-fold weaker in CRBN KO cells which share a similar antiproliferative nature as for VHL/CRBN dKO cells with  $EC_{50}$  = 832 and 804 nM, respectively. Reassuringly, the antiproliferation profiles of **94** share the same trends as for heterobivalent PROTAC dBET6, which also gives enhanced antiproliferation in WT and VHL KO cells ( $EC_{50}$ s = 256 and 291 nM, respectively), than in CRBN KO and VHL/CRBN dKO cells ( $EC_{50}$ s  $>$  10  $\mu$ M, Figure 10). Interestingly, **94** gave a  $>$ 5-fold larger antiproliferative effect than dBET6 in WT ( $EC_{50}$  = 48 vs 256 nM, respectively) and VHL KO ( $EC_{50}$  = 48 vs 291 nM, respectively) cell lines, while also giving a marked  $>$ 12-fold increased antiproliferative effect in both CRBN KO and VHL/CRBN dKO cells compared to dBET6 ( $EC_{50}$   $\sim$ 820 nM vs  $>$ 10  $\mu$ M, respectively), a trend similar to the comparison between **93** and MZ1. Curiously, while comprising of the same BET ligand JQ1, **27**, and **93** – **95**, show a much greater cell antiproliferation in VHL/CRBN dKO cells than MZ1 and dBET6, suggesting that **27**, and **93** – **95** have a stronger inhibitory effect (Figure 10 & Supplementary Table 6).

Finally, to further evaluate both the on- and off-target impact of **27**, we performed an unbiased mass spectrometry proteomics experiment by treating HEK293 cells with **27**, using *cis-neg*-AB3067 (**95**) and DMSO as negative and vehicle control, respectively. Of the 7276 proteins detected in this experiment, all three BET proteins, BRD2, BRD3 and BRD4, were significantly depleted upon **27** treatment, with no detectable induced degradation of CRBN observed (Figure 11). Another protein that was significantly downregulated by **27** treatment was EP300 interacting inhibitor protein of differentiation 2 (EID2). EID2 is a 28-kDa protein associated with inhibiting the acetyltransferase activity of p300.<sup>42</sup> We speculate that EID2 depletion upon **27** treatment is an immediate response to the loss of BET regulation of the cellular acetylation state. No protein was significantly downregulated upon treatment with the degrader inactive control, **95**.




**Figure 11. Proteomics of AB3067 (27) and *neg-cis*-AB3067 (95) treated HEK293 cells.** Volcano plot showing impact on the proteome of HEK293 cells after 4 h following a 250 nM treatment of either 27 (blue) or 95 (red) relative to a vehicle control (DMSO). The data plotted is  $\log_2$  of the normalized fold change in abundance against  $-\log_{10}$  of the P value per protein identified from TMT (tandem mass tagging) mass spectrometry analysis produced from five independent repeats. 7276 total proteins identified. Dashed lines on the x-axis indicates boundary line for proteins to be considered differential expressed at  $[\log_2=1]$ . Dashed line on the y-axis indicates boundary line for proteins to be considered statically significant; any proteins with a  $-\log_{10}(P \text{ value}) \geq 1.5$  to have a P value  $\leq 0.03$ .

## 2.8. Development of heterotrivalent BromoTag PROTAC AB3145 (97)

To show general applicability of our heterotrivalent PROTAC strategy, we designed an AB3067-like compound for targeting BromoTag.<sup>28, 43</sup> BromoTag is our recently reported inducible degradation system that leverages an engineered Leu-Ala version of BRD4-BD2 as universal tag for targeted protein degradation.<sup>28</sup> We designed and synthesized compound AB3145 (97), which (analogously to VHL-based bifunctional degrader AGB1) bears an ethyl-“bump” into the BET ligand, allowing for exquisite selectivity towards the BromoTag while sparingly degrading of endogenous BET proteins. To make the heterotrivalent BromoTag PROTAC, we followed a similar synthesis to 27 (c.f. Scheme 3), but now using the BromoTag selective ligand ET-JQ1-OH (96) instead of endogenous pan-BET ligand JQ1 (22) (Scheme 7).


**Scheme 7. Synthesis of heterotrivalent BromoTag PROTAC AB3145 (97)<sup>a</sup>**



<sup>a</sup> Reaction conditions: (a) SOCl<sub>2</sub>, DCM, r.t., 3 h; (b) i) 4N HCl in dioxane, MeOH, r.t., 3 h, ii) 96\*, DIPEA, DCM, r.t., 16 h.

Firstly, the MOM protecting group of **70** was hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The subsequent primary alcohol was immediately conjugated to an intermediate acid chloride (**96\***), formed after treating ET-JQ1-OH (**96**, synthesised through literature procedures<sup>43</sup>) with thionyl chloride in DCM, to afford the ester of heterotrivalent BromoTag PROTAC AB3145 (**97**) (Scheme 7).

Western blot degradation assays in homozygous CRISPR knock-in BromoTag-BRD4 HEK293 cell lines evidence highly potent degradation activity of **97** on the BromoTag-BRD4 protein (DC<sub>50</sub>: 120-140 pM; D<sub>max</sub>: 85-86%), maintaining a 250- and 6000-fold selectivity window over BRD3 (DC<sub>50</sub>: 33 nM; D<sub>max</sub>: 79%) and BRD2 (DC<sub>50</sub>: 770 nM; D<sub>max</sub>: 50%), respectively (Figure 12, Supplementary Figure 8 & Supplementary Table 7).



**Figure 12. Western blot evaluation of heterotrivalent BromoTag PROTAC AB3145 (97) in homozygous CRISPR knock-in HiBiT-BromoTag-BRD4 HEK293 cell line.** Plot of western blot data for BET and CRBN protein levels after 10 μM to 1 pM

treatments of **97** over 4 h in a homozygous endogenous HiBiT-BromoTag-BRD4 HEK293 cell line. Protein levels are normalised to tubulin and vehicle controls (DMSO) to derive DC<sub>50</sub> values. Data is mean ± S.D.; *n* = 2 biological replicates (BRD4, BRD3 and BRD2) or *n* = 1 biological replicate (CRBN). Calculated DC<sub>50</sub> and D<sub>max</sub> values are tabulated below.

Crucially, **97** proved to be 10 to 100-fold more potent than the current BromoTag degrader AGB1 (Supplementary Figure 8 & Supplementary Table 7), evidencing the advantage of the heterotrivalent strategy in augmenting protein degradation fitness for proteins of interest.

### 3.0. Conclusion

In summary, we report novel heterotrivalent dual ligase recruiting PROTACs that potently and rapidly degrade the engaged target protein. Trivalent CRBN-VHL-BET PROTAC AB3067 (**27**) qualified as the most potent and fastest degrader, and most cytotoxic in BET sensitive cells. AB3067-induced BRD4 degradation was shown to be a result of ternary complexes with VHL and CRBN, and ubiquitination by each E3, suggesting that both E3 ligases are contributing to its activity. This is consistent with the evidence that loss of AB3067 cellular activity requires simultaneous loss of both recruited E3 ligases. We further exemplify a heterotetavalent PROTAC bearing a further copy of the BET ligand, and a heterotrivalent PROTAC with much improved degradation potency for BromoTag. Altogether, our work suggests that increasing valency to recruit two E3 ligases by the same PROTAC molecule can be an attractive strategy to augment the efficacy of targeted protein degradation. This approach could offer an opportunity to delay or overcome resistance to PROTAC degraders. Future work will be directed at exploring this important concept in cancer cells. Establishing further mechanistic features of multifunctional PROTACs, for example, illuminating the formation of a potential 1:1:1:1 quaternary complex will also be warranted. It is also envisaged that exploration of other chemistries, and tri- or multi-functional core scaffolds will accelerate rapid high-throughput assembly and direct-to-biology testing of larger libraries of multifunctional PROTACs and other proximity-inducing agents.

### 4.0. Experimental

**Synthesis.** Chemicals, commercially available, were purchased from Apollo Scientific, Sigma-Aldrich, Fluorochem, or Manchester Organics and used without any further purification. All reactions were carried out using anhydrous solvents. Reactions were monitored using either: an Agilent Technologies 1200 series analytical HPLC (High Performance Liquid Chromatography) connected to an Agilent Technologies 6130 quadrupole LC/MS containing an Agilent diode array detector and a Waters XBridge C18 column (50 mm × 2.1 mm, 3.5 µm particle size). Samples were eluted with a 3 min gradient of 5% to 95% MeCN:water containing 0.1% HCOOH at a flow rate of 0.7 mL/min; or a Shimadzu HPLC/MS 2020 with photodiode array detector and a Hypersil Gold column (1.9 µm 50 × 2.1 mm). Samples were eluted with a 3 min gradient of 5% to 95% MeCN:water containing 0.1% HCOOH at a flow rate of 0.8 mL/min. Intermediates were purified by flash column chromatography using a Teledyne Isco Combiflash Rf or Rf200i, with Normal Phase RediSep Rf Disposable Columns or with Reverse Phase RediSep Rf Gold C18 Reusable Columns. Final compounds



were purified by HPLC using a Gilson Preparative HPLC System equipped with a Waters X-Bridge C18 column (100 mm x 19 mm; 5  $\mu$ m particle size) using a gradient from 5% to 95% of MeCN in water containing 0.1% HCOOH or ammonia over 10 min at a flow rate of 25 mL/min unless stated otherwise. Compound characterization using NMR was performed either on a Bruker 500 Ultrashield or Bruker Ascend 400 spectrometers. The proton ( $^1\text{H}$ ) and carbon ( $^{13}\text{C}$ ) reference solvents used were as follows:  $d_1$ -Chloroform –  $\text{CDCl}_3$  ( $\delta\text{H} = 7.26$  ppm /  $\delta\text{C} = 77.15$  ppm),  $d_4$ - $\text{CD}_3\text{OD}$  ( $\delta\text{H} = 3.31$  ppm /  $\delta\text{C} = 49.00$  ppm),  $d_6$ - $(\text{CD}_3)_2\text{SO}$  ( $\delta\text{H} = 2.50$  ppm /  $\delta\text{C} = 39.52$  ppm) Signal patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint.), multiplet (m), broad (br.), or a combination of the listed splitting patterns. Coupling constants (J) are measured in Hertz (Hz). NMR spectra for all compounds were processed using Bruker TopSpin 4.1.1. High resolution mass spectrometry (HRMS) data was performed on a Bruker MicrOTOF II focus ESI Mass Spectrometer connected in parallel to Dionex Ultimate 3000 RSLC system with diode array detector and a Waters XBridge C18 column (50mm x 2.1, 3.5  $\mu$ m particle size). Samples were eluted with a 6 min gradient of 5% to 95% MeCN: water containing 0.1% HCOOH at a flow rate of 0.6 mL/min. All compounds are >95% pure by HPLC.

**General Procedure A.** Alcohol/diol (1.0 eq.) was dissolved in DMF (2.4 mL/mmol) under  $\text{N}_2$  and cooled to  $0^\circ\text{C}$ . 60% NaH in paraffin oil (1.2 – 4.0 eq.) was carefully added and the flask was left to stir at  $0^\circ\text{C}$  for 30 min. A solution of mesylate (1.0 – 3.0 eq.) in DMF (0.5 – 0.8 mL/mmol) was then added to the flask dropwise and the reaction was left to stir at  $60^\circ\text{C}$  for 16 h. The mixture was then filtered through PTFE filters or celite and concentrated *in vacuo* and purified.

**General Procedure B.** To a solution of alkene (1.0 eq.) in dioxane (18 mL/mmol) and water (4.6 mL/mmol) was added  $\text{NaIO}_4$  (4.0 eq.), 2,6-lutidine (2.0 eq.) and 4%  $\text{OsO}_4$  in water (0.01 eq.). The reaction was left to stir at r.t. for 16 h. The resulting white suspension was quenched with saturated  $\text{Na}_2\text{SO}_3$  solution, extracted with DCM ( $4 \times 10$  mL), dried with  $\text{MgSO}_4$ , and concentrated *in vacuo*. The residue is then purified by flash column chromatography using a linear gradient of 0% to 10% MeOH in DCM to yield aldehydes as colourless oils.

**General Procedure C.** To a solution of aldehyde (1.0 eq.) in *t*-BuOH (18 mL/mmol) and water (5.9 mL/mmol) was added  $\text{NaH}_2\text{PO}_4$  (1.0 eq.),  $\text{NaClO}_2$  (3.95 eq.) followed by 2 M 2-methyl-2-butene in THF (5.0 eq.), and the reaction left to stir at r.t. for 16 h. The reaction was diluted with 2 M NaOH (aq) solution (1 mL) and then carefully neutralised 2 M HCl (1 mL). The mixture was extracted with DCM ( $4 \times 10$  mL), dried with  $\text{MgSO}_4$  and concentrated *in vacuo* to yield carboxylic acids as colourless oils without the need for further purification.

**General Procedure D.** To a solution of carboxylic acid (1.0 eq.) in DMF (7.7 mL/mmol) was added DIPEA (4.0 eq.). HATU (1.1 eq.) was then added, and the reaction was stirred at r.t. for 5 min. VH032-amine (**14** synthesised according to literature<sup>16, 21</sup>), Me-VH032-amine (**58**, synthesised according to literature<sup>29</sup>) or *cis*-Me-VH032-amine (**88**, synthesised according to literature<sup>29</sup>) (1.1 eq.) was then added and the reaction left to stir at r.t. for 2 h. The reaction is then concentrated under vacuum and purified by reverse phase flash column

chromatography (C18 gold column) using a linear gradient from 0% to 100% MeCN in 0.1% HCOOH in water to afford amides as colourless oils.

**General Procedure E.** (Step 1) MOM/MEM protected compound (1.0 eq.) was dissolved in MeOH (26 mL/mmol). 4N HCl in dioxane (13 mL/mmol) was then added and the reaction was left to stir for at r.t. for 2 h. The reaction was then concentrated under vacuum to quantitatively yield alcohols without the need for purification. (Step 2) In a separate flask was dissolved (+)-JQ1 carboxylic acid (**22**) or ET-JQ1-OH (**96**, synthesised through literature procedures<sup>43</sup>) (1.5 – 3.0 eq.) in anhydrous DCM (9.4 mL/mmol) under an atmosphere of N<sub>2</sub>. Neat SOCl<sub>2</sub> (22.5 – 45 eq.) was then added and left to stir at r.t. Conversion to the acid chloride was monitored by LC-MS by dissolving a sample in MeOH and observing the mass of the methyl ester of JQ1 (calc. for C<sub>20</sub>H<sub>20</sub>ClN<sub>4</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 415.9) or ET-JQ1-OH (calc. for C<sub>22</sub>H<sub>24</sub>ClN<sub>4</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 443.1). Complete conversion was observed after 1.5 h and the mixture was concentrated *in vacuo*. (Step 3) The acid chloride intermediate (1.5 – 3 eq.) was re-dissolved in anhydrous DCM (9.6 mL/mmol) and added to a N<sub>2</sub> purged flask containing alcohol (1.0 eq., from Step 1). Anhydrous DIPEA was added (3.0 – 5.0 eq., or until pH 9.0) and left to stir at r.t. for 16 h. The mixtures were then concentrated *in vacuo* and the residues were purified by HPLC.

**General Procedure F.** To a N<sub>2</sub> flushed flask containing a solution of triethylene (**33**) or diethylene glycol (**34**) (5.25 eq.) in DCM (0.5 mL/mmol), was added DIPEA (1.1 eq.). MEMCl or MOMBr (1.0 eq.) were then added dropwise, and the reaction was left to stir at r.t. for 16 h. The mixture was then diluted with DCM (20 mL) and water (20 mL), and the organic layer separated. The aqueous phase was extracted with DCM (3 × 20 mL), and the combined organic layers were dried with MgSO<sub>4</sub> and concentrated *in vacuo*. The residue was then purified by flash column chromatography to yield mono-MEM/MOM protected alcohols as colourless oils.

**General Procedure G.** To a solution of alcohol (1.0 eq.) is dissolved in anhydrous DCM (4.9 mL/mmol) was added DIPEA (3.0 eq.) before flushing the flask with N<sub>2</sub> and cooling to 0°C. MsCl (3.0 eq.) was then added dropwise, and the reaction was left to stir at 0°C for 20 min before warming to r.t. and stirring for 2 h. The reaction mixture was concentrated *in vacuo*. The residue was then purified by flash column chromatography using a linear gradient from 0% to 100% EtOAc in heptane to yield mesylates as orange/red oils.

**General Procedure H.** Azide (1.0 eq.) was dissolved in MeOH (58 mL/mmol). A catalytic amount of 10 wt.% Pd/C was added, and the reaction was stirred under an atmosphere of H<sub>2</sub> for 16 h. The reaction mixture was then filtered through PTFE syringe filters and evaporated to dryness to obtain the desired amine quantitative yields. The resulting amine (1.0 eq.) was added to a solution of thalidomide derivatives **19**, **65** or **87** (1.0 eq.) and DIPEA (4.0 eq.) in DMSO (24 mL/mmol) and the reaction was left to stir in a sealed vial at 90°C for 4 h. the reaction was then purified by HPLC using a linear gradient of 5% to 95% MeCN in 0.1% HCOOH in water over 10 min gradient unless otherwise stated.

**(2S,4R)-1-((20S)-20-(tert-butyl)-1-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-14-((2-(2-(2-((2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-**

**4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-methyl-2,18-dioxo-6,9,12,16-tetraoxa-3,19-diazahenicosan-21-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (MN666) (1).**

Azide **20** (12 mg, 10.6  $\mu\text{mol}$ ) was dissolved in MeOH (600  $\mu\text{L}$ ). A catalytic amount of 10 wt.% Pd/C (3 mg) was added, and the reaction was stirred under an atmosphere of hydrogen for 24 h. The reaction mixture was then filtered through a PTFE syringe filter and evaporated to dryness to leave crude amine intermediate. The crude amine (8 mg, 7.2  $\mu\text{mol}$ ) was dissolved in DMF (100  $\mu\text{L}$ ) and added to a solution of (+)-JQ1-acid (**22**) (3 mg, 7.5  $\mu\text{mol}$ ), HATU (3 mg, 7.9  $\mu\text{mol}$ ) and DIPEA (5  $\mu\text{L}$ , 28.7  $\mu\text{L}$ ) in DMF (400  $\mu\text{L}$ ) and stirred at r.t. for 2 h. After completion, the reaction was directly purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 5.4 mg (34%); Contains a mixture of four diastereomers;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 9.50–9.19 (m, 1H), 8.73–8.71 (m, 1H), 7.78–7.71 (m, 1H), 7.49–7.31 (m, 10H), 7.23–7.17 (m, 1H), 7.09–7.06 (m, 1H), 6.92–6.88 (m, 1H), 6.49 (s, 1H), 4.89–4.45 (m, 6H), 4.35–4.24 (m, 1H), 4.09–3.93 (m, 3H), 3.73–3.21 (m, 32H), 2.83–2.62 (m, 6H), 2.52–2.50 (m, 3H), 2.44–2.37 (m, 4H), 2.19–2.02 (m, 2H), 1.64 (s, 3H), 1.39–1.29 (m, 1H), 1.21–1.17 (m, 1H), 0.98–0.95 (m, 9H), 0.90–0.88 ppm (m, 3H); HRMS  $m/z$  calc. for  $\text{C}_{73}\text{H}_{92}\text{ClN}_{12}\text{O}_{16}\text{S}_2$   $[\text{M}+\text{H}]^+$  1491.5879, found: 1491.5907

**(2*S*,4*R*)-1-((17*S*)-17-(*tert*-butyl)-1-((*S*)-4-(4-chlorophenyl)-2,3,9-trimethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)-11-((2-(2-((2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)methyl)-11-methyl-2,15-dioxo-6,9,13-trioxa-3,16-diazaoctadecan-18-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (MN675) (2).**

Azide **21** (13 mg, 12.4  $\mu\text{mol}$ ) was dissolved in MeOH (600  $\mu\text{L}$ ). A catalytic amount of 10 wt.% Pd/C (3 mg) was added, and the reaction was stirred under an atmosphere of hydrogen for 24 h. The reaction mixture was then filtered through a PTFE syringe filter and evaporated to dryness to leave crude amine intermediate. The crude amine (13 mg, 12.4  $\mu\text{mol}$ ) was dissolved in DMF (100  $\mu\text{L}$ ) and added to a solution of (+)-JQ1-acid (**22**) (5 mg, 12.4  $\mu\text{mol}$ ), HATU (5 mg, 13.1  $\mu\text{mol}$ ) and DIPEA (10  $\mu\text{L}$ , 57.4  $\mu\text{L}$ ) in DMF (400  $\mu\text{L}$ ) and stirred at r.t. for 2 h. After completion, the reaction was directly purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 10 mg (59%); Contains a mixture of four diastereomers;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 9.89–9.55 (m, 1H), 8.72 (s, 1H), 7.93–7.79 (m, 1H), 7.49–7.31 (m, 10H), 7.28–7.23 (m, 1H), 7.07–7.05 (m, 1H), 6.92–6.88 (m, 1H), 6.50 (s, 1H), 4.90–4.83 (m, 1H), 4.78–4.47 (m, 5H), 4.32–4.27 (m, 1H), 4.15–3.95 (m, 3H), 3.71–3.22 (m, 24H), 2.78–2.61 (m, 6H), 2.52–2.50 (m, 3H), 2.40–2.31 (m, 4H), 2.17–1.98 (m, 2H), 1.64 (s, 3H), 1.38–1.29 (m, 1H), 1.21–1.16 (m, 1H), 0.98–0.94 (m, 9H), 0.90–0.87 ppm (m, 3H); HRMS  $m/z$  calc. for  $\text{C}_{69}\text{H}_{84}\text{ClN}_{12}\text{O}_{14}\text{S}_2$   $[\text{M}+\text{H}]^+$  1403.5354, found: 1403.5402.

**5-((allyloxy)methyl)-2,2,5-trimethyl-1,3-dioxane (4).**

(2,2,5-trimethyl-1,3-dioxan-5-yl)methanol (**3**) (2.0 g, 12.5 mmol) was dissolved in toluene (12.5 mL). KOH (2.1 g, 37.5 mmol) was dissolved in  $\text{H}_2\text{O}$  (2.1 mL) and added to the flask, followed by TBAB (403 mg, 1.25 mmol) and allyl bromide (4.53 g, 37.5 mmol). The reaction was stirred vigorously at r.t. for 16 h. DCM (20

mL) was added, and the aqueous layer was extracted with DCM (3 × 20 mL), dried with MgSO<sub>4</sub> and concentrated *in vacuo*. The residue was purified by flash column chromatography (40 g silica column) using a linear gradient from 0% to 50% EtOAc in heptane to afford **121 (4)** as a colourless oil. Yield: 1.4 g (54%); Analytics matched those reported in literature (ref. <sup>11</sup>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 5.95–5.85 (m, 1H), 5.27 (qd, *J* = 1.7, 17.3 Hz, 1H), 5.16 (qd, *J* = 1.5, 10.4 Hz, 1H), 4.00 (td, *J* = 1.5, 5.4 Hz, 2H), 3.72 (d, *J* = 12.0 Hz, 2H), 3.55 (d, *J* = 11.9 Hz, 2H), 3.43 (s, 2H), 1.43 (s, 3H), 1.40 (s, 3H), 0.89 ppm (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ = 135.2, 116.5, 98.0, 73.3, 72.5, 66.8, 34.5, 26.5, 21.4, 18.5.

#### **2-((allyloxy)methyl)-2-methylpropane-1,3-diol (5).**

5-((allyloxy)methyl)-2,2,5-trimethyl-1,3-dioxane (**4**) (1.4 g, 6.99 mmol) was dissolved in MeOH (10 mL) and H<sub>2</sub>O (6 mL). TFA (600 μL) was then added, and the reaction was left to stir at r.t. for 3 h. The mixture was then evaporated to dryness and the residue was purified by flash column chromatography (24 g silica column) using a linear gradient from 0% to 20% MeOH in DCM to afford **5** as a colourless oil. Yield: 874 mg (78%); Analytics matched those reported in literature (ref. <sup>11</sup>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 5.94–5.84 (m, 1H), 5.26 (qd, *J* = 1.6, 17.3 Hz, 1H), 5.20 (qd, *J* = 1.4, 10.4 Hz, 1H), 3.99 (td, *J* = 1.4, 5.5 Hz, 2H), 3.72 (d, *J* = 11.0 Hz, 2H), 3.61 (d, *J* = 10.9 Hz, 2H), 3.45 (s, 2H), 2.39 (br. s, 2H), 0.84 ppm (s, 3H).

#### **11-((allyloxy)methyl)-1,21-diazido-11-methyl-3,6,9,13,16,19-hexaoxahenicosane (8).**

Follow General Procedure A, using 1.0 eq. of diol **5**, 4 eq. of NaH and 3 eq. of 2-(2-(2-azidoethoxy)ethoxy)ethyl methanesulfonate (**6**). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 11 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 179 mg (60%); Analytics matched those reported in literature (ref. <sup>11</sup>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 5.96–5.84 (m, 1H), 5.26 (dd, *J* = 1.7, 17.2 Hz, 1H), 5.15 (dd, *J* = 1.5, 10.4 Hz, 1H), 4.01–3.93 (m, 2H), 3.76–3.61 (m, 16H), 3.62–3.55 (m, 4H), 3.44–3.37 (m, 4H), 3.37–3.33 (m, 4H), 3.33–3.29 (m, 2H), 0.96 (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ = 135.3, 116.0, 74.0, 73.0, 72.3, 71.1, 70.8, 70.7, 70.5, 70.0, 50.7, 41.0, 17.4.

#### **8-((allyloxy)methyl)-1,15-diazido-8-methyl-3,6,10,13-tetraoxapentadecane (9).**

Follow General Procedure A, using 1.0 eq. of diol **5**, 4 eq. of NaH and 3 eq. of 2-(2-azidoethoxy)ethyl methanesulfonate (**7**). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 11 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 507 mg (60%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 5.93–5.84 (m, 1H), 5.25 (qd, *J* = 1.7, 17.2 Hz, 1H), 5.14 (qd, *J* = 1.5, 10.4 Hz, 1H), 3.94 (td, *J* = 1.5, 5.3 Hz, 2H), 3.69–3.67 (m, 4H), 3.65–3.61 (m, 4H), 3.60–3.56 (m, 4H), 3.37 (t, *J* = 5.1 Hz, 4H), 3.35 (s, 4H), 3.31 (s, 2H), 0.96 ppm (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 135.4, 116.2, 74.2, 73.2, 72.4, 71.3, 70.7, 70.2, 51.0, 41.1, 17.6.

#### **1-azido-11-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-11-methyl-3,6,9,13-tetraoxapentadecan-15-ol (10).**

Follow General Procedure B, using alkene **8**. Yield: 16 mg (64 %); Analytics matched those reported in literature (ref. <sup>11</sup>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 9.73 (s, 1H), 4.02 (s, 2H), 3.74–3.52 (m, 20H), 3.46–3.26

(m, 10H), 0.98 (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  = 202.2, 77.0, 74.7, 73.9, 71.2, 70.9, 70.8, 70.7, 70.2, 50.9, 41.3, 17.5.

**2-(3-(2-(2-azidoethoxy)ethoxy)-2-((2-(2-azidoethoxy)ethoxy)methyl)-2-methylpropoxy)acetaldehyde (11).**

Follow General Procedure B, using alkene **9**. Yield: 83%;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 9.73 (t,  $J$  = 1.0 Hz, 1H), 4.02 (d,  $J$  = 1.0 Hz, 2H), 3.70–3.55 (m, 12H), 3.44 (s, 2H), 3.40–3.33 (m, 8H), 0.99 ppm (s, 3H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 202.1, 77.0, 74.7, 73.9, 71.2, 70.7, 70.2, 50.9, 41.3, 17.4.

**1-azido-11-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-11-methyl-3,6,9,13-tetraoxapentadecan-15-oic acid (12).**

Follow General Procedure C, using aldehyde **10**. Yield: 150 mg (97%); Analytics matched those reported in literature (ref. <sup>11</sup>);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  = 4.05 (s, 2H), 3.70–3.58 (m, 20H), 3.45–3.33 (m, 10H), 0.95 (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  = 172.1, 75.4, 74.7, 71.3, 70.9, 70.7, 70.4, 70.2, 68.8, 50.8, 40.8, 18.0.

**2-(3-(2-(2-azidoethoxy)ethoxy)-2-((2-(2-azidoethoxy)ethoxy)methyl)-2-methylpropoxy)acetic acid (13).**

Follow General Procedure C, using aldehyde **11**. Yield: 422 mg (95%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 4.06 (s, 2H), 3.69–3.60 (m, 12H), 3.48–3.44 (m, 4H), 3.40 (d,  $J$  = 9.3 Hz, 2H), 3.39–3.35 (m, 4H), 0.97 ppm (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 171.9, 75.7, 75.0, 71.4, 70.5, 70.2, 68.7, 50.9, 40.8, 18.0.

**(2S,4R)-1-((S)-1-azido-11-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-17-(tert-butyl)-11-methyl-15-oxo-3,6,9,13-tetraoxa-16-azaoctadecan-18-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (15).**

Follow General Procedure D, using carboxylic acid **13** and VH032-amine (**14**, synthesised through literature procedures<sup>21, 22</sup>). Yield: 55 mg (50 %); Analytics matched those reported in literature (ref. <sup>11</sup>);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm) = 8.68 (s, 1H), 7.39–7.30 (m, 5H), 7.10 (d,  $J$  = 8.5 Hz, 1H), 4.73 (t,  $J$  = 7.8 Hz, 1H), 4.59–4.51 (m, 2H), 4.48 (d,  $J$  = 8.7 Hz, 1H), 4.35 (dd,  $J$  = 5.5, 15.0 Hz, 1H), 4.09 (d,  $J$  = 12.0 Hz, 1H), 3.94 (dd,  $J$  = 15.4, 17.7 Hz, 2H), 3.71–3.53 (m, 21H), 3.46–3.30 (m, 10H), 2.60–2.49 (m, 1H), 2.51 (s, 3H), 2.16–2.08 (m, 1H), 0.96 (s, 3H), 0.95 (s, 9H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm) = 171.5, 170.8, 170.7, 150.5, 148.6, 138.3, 131.8, 131.1, 129.7, 128.3, 74.8, 74.2, 74.1, 71.2, 70.9, 70.8, 70.7, 70.6, 70.3, 70.2, 58.5, 57.2, 56.7, 50.8, 43.4, 41.1, 35.9, 35.0, 26.5, 17.7, 16.2. LC-MS  $m/z$  calc. for  $\text{C}_{41}\text{H}_{65}\text{N}_{10}\text{O}_{11}\text{S}$   $[\text{M}+\text{H}]^+$  905.5, found 905.3.

**(2S,4R)-1-((S)-15-azido-8-((2-(2-azidoethoxy)ethoxy)methyl)-2-(tert-butyl)-8-methyl-4-oxo-6,10,13-trioxa-3-azapentadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (16).**

Follow General Procedure D, using carboxylic acid **13** and VH032-amine (**14**, synthesised through literature procedures<sup>21, 22</sup>). Yield: 312 mg (77%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 8.68 (s, 1H), 7.39–7.30 (m, 5H), 7.12 (d,  $J$  = 8.3 Hz, 1H), 4.75 (t,  $J$  = 7.9 Hz, 1H), 4.60–4.51 (m, 2H), 4.45 (d,  $J$  = 8.5 Hz, 1H), 4.34 (dd,  $J$  = 5.4, 15.0 Hz, 1H), 4.14 (d,  $J$  = 11.1 Hz, 1H), 3.93 (s, 2H), 3.75–3.28 (m, 23H), 2.75 (s, 1H), 2.64–2.57 (m,



1H), 2.52 (s, 3H), 2.12 (dd,  $J = 7.9, 13.7$  Hz, 1H), 0.99 (s, 3H), 0.95 ppm (s, 9H); LCMS calc. for  $C_{37}H_{57}N_{10}O_9S$   $[M+H]^+$  is 817.4, found 817.9.

**(2S,4R)-1-((17S)-1-amino-11-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-17-(tert-butyl)-11-methyl-15-oxo-3,6,9,13-tetraoxa-16-azaoctadecan-18-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (17).**

Diazide **15** (148 mg, 0.163 mmol) was dissolved in a 4:1:5 ratio of EtOAc (4.5 mL), THF (1.1 mL) and 1 M HCl (aq) solution (5.6 mL).  $PPh_3$  (43 mg, 0.163 mmol) was then dissolved in EtOAc (4.2 mL) and added dropwise over 3 h (0.5 mL/h) to the flask containing the diazide solution. The reaction was then left to stir vigorously at r.t. for 16 h. The reaction was then diluted with 2 M HCl (aq) solution (5 mL), and the aqueous layer was separated and concentrated *in vacuo*. The residue was then purified by HPLC using a linear gradient over 10 min from 5% to 95% MeCN in 0.1%  $NH_3$  in water to afford mono amine **17**. Yield: 51 mg (36%); Contains a mixture of two diastereomers; Analytics matched those reported in literature (ref. <sup>11</sup>);  $^1H$  NMR (500 MHz,  $CDCl_3$ )  $\delta$  (ppm) = 8.67 (s, 1H), 8.52 (br. s, 1H), 7.38–7.33 (m, 4H), 7.17 (m, 1H), 4.67 (m, 1H), 4.55–4.47 (m, 3H), 4.38 (m, 1H), 4.07–3.94 (m, 4H), 3.70–3.21 (m, 31H), 2.98 (m, 2H), 2.51 (s, 3H), 2.31 (s, 1H), 2.23 (s, 1H), 1.02–0.93 (m, 12H);  $^{13}C$  NMR (126 MHz,  $CDCl_3$ )  $\delta$  (ppm) = 171.4, 171.03, 170.98, 170.72, 170.65, 169.4, 150.2, 148.4, 138.51, 138.47, 131.6, 130.67, 130.66, 129.36, 129.35, 127.97, 74.2, 74.1, 74.0, 73.9, 73.1, 71.1, 70.87, 70.84, 70.80, 71.72, 70.70, 70.62, 70.45, 70.42, 70.38, 70.34, 70.3, 70.2, 70.2, 70.0, 69.9, 68.6, 68.5, 59.0, 57.3, 57.0, 50.6, 43.0, 42.99, 41.03, 41.01, 39.8, 37.07, 36.98, 35.17, 35.10, 26.4, 17.5, 16.0; LC-MS calc. for  $C_{41}H_{67}N_8O_{11}S$   $[M+H]^+$  879.5, found 879.5.

**(2S,4R)-1-((2S)-15-amino-8-((2-(2-azidoethoxy)ethoxy)methyl)-2-(tert-butyl)-8-methyl-4-oxo-6,10,13-trioxa-3-azapentadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (18).**

Diazide **16** (256 mg, 0.313 mmol) was dissolved in a 1:1 ratio of EtOAc (2 mL) and 2 M HCl (aq) solution (2 mL).  $PPh_3$  (82 mg, 0.313 mmol) was then dissolved in EtOAc (2 mL) and added dropwise over 3 h (0.5 mL/h) to the flask containing the diazide solution. The reaction was then left to stir at r.t. for 16 h. The reaction was then diluted with 2 M HCl (aq) solution (3 mL), and the aqueous layer was separated, neutralised with 7N  $NH_3$  in MeOH and then concentrated *in vacuo*. The residue was then purified by HPLC using a linear gradient over 10 min from 5% to 95% MeCN in 0.1% HCOOH in water to afford amine **18**. Yield: 120 mg (48%); Contains a mixture of two diastereomers;  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  = 8.65 (s, 1H), 8.44 (s, 1H), 8.33–8.26 (m, 1H), 7.36 (d,  $J = 8.1$  Hz, 4H), 7.32 (d,  $J = 8.3$  Hz, 4H), 7.20–7.14 (m, 1H), 4.62 (t,  $J = 8.7$  Hz, 1H), 4.57–4.44 (m, 3H), 4.32 (dd,  $J = 5.3, 14.7$  Hz, 1H), 4.04–3.99 (m, 3H), 3.69–3.22 (m, 22H), 3.01–2.86 (m, 2H), 2.50 (s, 3H), 2.24–2.12 (m, 2H), 1.01 (s, 9H), 0.96–0.92 ppm (m, 3H);  $^{13}C$  NMR (126 MHz,  $CDCl_3$ ):  $\delta$  = 171.8, 171.02, 171.00, 170.96, 170.9, 169.0, 150.3, 148.5, 139.01, 138.99, 131.8, 130.7, 129.4, 128.1, 74.7, 74.6, 74.5, 74.3, 73.5, 73.4, 71.31, 71.26, 71.20, 71.16, 70.82, 70.77, 70.7, 70.5, 70.2, 70.1, 67.3, 59.3, 57.6, 57.24, 57.21, 50.9, 43.0, 41.2, 39.6, 37.6, 35.4, 26.5, 17.81, 17.78, 16.2; LC-MS calc. for  $C_{37}H_{59}N_8O_9S$   $[M+H]^+$  791.4, found 879.5.



**(2*S*,4*R*)-1-((17*S*)-1-azido-17-(*tert*-butyl)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-11-methyl-15-oxo-3,6,9,13-tetraoxa-16-azaoctadecan-18-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (20).**

To a solution of amine **17** (17 mg, 19.3  $\mu$ mol) and DIPEA (20  $\mu$ L, 116  $\mu$ mol) dissolved in NMP (300  $\mu$ L) was added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (**19**) (5.3 mg, 19.3  $\mu$ mol). The reaction was left to stir in a sealed vial at 100°C for 4 h. the reaction was then purified by HPLC using a linear gradient of 5% to 95% MeCN in 0.1% HCOOH in water over 10 min gradient. Yield: 12 mg (54%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 9.36–9.13 (m, 1H), 8.68 (s, 1H), 7.50–7.40 (m, 2H), 7.38–7.33 (m, 4H), 7.19–7.13 (m, 1H), 7.09 (d, *J* = 6.7 Hz, 1H), 6.92–6.88 (m, 1H), 6.53–6.48 (m, 1H), 4.91–4.81 (m, 1H), 4.73–4.68 (m, 1H), 4.63–4.46 (m, 3H), 4.36–4.26 (m, 1H), 4.11 (d, *J* = 11.5 Hz, 1H), 3.98–3.88 (m, 2H), 3.73–3.25 (m, 32H), 2.87–2.61 (m, 3H), 2.56–2.48 (m, 4H), 2.15–2.04 (m, 2H), 0.96–0.93 ppm (m, 12H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  = 171.79, 171.76, 171.7, 171.5, 171.4, 171.0, 170.90, 170.85, 170.83, 170.78, 169.43, 169.38, 168.95, 168.90, 168.8, 167.8, 150.4, 148.7, 148.6, 147.01, 146.98, 138.5, 138.4, 136.1, 132.7, 131.8, 131.0, 129.6, 128.35, 128.29, 116.91, 116.87, 111.8, 111.7, 110.6, 74.5, 74.11, 74.06, 73.9, 73.8, 71.31, 71.25, 71.2, 71.01, 70.97, 70.9, 70.83, 70.78, 70.7, 70.6, 70.39, 70.37, 70.2, 69.6, 69.5, 58.75, 58.66, 57.2, 57.1, 56.8, 50.9, 49.1, 49.0, 43.4, 42.6, 42.6, 41.1, 36.2, 36.1, 35.1, 35.0, 31.6, 26.5, 22.9, 17.6, 16.2 LC-MS calc. for C<sub>54</sub>H<sub>76</sub>N<sub>10</sub>O<sub>15</sub>S [M+2H]<sup>2+</sup> is 568.3, found 568.4.

**(2*S*,4*R*)-1-((2*S*)-15-azido-2-(*tert*-butyl)-8-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)methyl)-8-methyl-4-oxo-6,10,13-trioxa-3-azapentadecanoyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (21).**

To a solution of amine **18** (36 mg, 45.5  $\mu$ mol) and DIPEA (50  $\mu$ L, 287  $\mu$ mol) dissolved in NMP (1 mL) was added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (**19**) (15 mg, 54.3  $\mu$ mol). The reaction was left to stir in a sealed vial at 120°C for 4 h. the reaction was then purified by HPLC using a linear gradient of 40% to 95% MeCN in 0.1% HCOOH in water over 8 min gradient. Yield: 13 mg (28%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.67 (s, 1H), 7.50–7.40 (m, 2H), 7.40–7.29 (m, 4H), 7.20–7.11 (m, 1H), 7.08 (d, *J* = 7.2 Hz, 1H), 6.92–6.88 (m, 1H), 6.55–6.46 (m, 1H), 4.93–4.83 (m, 1H), 4.71 (t, *J* = 7.8 Hz, 1H), 4.62–4.47 (m, 3H), 4.36–4.27 (m, 1H), 4.09 (d, *J* = 11.6 Hz, 1H), 3.98–3.82 (m, 2H), 3.75–3.27 (m, 23H), 2.86–2.61 (m, 3H), 2.54–2.46 (m, 4H), 2.19–2.02 (m, 2H), 0.98–0.93 ppm (m, 12H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  = 172.30, 172.28, 172.09, 172.07, 171.5, 171.4, 171.0, 170.85, 170.82, 169.4, 168.95, 168.91, 168.8, 167.8, 150.4, 148.6, 147.0, 146.9, 138.4, 136.1, 132.8, 132.7, 131.8, 131.7, 131.0, 129.6, 128.3, 116.9, 116.8, 111.72, 111.69, 110.5, 74.65, 74.56, 74.54, 74.46, 74.0, 73.93, 73.86, 73.8, 71.31, 71.27, 71.22, 71.17, 71.15, 70.8, 70.6, 70.4, 70.2, 69.67, 69.66, 69.59, 69.55, 58.82, 58.78, 58.76, 57.14, 57.11, 57.0, 56.9, 56.8, 50.9, 49.1, 49.0, 43.3, 42.7, 41.1, 36.2, 35.2, 35.0, 31.6, 26.5, 22.9, 17.5, 16.2; LC-MS calc. for C<sub>50</sub>H<sub>68</sub>N<sub>10</sub>O<sub>13</sub>S [M+2H]<sup>2+</sup> is 524.3, found 524.3.

**(17*S*)-11-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-**

**yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (AB3062) (23).**

Follow General Procedure E, using compound **66** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.0 mg (26%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 9.36–9.09 (m, 1H), 8.76 (s, 1H), 7.50–7.44 (m, 2H), 7.42–7.32 (m, 8H), 7.20–7.13 (m, 1H), 7.09 (d, *J* = 7.0 Hz, 1H), 6.91 (dd, *J* = 5.8, 8.0 Hz, 1H), 6.52 (m, 1H), 4.94–4.80 (m, 1H), 4.73–4.69 (m, 1H), 4.64–4.48 (m, 4H), 4.37–4.26 (m, 3H), 4.11 (d, *J* = 11.7 Hz, 1H), 3.98–3.88 (m, 2H), 3.77–3.70 (m, 4H), 3.68–3.50 (m, 19H), 3.47–3.24 (m, 8H), 2.86–2.66 (m, 5H), 2.54–2.46 (m, 4H), 2.42 (s, 3H), 2.35–2.32 (m, 1H), 2.16 (m, 1H), 2.07 (m, 1H), 1.69 (s, 3H), 0.99–0.94 ppm (m, 12H); HRMS *m/z* calc. for C<sub>73</sub>H<sub>91</sub>ClN<sub>11</sub>O<sub>17</sub>S<sub>2</sub> [M+H]<sup>+</sup> 1492.5719, found: 1492.5336.

**(17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (AB3066) (24).**

Follow General Procedure E, using compound **67** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.6 mg (25%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 9.07–8.90 (m, 1H), 8.67 (s, 1H), 7.50–7.36 (m, 8H), 7.32 (d, *J* = 8.3 Hz, 2H), 7.20–7.16 (m, 1H), 7.09 (d, *J* = 6.9 Hz, 1H), 6.91 (dd, *J* = 2.0, 8.6 Hz, 1H), 6.52–6.49 (m, 1H), 5.09 (dq, *J* = 7.2, 7.2 Hz, 1H), 4.92–4.88 (m, 1H), 4.73 (t, *J* = 7.6 Hz, 1H), 4.60 (dd, *J* = 6.6, 7.4 Hz, 1H), 4.56–4.50 (m, 2H), 4.34–4.26 (m, 2H), 4.12 (d, *J* = 10.9 Hz, 1H), 3.95 (s, 2H), 3.76–3.70 (m, 4H), 3.68–3.54 (m, 19H), 3.47–3.29 (m, 8H), 2.87–2.65 (m, 6H), 2.53–2.47 (m, 4H), 2.41 (s, 3H), 2.12–2.06 (m, 2H), 1.69 (s, 3H), 1.48 (d, *J* = 6.7 Hz, 3H), 1.05 (s, 9H), 0.98–0.95 ppm (m, 3H); HRMS *m/z* calc. for C<sub>74</sub>H<sub>93</sub>ClN<sub>11</sub>O<sub>17</sub>S<sub>2</sub> [M+H]<sup>+</sup> 1506.5875, found: 1506.6135.

**(14S)-8-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (AB3064) (25).**

Follow General Procedure E, using compound **68** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.0 mg (32%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 9.25–8.99 (m, 1H), 8.69 (s, 1H), 7.50–7.43 (m, 2H), 7.40 (d, *J* = 8.1 Hz, 2H), 7.37–7.34 (m, 4H), 7.33 (d, *J* = 8.1 Hz, 2H), 7.19–7.13 (m, 1H), 7.09 (d, *J* = 6.9 Hz, 1H), 6.91 (dd, *J* = 6.0, 8.4 Hz, 1H), 6.55–6.48 (m, 1H), 4.92–4.82 (m, 1H), 4.76–4.71 (m, 1H), 4.63–4.48 (m, 4H), 4.37–4.24 (m, 3H), 4.11 (d, *J* = 10.9 Hz, 1H), 3.98–3.88 (m, 2H), 3.75–3.69 (m, 4H), 3.68–3.51

(m, 15H), 3.47–3.27 (m, 8H), 2.86–2.66 (m, 5H), 2.53–2.46 (m, 4H), 2.41 (s, 3H), 2.36–2.33 (m, 1H), 2.19–2.14 (m, 1H), 2.11–2.05 (m, 1H), 1.69 (s, 3H), 0.97–0.93 ppm (m, 12H); HRMS *m/z* calc. for C<sub>71</sub>H<sub>87</sub>ClN<sub>11</sub>O<sub>16</sub>S<sub>2</sub> [M+H]<sup>+</sup> 1448.5457, found: 1448.5256.

**(17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetate (AB3063) (26).**

Follow General Procedure E, using compound **69** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.6 mg (25%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.68 (s, 1H), 8.58–8.53 (m, 1H), 7.46–7.38 (m, 8H), 7.35 (d, *J* = 2.2 Hz, 8H), 7.32 (d, *J* = 8.8 Hz, 2H), 7.17–7.13 (m, 1H), 7.13–7.10 (m, 1H), 5.28–5.23 (m, 1H), 4.89 (dd, *J* = 5.1, 12.5 Hz, 1H), 4.72 (t, *J* = 7.9 Hz, 1H), 4.62–4.52 (m, 3H), 4.51–4.47 (m, 1H), 4.38–4.25 (m, 3H), 4.09 (d, *J* = 11.7 Hz, 1H), 3.95–3.86 (m, 2H), 3.77–3.72 (m, 4H), 3.70–3.51 (m, 19H), 3.48–3.42 (m, 2H), 3.41–3.27 (m, 6H), 2.86 (d, *J* = 17.2 Hz, 1H), 2.82–2.66 (m, 5H), 2.55–2.48 (m, 4H), 2.41 (s, 3H), 2.20–2.09 (m, 2H), 1.68 (s, 3H), 0.96–0.94 ppm (m, 12H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.7, 171.4, 171.3, 171.0, 170.6, 170.5, 168.44, 168.40, 167.6, 164.0, 155.4, 153.99 (d, *J*<sub>C-F</sub> = 248.5 Hz), 150.5, 150.1, 148.4, 142.89 (d, *J*<sub>C-F</sub> = 13.2 Hz), 138.5, 137.0, 136.7, 132.3, 131.9, 131.1, 131.0, 130.9, 130.6, 130.18 (d, *J*<sub>C-F</sub> = 2.2 Hz), 130.0, 129.59, 129.58, 128.8, 128.3, 118.70 (d, *J*<sub>C-F</sub> = 6.2 Hz), 110.4, 110.30 (d, *J*<sub>C-F</sub> = 21.0 Hz), 106.02–105.96 (m), 74.52, 74.50, 74.48, 73.99, 73.98, 73.9, 73.83, 73.81, 73.79, 71.23, 71.19, 71.1, 70.9, 70.84, 70.81, 70.75, 70.72, 70.6, 70.5, 70.3, 69.21, 69.18, 64.2, 58.8, 58.7, 57.1, 57.05, 57.03, 56.8, 53.9, 49.4, 43.4, 43.1, 41.1, 36.9, 36.3, 35.2, 35.2, 31.6, 26.5, 22.9, 17.6, 16.1, 14.6, 13.3, 11.9; <sup>19</sup>F{<sup>1</sup>H} NMR (471 MHz, CDCl<sub>3</sub>) δ = -127.25\*, -127.28\*, -127.30\*, -127.33\* (1F); HRMS *m/z* calc. for C<sub>73</sub>H<sub>90</sub>ClFN<sub>11</sub>O<sub>17</sub>S<sub>2</sub> [M+H]<sup>+</sup> 1510.5625, found: 1510.5262.

**(17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetate (AB3067) (27).**

Follow General Procedure E, using compound **70** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.4 mg (21%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.68 (s, 1H), 8.64–8.58 (m, 1H), 7.50–7.45 (m, 1H), 7.41–7.35 (m, 7H), 7.32 (d, *J* = 8.6 Hz, 2H), 7.22–7.18 (m, 1H), 7.11 (d, *J*<sub>H-F</sub> = 6.9 Hz, 1H), 5.31–5.25 (m, 1H), 5.08 (dq, *J* = 7.2, 7.2 Hz, 1H), 4.90 (dd, *J* = 5.5, 12.4 Hz, 1H), 4.72 (t, *J* = 7.9 Hz, 1H), 4.60 (dd, *J* = 6.1, 7.9 Hz, 1H), 4.56–4.49 (m, 2H), 4.35–4.25 (m, 2H), 4.09 (d, *J* = 11.0 Hz, 1H), 3.95 (d, *J* = 15.9 Hz, 1H), 3.92 (d, *J* = 16.4 Hz, 1H), 3.77–3.71 (m, 4H), 3.67–3.54 (m, 19H), 3.48–3.30 (m, 8H), 2.90–2.70 (m,

3H), 2.66 (s, 3H), 2.52–2.45 (m, 4H), 2.41 (s, 3H), 2.14–2.07 (m, 2H), 1.68 (s, 3H), 1.49–1.45 (m, 3H), 1.05 (s, 9H), 0.98–0.96 ppm (m, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.7, 171.49, 171.46, 171.38, 171.36, 170.7, 170.0, 168.54, 168.49, 167.6, 167.04, 167.02, 164.0, 162.7, 155.4, 153.97 (d, *J*<sub>C-F</sub> = 248.7 Hz), 150.5, 150.1, 148.5, 143.5, 142.87 (d, *J*<sub>C-F</sub> = 12.5 Hz), 136.9, 136.7, 132.3, 131.8, 131.04, 131.02, 130.8, 130.6, 130.16 (d, *J*<sub>C-F</sub> = 2.1 Hz), 130.04, 130.00, 129.6, 128.8, 126.6, 118.65 (d, *J*<sub>C-F</sub> = 8.3 Hz), 110.28 (d, *J*<sub>C-F</sub> = 22.5 Hz), 105.96 (d, *J*<sub>C-F</sub> = 5.3 Hz), 74.5, 74.0, 73.9, 73.8, 72.7, 71.2, 71.1, 70.9, 70.84, 70.76, 70.7, 70.6, 70.5, 70.2, 69.2, 69.11, 69.09, 69.08, 64.2, 58.64, 58.61, 57.1, 56.8, 53.8, 49.4, 49.0, 43.0, 41.1, 36.9, 35.8, 35.3, 31.6, 26.6, 22.9, 22.4, 17.6, 16.2, 14.5, 13.2, 11.9; <sup>19</sup>F{<sup>1</sup>H} NMR (471 MHz, CDCl<sub>3</sub>) δ = -127.22\*, -127.26\*, -127.26\*, -127.29\* (1F); HRMS *m/z* calc. for C<sub>74</sub>H<sub>92</sub>ClFN<sub>11</sub>O<sub>17</sub>S<sub>2</sub> [M+H]<sup>+</sup> 1524.5781, found: 1524.5365.

**(14S)-8-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-aza-hexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetate (AB3065) (28).**

Follow General Procedure E, using compound **71** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 3.1 mg (27%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.67 (s, 1H), 8.67–8.48 (m, 1H), 7.45–7.38 (m, 4H), 7.37–7.34 (m, 4H), 7.32 (d, *J* = 8.4 Hz, 2H), 7.17–7.07 (m, 2H), 5.27–5.23 (m, 1H), 4.89 (dd, *J* = 4.7, 12.3 Hz, 1H), 4.74 (t, *J* = 8.1 Hz, 1H), 4.62–4.47 (m, 4H), 4.40–4.24 (m, 3H), 4.10 (d, *J* = 12.4 Hz, 1H), 3.94 (d, *J* = 15.1 Hz, 1H), 3.89 (d, *J* = 15.0 Hz, 1H), 3.75 (t, *J* = 5.2 Hz, 2H), 3.71 (t, *J* = 5.0 Hz, 2H), 3.69–3.54 (m, 15H), 3.47–3.30 (m, 8H), 2.88–2.66 (m, 5H), 2.53–2.47 (m, 4H), 2.41 (s, 3H), 2.38–2.34 (m, 1H), 2.22–2.10 (m, 2H), 1.69 (s, 3H), 0.97–0.93 ppm (m, 12H); <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) δ = -127.23–-127.34 (m, 1F); HRMS *m/z* calc. for C<sub>71</sub>H<sub>86</sub>ClFN<sub>11</sub>O<sub>16</sub>S<sub>2</sub> [M+H]<sup>+</sup> 1466.5362, found: 1466.5243.

**(17S)-11-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetate (AB3126) (29).**

Follow General Procedure E, using compound **72** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 15 min from 10% to 95% MeCN in 0.1% HCOOH in water. Yield: 3.1 mg (27%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.68 (s, 1H), 8.66–8.57 (m, 1H), 7.49–7.44 (m, 1H), 7.43–7.39 (m, 3H), 7.36 (s, 4H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.17 (d, *J* = 7.9 Hz, 1H), 7.14–7.10 (m, 1H), 5.28–5.22 (m, 1H), 4.89 (d, *J* = 12.1 Hz, 1H), 4.73 (t, *J* = 7.8 Hz, 1H), 4.63–4.47 (m, 4H), 4.39–4.27 (m, 3H), 4.11–4.08 (m, 1H), 3.98–3.86 (m, 2H), 3.76–3.70 (m, 4H), 3.69–3.51 (m, 15H), 3.47–3.25 (m, 8H), 2.87–2.65 (m, 6H), 2.52–2.46 (m, 4H), 2.41 (s, 3H), 2.21–2.10 (m, 2H), 1.67 (s, 3H), 0.96 (s, 9H), 0.93 ppm (s, 3H); <sup>19</sup>F{<sup>1</sup>H} NMR (471 MHz, CDCl<sub>3</sub>) δ =

-127.35\*, -127.36\*, -127.41\*, -127.41\* (1F); HRMS  $m/z$  calc. for  $C_{71}H_{86}ClFN_{11}O_{16}S_2$   $[M+H]^+$  1466.5362, found: 1466.5441.

**(14S)-8-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)methyl)-14-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (AB3125) (30).**

Follow General Procedure E, using compound **73** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 15 min from 10% to 95% MeCN in 0.1% HCOOH in water. Yield: 3.2 mg (44%);  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  = 8.68 (s, 1H), 8.61–8.52 (m, 1H), 7.50–7.45 (m, 1H), 7.43–7.34 (m, 7H), 7.32 (d,  $J$  = 8.7 Hz, 2H), 7.20–7.16 (m, 1H), 7.14–7.11 (m, 1H), 5.31–5.26 (m, 1H), 4.92–4.87 (m, 1H), 4.73 (t,  $J$  = 8.1 Hz, 1H), 4.62–4.54 (m, 3H), 4.51–4.48 (m, 1H), 4.37–4.29 (m, 2H), 4.28–4.23 (m, 1H), 4.13–4.09 (m, 1H), 3.96–3.86 (m, 2H), 3.74–3.69 (m, 4H), 3.69–3.54 (m, 11H), 3.47–3.27 (m, 8H), 2.88–2.65 (m, 5H), 2.52–2.47 (m, 4H), 2.41 (s, 3H), 2.37–2.33 (m, 1H), 2.22–2.16 (m, 1H), 2.13–2.10 (m, 1H), 1.68 (s, 3H), 0.96 (s, 9H), 0.94–0.91 ppm (m, 3H);  $^{19}F\{^1H\}$  NMR (471 MHz,  $CDCl_3$ )  $\delta$  = -127.34\*, -127.34\*, -127.39\*, -127.40\* (1F); HRMS  $m/z$  calc. for  $C_{69}H_{82}ClFN_{11}O_{15}S_2$   $[M+H]^+$  1422.5100, found: 1422.5332.

**(17S)-11-((2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (AB3029) (31).**

To solution of Boc-protected compound **76** (55 mg, 0.12 mmol) in DCM (2 mL), was added 4N HCl in dioxane (0.62 mL, 2.48 mmol) and the solution was left to stir at r.t. for 16 h. The reaction was then evaporated to dryness to quantitatively yield an amine intermediate as a HCl salt (46 mg, 0.12 mmol). The amine intermediate (3.4 mg, 9.1  $\mu$ mol) was dissolved in DMF (100  $\mu$ L) followed by the addition of DIPEA (5.4  $\mu$ L, 30  $\mu$ mol). This was then added to a solution containing mesylate **75** (5.3 mg, 4.0  $\mu$ mol) in DMF (200  $\mu$ L) and stirred for 16 h at 80°C. The reaction was concentrated in vacuo and purified by HPLC using a linear gradient over 10 min from 5% to 95% MeCN in 0.1% HCOOH in water. Yield: 4.0 mg (68%); Contains a mixture of four diastereomers;  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  = 8.75–8.66 (m, 2H), 7.59 (t,  $J$  = 7.7 Hz, 1H), 7.45–7.39 (m, 4H), 7.36 (s, 4H), 7.32 (d,  $J$  = 8.5 Hz, 2H), 7.18–7.15 (m, 2H), 4.96–4.91 (m, 1H), 4.74–4.70 (m, 1H), 4.62–4.49 (m, 4H), 4.39–4.26 (m, 3H), 4.09 (d,  $J$  = 11.4 Hz, 1H), 3.96 (d,  $J$  = 15.3 Hz, 1H), 3.92 (d,  $J$  = 15.1 Hz, 1H), 3.75–3.72 (m, 2H), 3.69–3.53 (m, 23H), 3.43–3.29 (m, 10H), 2.88–2.66 (m, 11H), 2.54–2.48 (m, 4H), 2.41 (s, 3H), 2.19–2.13 (m, 1H), 2.12–2.06 (m, 1H), 1.69 (s, 3H), 0.98–0.96 ppm (m, 12H); HRMS  $m/z$  calc. for  $C_{77}H_{98}ClN_{12}O_{17}S_2$   $[M+H]^+$  1561.6297, found: 1561.6552.

**(17S)-11-((2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-**



**yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-  
azanonadecyl 2-((*S*)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-  
*a*][1,4]diazepin-6-yl)acetate (AB3030) (32).**

To solution of Boc-protected compound **77** (77 mg, 0.16 mmol) in DCM (1.3 mL), was added 4N HCl in dioxane (0.84 mL, 3.3 mmol) and the solution was left to stir at r.t. for 16 h. The reaction was then evaporated to dryness to quantitatively yield an amine intermediate as a HCl salt (63 mg, 0.16 mmol). The amine intermediate (3.6 mg, 9.1  $\mu$ mol) was dissolved in DMF (100  $\mu$ L) followed by the addition of DIPEA (5.4  $\mu$ L, 30  $\mu$ mol). This was then added to a solution containing mesylate **75** (5.3 mg, 4.0  $\mu$ mol) in DMF (200  $\mu$ L) and stirred for 16 h at 80°C. The reaction was concentrated in vacuo and purified by HPLC using a linear gradient over 10 min from 5% to 95% MeCN in 0.1% HCOOH in water. Yield: 4.1 mg (68%); Contains a mixture of four diastereomers;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 8.68 (s, 1H), 8.28 (d,  $J$  = 31.3 Hz, 1H), 7.49–7.36 (m, 9H), 7.32 (d,  $J$  = 8.6 Hz, 2H), 7.15 (d,  $J$  = 8.0 Hz, 1H), 4.92 (dd,  $J$  = 5.2, 12.2 Hz, 1H), 4.73 (t,  $J$  = 7.7 Hz, 1H), 4.62–4.53 (m, 3H), 4.50 (d,  $J$  = 8.4 Hz, 1H), 4.40–4.26 (m, 3H), 4.08 (d,  $J$  = 11.1 Hz, 1H), 3.98–3.88 (m, 2H), 3.76–3.72 (m, 2H), 3.70–3.53 (m, 23H), 3.44–3.29 (m, 10H), 2.91–2.66 (m, 11H), 2.51 (s, 4H), 2.41 (s, 3H), 2.20–2.12 (m, 2H), 1.68 (s, 3H), 0.98–0.94 ppm (m, 12H);  $^{19}\text{F}$  NMR (471 MHz,  $\text{CDCl}_3$ )  $\delta$  = –110.75––110.81 (m, 1F); HRMS  $m/z$  calc. for  $\text{C}_{77}\text{H}_{97}\text{ClFN}_{12}\text{O}_{17}\text{S}_2$   $[\text{M}+\text{H}]^+$  1579.6203, found: 1579.6465.

**2,5,7,10,13-pentaoxapentadecan-15-ol (35).**

Follow General Procedure F, using triethylene glycol (**33**) and MEMCl. Purified by flash column chromatography (80 g silica column) using a linear gradient from 0% to 20% MeOH in DCM. Yield: 3.15 g (66%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 4.76 (s, 2H), 3.75–3.70 (m, 6H), 3.70–3.65 (m, 6H), 3.63–3.60 (m, 2H), 3.58–3.55 (m, 2H), 3.39 (s, 3H), 2.39 ppm (t,  $J$  = 6.3 Hz, 1H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 95.8, 72.6, 71.9, 70.8, 70.7, 70.6, 67.0, 67.0, 61.9, 59.1.

**2,5,7,10-tetraoxadodecan-12-ol (36).**

Follow General Procedure F, using diethylene glycol (**34**) and MEMCl. Purified by flash column chromatography (24 g silica column) using a linear gradient from 0% to 6% MeOH in DCM. Yield: 615 mg (40%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 4.76 (s, 2H), 3.76–3.70 (m, 6H), 3.70–3.67 (m, 2H), 3.61 (dd,  $J$  = 4.6, 4.6 Hz, 2H), 3.56 (dd,  $J$  = 4.7, 4.7 Hz, 2H), 3.39 (3H, s), 2.31 ppm (dt,  $J$  = 2.3, 6.3 Hz, 1H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 95.8, 72.5, 72.0, 70.6, 67.2, 67.1, 62.0, 59.1.

**2,4,7,10-tetraoxadodecan-12-ol (37).**

Follow General Procedure F, using triethylene glycol (**33**) and MOMBr. Purified by flash column chromatography (80 g silica column) using a linear gradient from 0% to 8% MeOH in DCM. Yield: 2.86 g (74%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 4.66 (s, 2H), 3.75–3.66 (m, 10H), 3.61 (dd,  $J$  = 4.5, 4.5 Hz, 2H), 3.37 (s, 3H), 2.44 ppm (t,  $J$  = 6.3 Hz, 1H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 96.7, 72.6, 70.8, 70.7, 70.6, 66.9, 61.9, 55.4.

**2,5,7,10,13-pentaoxapentadecan-15-yl methanesulfonate (38).**



Follow General Procedure G, using alcohol **35**. Yield: 729 mg (37%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 4.75 (s, 2H), 4.39–4.36 (m, 2H), 3.78–3.75 (m, 2H), 3.73–3.63 (m, 10H), 3.57–3.54 (m, 2H), 3.39 (s, 3H), 3.07 ppm (s, 3H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 95.8, 71.9, 70.8, 70.7, 69.3, 69.2, 67.0, 59.1, 37.9.

**2,5,7,10-tetraoxadodecan-12-yl methanesulfonate (39).**

Follow General Procedure G, using alcohol **36**. Yield: 659 mg (77%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 4.74 (s, 2H), 4.39–4.37 (m, 2H), 3.79–3.76 (m, 2H), 3.75–3.66 (m, 6H), 3.57–3.54 (m, 2H), 3.39 (s, 3H), 3.06 ppm (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 95.8, 71.9, 70.8, 69.22, 69.16, 67.1, 67.0, 59.2, 37.8.

**2,4,7,10-tetraoxadodecan-12-yl methanesulfonate (40).**

Follow General Procedure G, using alcohol **37**. Yield: 1.14 g (81%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 4.65 (s, 2H), 4.39–4.37 (m, 2H), 3.79–3.76 (m, 2H), 3.71–3.63 (m, 8H), 3.37 (s, 3H), 3.07 ppm (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 96.7, 70.9, 70.8, 70.7, 69.3, 69.2, 66.9, 55.4, 37.9.

**3-(allyloxy)-2-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-2-methylpropan-1-ol (41).**

Follow General Procedure A, using 1.0 eq. diol **5**, 1.2 eq. of NaH and 1.0 eq. of 2-(2-(2-azidoethoxy)ethoxy)ethyl methanesulfonate (**6**). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 11 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 315 mg (60%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 5.93–5.84 (m, 1H), 5.26 (qd,  $J$  = 1.7, 17.4 Hz, 1H), 5.16 (qd,  $J$  = 1.4, 10.6 Hz, 1H), 3.97 (td,  $J$  = 1.3, 5.3 Hz, 2H), 3.69–3.59 (m, 11H), 3.56 (s, 2H), 3.51 (d,  $J$  = 9.0 Hz, 1H), 3.44–3.38 (m, 5H), 2.99 (br. s, 1H), 0.88 ppm (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 135.0, 116.7, 76.0, 74.7, 72.6, 71.1, 70.9, 70.8, 70.6, 70.2, 69.2, 50.9, 40.8, 17.7.

**3-(allyloxy)-2-((2-(2-azidoethoxy)ethoxy)methyl)-2-methylpropan-1-ol (42).**

Follow General Procedure A, using 1.0 eq. diol **5**, 1.2 eq. of NaH and 1.0 eq. of 2-(2-azidoethoxy)ethyl methanesulfonate (**7**). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 244 mg (33%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 5.95–5.84 (m, 1H), 5.26 (dd,  $J$  = 1.3, 17.2 Hz, 1H), 5.16 (d,  $J$  = 10.3 Hz, 1H), 3.97 (d,  $J$  = 5.3 Hz, 2H), 3.70–3.59 (m, 6H), 3.57 (s, 2H), 3.53 (d,  $J$  = 9.1 Hz, 1H), 3.47–3.35 (m, 5H), 2.91 (br. s, 1H), 0.88 ppm (s, 3H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 134.9, 116.8, 76.0, 74.9, 72.6, 71.2, 70.6, 70.2, 69.3, 50.9, 40.8, 17.7.

**15-((allyloxy)methyl)-25-azido-15-methyl-2,4,7,10,13,17,20,23-octaoxapentacosane (43).**

Follow General Procedure A, using 1.0 eq of alcohol **41**, 1.5 eq. of NaH and 1.5 eq. of mesylate **40**. Purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 78 mg (50%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 5.92–5.83 (m, 1H), 5.24 (dd,  $J$  = 1.5, 17.3 Hz, 1H), 5.13 (dd,  $J$  = 1.2, 10.5 Hz, 1H), 4.65 (s, 2H), 3.94 (d,  $J$  = 5.4 Hz, 2H), 3.70–3.60 (m, 18H), 3.58–3.53 (m, 4H), 3.40–3.36 (m, 5H), 3.33 (s, 4H), 3.29 (s, 2H), 0.94 ppm (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 135.5, 116.2, 96.7, 74.1, 73.2, 72.4, 71.24, 71.22, 71.0, 70.9, 70.85, 70.82, 70.7, 70.6, 70.2, 67.0, 55.3, 50.9, 41.1, 17.5.

**15-((allyloxy)methyl)-25-azido-15-methyl-2,5,7,10,13,17,20,23-octaoxapentacosane (44).**

Follow General Procedure A, using 1.0 eq of alcohol **40**, 1.5 eq. of NaH and 1.5 eq. of mesylate **39**. Purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 82 mg (53%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 5.92–5.84 (m, 1H), 5.24 (dd,  $J$  = 1.6, 17.2 Hz, 1H), 5.13 (dd,  $J$  = 1.1, 10.4 Hz, 1H), 4.75 (s, 2H), 3.94 (d,  $J$  = 5.3 Hz, 2H), 3.72–3.60 (m, 16H), 3.58–3.54 (m, 6H), 3.40–3.36 (m, 5H), 3.33 (s, 4H), 3.29 (s, 2H), 0.94 ppm (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 135.5, 116.2, 95.8, 74.1, 73.2, 72.4, 72.0, 71.2, 71.0, 70.9, 70.7, 70.65, 70.58, 70.2, 67.2, 67.0, 59.1, 50.9, 41.1, 17.6.

**15-((allyloxy)methyl)-22-azido-15-methyl-2,4,7,10,13,17,20-heptaodocosane (45).**

Follow General Procedure A, using 1.0 eq of alcohol **42**, 1.5 eq. of NaH and 1.5 eq. of mesylate **40**. Purified by reverse phase flash column chromatography (30 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 130 mg (52%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 5.94–5.83 (m, 1H), 5.25 (dd,  $J$  = 1.6, 17.3 Hz, 1H), 5.14 (dd,  $J$  = 1.4, 10.3 Hz, 1H), 3.94 (d,  $J$  = 5.3 Hz, 2H), 3.71–3.53 (m, 18H), 3.40–3.29 (m, 11H), 0.96 ppm (s, 3H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 135.5, 116.2, 96.7, 74.2, 74.1, 73.2, 72.4, 71.3, 71.2, 70.9, 70.8, 70.7, 70.6, 70.2, 67.0, 55.3, 51.0, 41.1, 17.6.

**15-((allyloxy)methyl)-22-azido-15-methyl-2,5,7,10,13,17,20-heptaodocosane (46).**

Follow General Procedure A, using 1.0 eq of alcohol **42**, 1.5 eq. of NaH and 1.5 eq. of mesylate **39**. Purified by reverse phase flash column chromatography (30 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 111 mg (56%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 5.94–5.84 (m, 1H), 5.25 (dd,  $J$  = 1.5, 17.2 Hz, 1H), 5.13 (dd,  $J$  = 1.1, 10.5 Hz, 1H), 3.94 (d,  $J$  = 5.5 Hz, 2H), 3.73–3.55 (m, 18H), 3.40–3.34 (m, 9H), 3.30 (s, 2H), 0.95 ppm (s, 3H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 135.5, 116.2, 95.8, 74.2, 74.1, 73.2, 72.4, 72.0, 71.3, 71.2, 70.7, 70.65, 70.59, 70.2, 67.2, 67.0, 59.1, 51.0, 41.1, 17.6.

**18-((allyloxy)methyl)-18-methyl-2,5,7,10,13,16,20,23,26,29,31,34-dodecaoxapentatriacontane (47).**

Follow General Procedure A, using 1.0 eq of diol **5**, 4 eq. of NaH and 3 eq. of mesylate **38**. Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 11 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 205 mg (55%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 5.93–5.83 (m, 1H), 5.24 (qd,  $J$  = 1.7, 17.2 Hz, 1H), 5.13 (qd,  $J$  = 1.5, 10.4 Hz, 1H), 4.75 (s, 4H), 3.94 (td,  $J$  = 1.5, 5.4 Hz, 2H), 3.74–3.60 (m, 24H), 3.57–3.53 (m, 8H), 3.39 (s, 6H), 3.32 (s, 4H), 3.29 (s, 2H), 0.94 ppm (s, 3H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 135.5, 116.2, 95.8, 74.1, 73.2, 72.4, 72.0, 71.2, 70.84, 70.81, 70.7, 70.6, 67.1, 67.0, 59.1, 41.1, 17.6.

**15-((2-(2-(2-azidoethoxy)ethoxy)methyl)-15-methyl-2,4,7,10,13,17-hexaoxonadecan-19-yl (48).**

Follow General Procedure B, using alkene **43**. Yield: 200 mg (89%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 9.71 (s, 1H), 4.63 (s, 2H), 4.00 (d,  $J$  = 0.8 Hz, 2H), 3.70–3.28 (m, 32H), 0.95 ppm (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 202.2, 96.7, 77.0, 74.7, 73.9, 71.22, 71.20, 70.9, 70.83, 70.81, 70.7, 70.6, 70.2, 67.0, 55.3, 50.9, 41.3, 17.5.

**15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-methyl-2,5,7,10,13,17-hexaoxonadecan-19-al (49).**

Follow General Procedure B, using alkene **44**. Yield: 62 mg (76%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 9.71 (s, 1H), 4.72 (s, 2H), 4.00 (s, 2H), 3.73–3.29 (m, 33H), 0.95 ppm (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): 202.1, 95.8, 77.0, 74.7, 73.90, 73.86, 71.9, 71.2, 70.9, 70.8, 70.7, 70.65, 70.57, 70.2, 67.1, 67.0, 59.1, 50.9, 41.3, 17.5.

**15-((2-(2-(2-azidoethoxy)ethoxy)methyl)-15-methyl-2,4,7,10,13,17-hexaoxonadecan-19-al (50).**

Follow General Procedure B, using alkene **45**. Yield: 62 mg (76%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 9.74 (s, 1H), 4.66 (s, 2H), 4.02 (s, 2H), 3.72–3.30 (m, 29H), 0.99 ppm (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ = 202.1, 96.7, 77.0, 74.7, 74.0, 73.9, 71.25, 71.21, 70.84, 70.81, 70.75, 70.7, 70.6, 70.2, 67.0, 55.3, 51.0, 41.3, 17.5.

**15-((2-(2-(2-azidoethoxy)ethoxy)methyl)-15-methyl-2,5,7,10,13,17-hexaoxonadecan-19-al (51).**

Follow General Procedure B, using alkene **46**. Yield: 97 mg (90%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 9.74 (s, 1H), 4.75 (s, 2H), 4.02 (s, 2H), 3.72–3.31 (m, 29H), 0.98 ppm (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 202.1, 95.8, 74.7, 74.0, 73.9, 72.0, 71.25, 71.22, 70.8, 70.7, 70.6, 70.2, 67.1, 67.0, 59.1, 51.0, 41.3, 17.5.

**18-(2,5,7,10,13,16-hexaoxaheptadecan-17-yl)-18-methyl-2,5,7,10,13,16,20-heptaodocosan-22-al (52).**

Follow General Procedure B, using alkene **47**. Yield: 170 mg (87%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 9.73 (t, *J* = 1.0 Hz, 1H), 4.75 (s, 4H), 4.02 (d, *J* = 1.1 Hz, 2H), 3.73–3.55 (m, 32H), 3.43–3.31 (m, 12H), 0.97 ppm (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 202.1, 95.8, 77.1, 74.7, 73.9, 72.0, 71.2, 70.82, 70.80, 70.7, 70.6, 67.1, 67.0, 59.1, 41.3, 17.5.

**15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-methyl-2,4,7,10,13,17-hexaoxonadecan-19-oic acid (53).**

Follow General Procedure C, using aldehyde **48**. Yield: 199 mg (98%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 4.63 (s, 2H), 4.02 (s, 2H), 3.68–3.52 (m, 22H), 3.43–3.33 (m, 11H), 0.92 ppm (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 172.3, 96.6, 75.2, 74.60, 74.55, 71.3, 71.2, 70.8, 70.7, 70.65, 70.58, 70.42, 70.36, 70.1, 66.9, 55.3, 50.8, 40.8, 17.8.

**15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-methyl-2,5,7,10,13,17-hexaoxonadecan-19-oic acid (54).**

Follow General Procedure C, using aldehyde **49**. Yield: 64 mg (99%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 4.72 (s, 2H), 3.95 (s, 2H), 3.72–3.51 (m, 22H), 3.42–3.23 (m, 11H), 0.90 ppm (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 173.7, 95.7, 75.3, 74.6, 71.9, 71.1, 70.8, 70.6, 70.5, 70.4, 70.3, 70.1, 67.0, 66.91, 66.88, 59.0, 50.8, 40.9, 17.8.

**15-((2-(2-(2-azidoethoxy)ethoxy)methyl)-15-methyl-2,4,7,10,13,17-hexaoxonadecan-19-oic acid (55).**

Follow General Procedure C, using aldehyde **50**. Yield: 88 mg (95%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 4.64 (s, 2H), 4.03 (s, 2H), 3.71–3.50 (m, 18H), 3.43–3.27 (m, 11H), 0.94 ppm (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):

$\delta = 172.3, 96.6, 75.3, 74.8, 74.5, 71.3, 71.2, 70.70, 70.65, 70.6, 70.5, 70.4, 70.1, 68.8, 66.9, 55.3, 50.9, 40.8, 17.8.$

**15-((2-(2-azidoethoxy)ethoxy)methyl)-15-methyl-2,5,7,10,13,17-hexaoxonadecan-19-oic acid (56).**

Follow General Procedure C, using aldehyde **51**. Yield: 62 mg (63%);  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 4.73$  (s, 2H), 4.01 (s, 2H), 3.72–3.51 (m, 18H), 3.42–3.30 (m, 11H), 0.93 ppm (s, 3H);  $^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ ):  $\delta = 173.0, 95.7, 75.5, 74.9, 74.8, 71.9, 71.3, 71.2, 70.5, 70.5, 70.2, 70.1, 69.5, 67.0, 66.9, 59.1, 50.9, 40.8, 17.9.$

**18-(2,5,7,10,13,16-hexaoxaheptadecan-17-yl)-18-methyl-2,5,7,10,13,16,20-heptaodocosan-22-oic acid (57).**

Follow General Procedure C, using aldehyde **52**. Yield: 147 mg (91%);  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 4.75$  (s, 4H), 4.05 (s, 2H), 3.74–3.55 (m, 32H), 3.44 (s, 2H), 3.42 (d,  $J = 9.0$  Hz, 2H), 3.39 (s, 6H), 3.36 (d,  $J = 9.1$  Hz, 2H), 0.95 ppm (s, 3H);  $^{13}\text{C NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta = 171.9, 95.7, 75.2, 74.7, 71.9, 71.3, 70.8, 70.7, 70.6, 70.4, 68.8, 67.0, 66.9, 59.1, 40.7, 18.0.$

**(2S,4R)-1-((21S)-15-((2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21-(tert-butyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (59).**

Follow General Procedure D, using carboxylic acid **53** and VH032-amine (**14**, synthesised through literature procedures<sup>21,22</sup>). Yield: 64 mg (59%); Contains a mixture of two diastereomers;  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.65$  (s, 1H), 7.39 (t,  $J = 6.0$  Hz, 1H), 7.34 (d,  $J = 8.4$  Hz, 2H), 7.31 (d,  $J = 8.5$  Hz, 2H), 7.13 (d,  $J = 8.9$  Hz, 1H), 4.69 (t,  $J = 7.8$  Hz, 1H), 4.62 (s, 2H), 4.56–4.47 (m, 3H), 4.32 (dd,  $J = 5.3, 15.0$  Hz, 1H), 4.01 (d,  $J = 11.1$  Hz, 1H), 3.92 (d,  $J = 15.9$  Hz, 1H), 3.88 (d,  $J = 15.8$  Hz, 1H), 3.68–3.50 (m, 23H), 3.41 (d,  $J = 9.0$  Hz, 1H), 3.38 (d,  $J = 9.6$  Hz, 1H), 3.31 (t,  $J = 18.7$  Hz, 9H), 2.51–2.45 (m, 4H), 2.33 ppm (br. s, 1H), 2.09 (dd,  $J = 7.9, 13.6$  Hz, 1H), 0.95 (s, 3H), 0.93 ppm (s, 9H);  $^{13}\text{C NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta = 171.3, 170.9, 170.4, 150.3, 148.5, 138.3, 131.7, 131.0, 129.5, 128.2, 96.6, 74.6, 73.9, 73.8, 71.1, 71.1, 70.8, 70.71, 70.69, 70.66, 70.6, 70.54, 70.45, 70.1, 66.9, 58.6, 56.9, 56.7, 55.2, 50.8, 43.3, 41.1, 36.1, 35.2, 26.5, 17.5, 16.1$ ; LC-MS  $m/z$  calc. for  $\text{C}_{43}\text{H}_{70}\text{N}_7\text{O}_{13}\text{S}$   $[\text{M}+\text{H}]^+$  924.5, found: 924.8.

**(2S,4R)-1-((21S)-15-((2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21-(tert-butyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (60).**

Follow General Procedure D, using carboxylic acid **53** and Me-VH032-amine (**58**, synthesised through literature procedure<sup>38</sup>). Yield: 89 mg (66%); Contains a mixture of two diastereomers;  $^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.66$  (s, 1H), 7.46 (d,  $J = 7.8$  Hz, 1H), 7.38 (d,  $J = 8.3$  Hz, 2H), 7.34 (d,  $J = 8.2$  Hz, 2H), 7.17 (d,  $J = 8.5$  Hz, 1H), 5.05 (dq,  $J = 7.1, 7.2$  Hz, 1H), 4.71 (t,  $J = 7.7$  Hz, 1H), 4.63 (s, 2H), 4.52 (d,  $J = 8.8$  Hz, 1H), 4.48 (br. s, 1H), 4.03 (d,  $J = 11.9$  Hz, 1H), 3.92 (s, 2H), 3.68–3.51 (m, 23H), 3.43 (d,  $J = 9.0$  Hz, 1H), 3.39 (d,  $J = 8.9$  Hz, 1H), 3.38–3.27 (m, 9H), 2.53–2.45 (m, 4H), 2.35 (br. s, 1H), 2.03 (dd,  $J = 8.3, 13.1$  Hz, 1H), 1.45 (d,  $J = 7.0$  Hz, 3H), 1.04 (s, 9H), 0.97 ppm (s, 3H);  $^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ ):  $\delta = 171.6, 170.6, 169.8,$

150.4, 148.6, 143.3, 131.7, 131.0, 129.7, 126.5, 96.7, 74.7, 73.94, 73.87, 71.2, 71.1, 70.9, 70.8, 70.7, 70.65, 70.60, 70.5, 70.1, 66.9, 58.4, 57.1, 56.6, 55.3, 50.8, 49.0, 41.1, 35.5, 35.1, 26.6, 22.3, 17.6, 16.2; LC-MS m/z calc. for C<sub>44</sub>H<sub>72</sub>N<sub>7</sub>O<sub>13</sub>S [M+H]<sup>+</sup> 938.5, found: 938.8.

**(2*S*,4*R*)-1-((21*S*)-15-((2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21-(*tert*-butyl)-15-methyl-19-oxo-2,5,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (61).**

Follow General Procedure D, using carboxylic acid **54** and VH032-amine (**14**, synthesised through literature procedures<sup>21,22</sup>). Yield: 58 mg (50%); Contains a mixture of two diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.65 (s, 1H), 7.38 (t, *J* = 5.9 Hz, 1H), 7.33 (d, *J* = 8.5 Hz, 2H), 7.32 (d, *J* = 8.6 Hz, 2H), 7.13 (d, *J* = 9.0 Hz, 1H), 4.71–4.67 (m, 3H), 4.55–4.46 (m, 3H), 4.32 (dd, *J* = 5.3, 15.0 Hz, 1H), 4.01 (d, *J* = 11.3 Hz, 1H), 3.90 (s, 2H), 3.68–3.51 (m, 23H), 3.40 (d, *J* = 8.8 Hz, 1H), 3.38 (d, *J* = 9.0 Hz, 1H), 3.32 (d, *J* = 34.6 Hz, 9H), 2.50–2.44 (m, 4H), 2.30 (br. s, 1H), 2.08 (dd, *J* = 7.7, 13.5 Hz, 1H), 0.95 (s, 3H), 0.92 ppm (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  = 171.3, 171.0, 170.4, 150.3, 148.5, 138.3, 131.7, 131.0, 129.5, 128.1, 95.7, 74.6, 73.9, 73.8, 71.8, 71.12, 71.09, 70.8, 70.7, 70.5, 70.4, 70.1, 67.0, 66.9, 59.0, 58.6, 56.9, 56.7, 50.8, 43.3, 41.1, 36.1, 35.2, 26.4, 17.5, 16.1; LC-MS m/z calc. for C<sub>43</sub>H<sub>70</sub>N<sub>7</sub>O<sub>13</sub>S [M+H]<sup>+</sup> 924.5, found: 924.8.

**(2*S*,4*R*)-1-((21*S*)-15-((2-(2-azidoethoxy)ethoxy)methyl)-21-(*tert*-butyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (62).**

Follow General Procedure D, using carboxylic acid **55** and VH032-amine (**14**, synthesised through literature procedures<sup>21,22</sup>). Yield: 51 mg (61%); Contains a mixture of two diastereomers; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.65 (s, 1H), 7.39 (t, *J* = 5.5 Hz, 1H), 7.36–7.28 (m, 4H), 7.15 (d, *J* = 8.6 Hz, 1H), 4.70 (t, *J* = 7.7 Hz, 1H), 4.62 (s, 2H), 4.57–4.46 (m, 3H), 4.32 (dd, *J* = 5.1, 15.1 Hz, 1H), 4.02 (d, *J* = 11.1 Hz, 1H), 3.90 (s, 2H), 3.68–3.47 (m, 19H), 3.42 (d, *J* = 9.3 Hz, 1H), 3.38 (d, *J* = 9.2 Hz, 1H), 3.36–3.26 (m, 9H), 2.50–2.42 (m, 4H), 2.13–2.03 (m, 1H), 0.96 (s, 3H), 0.94 ppm (s, 9H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  = 171.3, 171.0, 170.4, 150.4, 148.5, 138.3, 131.7, 131.0, 129.5, 128.1, 96.6, 74.6, 74.0, 73.9, 73.84, 73.78, 71.15, 71.08, 70.8, 70.69, 70.66, 70.6, 70.5, 70.1, 66.9, 58.7, 56.9, 56.7, 55.2, 50.8, 43.3, 41.1, 36.1, 35.2, 26.5, 17.5, 16.1; LC-MS m/z calc. for C<sub>41</sub>H<sub>64</sub>N<sub>7</sub>O<sub>12</sub>S [M-H]<sup>-</sup> 878.4, found: 878.2.

**(2*S*,4*R*)-1-((21*S*)-15-((2-(2-azidoethoxy)ethoxy)methyl)-21-(*tert*-butyl)-15-methyl-19-oxo-2,5,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (63).**

Follow General Procedure D, using carboxylic acid **56** and VH032-amine (**14**, synthesised through literature procedures<sup>21,22</sup>). Yield: 45 mg (78%); Contains a mixture of two diastereomers; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.66 (s, 1H), 7.40–7.29 (m, 5H), 7.13 (d, *J* = 8.7 Hz, 1H), 4.75–4.66 (m, 3H), 4.58–4.45 (m, 3H), 4.32 (dd, *J* = 5.3, 15.0 Hz, 1H), 4.05 (d, *J* = 10.8 Hz, 1H), 3.92 (s, 2H), 3.71–3.49 (m, 19H), 3.45–3.27 (m, 11H), 2.56–2.45 (m, 4H), 2.14–2.04 ppm (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  = 171.4, 170.9, 170.5, 150.4, 148.6, 138.3, 131.7, 131.0, 129.6, 128.2, 95.7, 74.6, 74.0, 73.93, 73.91, 73.8, 71.9, 71.2, 71.1, 70.8, 70.63, 70.57,



70.5, 70.2, 67.1, 66.9, 59.1, 58.6, 57.0, 56.7, 50.9, 43.3, 41.1, 36.0, 35.1, 26.5, 17.6, 16.1; LC-MS  $m/z$  calc. for  $C_{41}H_{66}N_7O_{12}S$   $[M+H]^+$  880.4, found: 880.7.

**(2*S*,4*R*)-1-((*S*)-24-(*tert*-butyl)-18-(2,5,7,10,13,16-hexaoxaheptadecan-17-yl)-18-methyl-22-oxo-2,5,7,10,13,16,20-heptaoxa-23-azapentacosan-25-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (64).**

Follow General Procedure D, using carboxylic acid **57** and VH032-amine (**14**, synthesised through literature procedures<sup>21, 22</sup>). Yield: 179 mg (73%);  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  = 8.67 (s, 1H), 7.40–7.29 (m, 5H), 7.13 (d,  $J$  = 8.9 Hz, 1H), 4.73–4.67 (m, 5H), 4.58–4.46 (m, 3H), 4.32 (dd,  $J$  = 5.3, 15.0 Hz, 1H), 4.03 (d,  $J$  = 11.3 Hz, 1H), 3.93 (d,  $J$  = 15.4 Hz, 1H), 3.87 (d,  $J$  = 15.5 Hz, 1H), 3.71–3.49 (m, 33H), 3.43–3.26 (m, 12H), 2.55–2.45 (m, 4H), 2.09 (dd,  $J$  = 8.0, 13.2 Hz, 1H), 0.95 (s, 3H), 0.94 ppm (s, 9H);  $^{13}C$  NMR (101 MHz,  $CDCl_3$ ):  $\delta$  = 171.4, 170.9, 170.4, 150.4, 148.5, 138.3, 131.7, 131.0, 129.6, 128.2, 95.7, 74.6, 73.9, 73.8, 71.9, 71.1, 70.8, 70.71, 70.68, 70.6, 70.5, 70.2, 67.0, 66.9, 59.1, 58.6, 57.0, 56.7, 43.3, 41.1, 36.1, 35.2, 26.5, 17.6, 16.1.

**(2*S*,4*R*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (66).**

Follow General Procedure H, using azide **59** and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (**19**). Yield: 6 mg (47%); Contains a mixture of four diastereomers;  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  = 9.34–9.09 (m, 1H), 8.68 (s, 1H), 7.51–7.29 (m, 6H), 7.17–7.12 (m, 1H), 7.09 (d,  $J$  = 7.3 Hz, 1H), 6.91 (dd,  $J$  = 6.5, 8.1 Hz, 1H), 6.53–6.49 (m, 1H), 4.95–4.81 (m, 1H), 4.74–4.69 (m, 1H), 4.64 (s, 2H), 4.62–4.45 (m, 3H), 4.36–4.26 (m, 1H), 4.12 (d,  $J$  = 11.0 Hz, 1H), 3.97–3.89 (m, 2H), 3.78–3.50 (m, 23H), 3.48–3.25 (m, 11H), 2.88–2.64 (m, 3H), 2.56–2.49 (m, 4H), 2.14–2.05 (m, 2H), 0.97–0.93 ppm (m, 12H); LC-MS  $m/z$  calc. for  $C_{56}H_{80}N_7O_{17}S$   $[M+H]^+$  1154.5, found: 1155.1.

**(2*S*,4*R*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-((*S*)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (67).**

Follow General Procedure H, using azide **60** and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (**19**). Yield: 8 mg (43%); Contains a mixture of four diastereomers;  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  = 9.26–9.01 (m, 1H), 8.68 (s, 1H), 7.53–7.44 (m, 2H), 7.42–7.35 (m, 4H), 7.22–7.15 (m, 1H), 7.09 (d,  $J$  = 6.7 Hz, 1H), 6.90 (dd,  $J$  = 2.9, 8.6 Hz, 1H), 6.54–6.48 (m, 1H), 5.08 (dq,  $J$  = 7.1, 7.1 Hz, 1H), 4.94–4.87 (m, 1H), 4.75–4.71 (m, 1H), 4.65 (s, 2H), 4.57–4.47 (m, 2H), 4.13 (d,  $J$  = 11.7 Hz, 1H), 3.99–3.91 (m, 2H), 3.77–3.51 (m, 23H), 3.48–3.28 (m, 11H), 2.89–2.69 (m, 3H), 2.56–2.48 (m, 4H), 2.14–2.04 (m, 2H), 1.47 (d,  $J$  = 6.7 Hz, 3H), 1.05 (s, 9H), 0.98–0.95 ppm (m, 3H);  $^{13}C$  NMR (126 MHz,  $CDCl_3$ ):  $\delta$  = 171.9, 171.7, 171.6, 170.90, 170.88, 170.87, 170.8, 169.9, 169.8, 169.41, 169.40, 168.81, 168.79, 168.78, 167.81, 167.80, 150.4, 148.6, 147.0, 143.4, 136.2, 132.7, 131.8, 131.0, 129.7, 126.6, 116.9, 111.78, 111.76, 110.50, 110.49, 96.7, 74.5, 74.1, 73.9, 73.8, 71.32, 71.26, 71.2, 71.1, 71.01, 70.99, 70.97, 70.9, 70.82, 70.76, 70.73, 70.71, 70.65, 70.53, 70.52,



70.3, 69.59, 69.57, 69.5, 66.9, 58.5, 57.2, 57.1, 56.8, 55.3, 49.07, 49.05, 49.0, 42.5, 41.1, 35.7, 35.6, 35.1, 35.1, 35.0, 31.6, 29.8, 26.6, 22.9, 22.4, 22.3, 17.6, 16.2; LC-MS *m/z* calc. for C<sub>57</sub>H<sub>82</sub>N<sub>7</sub>O<sub>17</sub>S [M+H]<sup>+</sup> 1168.5, found: 1169.2.

**(2*S*,4*R*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,5,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (68).**

Follow General Procedure H, using azide **61** and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (**19**). Yield: 5 mg (32%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 9.33–9.08 (m, 1H), 8.68 (s, 1H), 7.51–7.40 (m, 2H), 7.39–7.33 (m, 4H), 7.18–7.12 (m, 1H), 7.10 (d, *J* = 7.0 Hz, 1H), 6.93–6.88 (m, 1H), 6.54–6.48 (m, 1H), 4.95–4.81 (m, 1H), 4.74–4.70 (m, 3H), 4.64–4.45 (m, 3H), 4.36–4.27 (m, 1H), 4.12 (d, *J* = 10.8 Hz, 1H), 3.98–3.88 (m, 2H), 3.78–3.49 (m, 23H), 3.48–3.26 (m, 11H), 2.86–2.65 (m, 3H), 2.57–2.49 (m, 4H), 2.14–2.05 (m, 2H), 0.97–0.91 ppm (m, 12H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.83, 171.79, 171.5, 171.4, 171.0, 170.9, 170.8, 169.4, 169.4, 168.8, 167.8, 150.4, 148.6, 148.6, 147.0, 146.9, 138.5, 138.40, 138.38, 136.1, 132.7, 131.8, 131.0, 129.59, 129.56, 128.34, 128.28, 116.9, 116.8, 111.8, 111.7, 110.5, 110.5, 95.7, 74.4, 74.0, 73.9, 73.8, 71.9, 71.3, 71.23, 71.15, 71.1, 71.02, 70.96, 70.89, 70.86, 70.81, 70.77, 70.7, 70.59, 70.57, 70.5, 70.39, 70.36, 69.6, 69.5, 67.1, 66.9, 59.1, 58.7, 58.6, 57.1, 57.0, 56.9, 56.8, 49.3, 49.05, 49.00, 48.97, 43.4, 42.6, 42.5, 41.1, 36.2, 36.1, 35.1, 35.0, 31.6, 26.5, 22.9, 17.6, 16.2; LC-MS *m/z* calc. for C<sub>56</sub>H<sub>80</sub>N<sub>7</sub>O<sub>17</sub>S [M+H]<sup>+</sup> 1154.5, found: 1155.2.

**(2*S*,4*R*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (69).**

Follow General Procedure H, using azide **59** and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisindoline-1,3-dione (**65**). Yield: 8 mg (62%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.68 (s, 1H), 8.58 (d, *J* = 14.0 Hz, 1H), 7.43–7.34 (m, 6H), 7.13–7.12 (m, 2H), 5.22–5.20 (m, 1H), 4.90 (dd, *J* = 4.8, 12.0 Hz, 1H), 4.72 (t, *J* = 7.9 Hz, 1H), 4.64 (s, 2H), 4.58 (dd, *J* = 6.6, 14.9 Hz, 1H), 4.54 (br. s, 1H), 4.47 (d, *J* = 8.1 Hz, 1H), 4.34 (dd, *J* = 4.3, 14.7 Hz, 1H), 4.11 (d, *J* = 11.3 Hz, 1H), 3.95–3.87 (m, 2H), 3.75 (t, *J* = 5.0 Hz, 2H), 3.70–3.50 (m, 21H), 3.48–3.42 (m, 2H), 3.42–3.26 (m, 9H), 2.88–2.67 (m, 3H), 2.59–2.51 (m, 4H), 2.16–2.10 (m, 2H), 0.96–0.90 ppm (m, 12H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.53, 171.50, 171.48, 171.40, 171.38, 170.83, 170.82, 170.73, 170.71, 168.49, 168.47, 167.6, 167.05, 167.03, 153.98 (d, *J*<sub>C-F</sub> = 248.6 Hz), 150.4, 148.6, 143.2, 142.87 (d, *J*<sub>C-F</sub> = 12.6 Hz), 138.3, 131.7, 131.0, 130.18, 130.16, 129.61, 129.60, 128.3, 118.72 (d, *J*<sub>C-F</sub> = 7.4 Hz), 110.31 (d, *J*<sub>C-F</sub> = 22.5 Hz), 105.99 (d, *J*<sub>C-F</sub> = 4.8 Hz), 96.7, 74.50, 74.48, 74.4, 73.9, 73.8, 71.2, 71.12, 71.10, 70.9, 70.8, 70.75, 70.71, 70.66, 70.6, 70.5, 70.33, 70.32, 69.2, 69.13, 69.10, 66.9, 58.6, 58.5, 57.11, 57.08, 56.8, 55.3, 49.4, 43.4, 43.1, 41.1, 36.03, 36.00, 34.9, 31.6, 26.5, 22.9, 17.6, 16.2; <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>): δ = –127.33––127.44 (m, 1F); LC-MS *m/z* calc. for C<sub>56</sub>H<sub>79</sub>FN<sub>7</sub>O<sub>17</sub>S [M+H]<sup>+</sup> 1172.5, found: 1173.1.

**(2*S*,4*R*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-((*S*)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (70).**

Follow General Procedure H, using azide (60) and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisindoline-1,3-dione (65). Yield: 9 mg (47%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.67 (s, 1H), 8.62–8.55 (m, 1H), 7.46 (d, *J* = 7.3 Hz, 1H), 7.42–7.39 (m, 3H), 7.36 (d, *J* = 8.3 Hz, 2H), 7.17 (d, *J*<sub>H-F</sub> = 8.7 Hz, 1H), 7.13 (d, *J* = 6.9 Hz, 1H), 5.25–5.20 (m, 1H), 5.08 (dq, *J* = 7.0, 7.1 Hz, 1H), 4.90 (dd, *J* = 5.3, 12.4 Hz, 1H), 4.73 (t, *J* = 7.4 Hz, 1H), 4.65 (s, 2H), 4.53–4.49 (m, 2H), 4.12 (d, *J* = 11.2 Hz, 1H), 3.93 (s, 2H), 3.75 (t, *J* = 4.9 Hz, 2H), 3.70–3.55 (m, 21H), 3.48–3.29 (m, 11H), 2.99 (br. s, 1H), 2.91–2.69 (m, 3H), 2.58–2.53 (m, 4H), 2.16–2.09 (m, 1H), 2.09–2.04 (m, 1H), 1.49–1.45 (m, 3H), 1.05 (s, 9H), 0.97–0.96 ppm (m, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.71, 171.68, 171.3, 170.8, 169.8, 168.50, 168.45, 167.6, 167.04, 167.01, 153.98 (d, *J*<sub>C-F</sub> = 248.7 Hz), 150.4, 148.6, 143.3, 142.86 (d, *J*<sub>C-F</sub> = 12.7 Hz), 131.7, 131.0, 130.19 (d, *J*<sub>C-F</sub> = 1.9 Hz), 129.7, 126.6, 118.73 (d, *J*<sub>C-F</sub> = 8.8 Hz), 110.29 (d, *J*<sub>C-F</sub> = 22.3 Hz), 105.96 (d, *J*<sub>C-F</sub> = 5.2 Hz), 105.97, 96.7, 74.5, 74.0, 73.9, 73.8, 71.2, 71.1, 70.9, 70.78, 70.75, 70.73, 70.66, 70.6, 70.5, 70.3, 69.14, 69.09, 66.9, 58.5, 58.4, 57.2, 57.1, 56.7, 55.3, 49.4, 49.0, 43.1, 41.1, 35.5, 35.0, 31.6, 26.6, 22.9, 22.4, 17.6, 16.2; <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>): δ = –127.34––127.44 (m, 1F); LC-MS *m/z* calc. for C<sub>57</sub>H<sub>81</sub>FN<sub>7</sub>O<sub>17</sub>S [M+H]<sup>+</sup> 1186.5, found: 1187.2.

**(2*S*,4*R*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,5,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (71).**

Follow General Procedure H, using azide 61 and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisindoline-1,3-dione (65). Yield: 9 mg (57%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.68 (s, 1H), 8.65–8.60 (m, 1H), 7.43–7.33 (m, 6H), 7.13–7.11 (m, 2H), 5.24–5.18 (m, 1H), 4.89 (dd, *J* = 4.5, 12.1 Hz, 1H), 4.74–4.71 (m, 3H), 4.58 (dd, *J* = 6.6, 14.8 Hz, 1H), 4.55–4.51 (m, 1H), 4.47 (d, *J* = 8.6 Hz, 1H), 4.34 (dd, *J* = 4.6, 15.5 Hz, 1H), 4.10 (d, *J* = 11.3 Hz, 1H), 3.93 (d, *J* = 17.1 Hz, 1H), 3.89 (d, *J* = 16.5 Hz, 1H), 3.77–3.72 (m, 2H), 3.71–3.50 (m, 21H), 3.48–3.42 (m, 2H), 3.42–3.34 (m, 5H), 3.31–3.26 (m, 4H), 2.90–2.67 (m, 3H), 2.58–2.51 (m, 4H), 2.16–2.10 (m, 2H), 0.96–0.91 ppm (m, 12H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.5, 171.43, 171.41, 170.9, 170.70, 170.69, 168.52, 168.50, 167.05, 167.03, 153.98 (d, *J*<sub>C-F</sub> = 249.2 Hz), 150.4, 148.6, 142.85 (d, *J*<sub>C-F</sub> = 11.6 Hz), 138.35, 138.34, 131.7, 131.0, 130.17 (d, *J*<sub>C-F</sub> = 2.3 Hz), 129.60, 129.59, 128.3, 118.71 (d, *J*<sub>C-F</sub> = 9.3 Hz), 110.29 (d, *J*<sub>C-F</sub> = 22.4 Hz), 105.99 (d, *J*<sub>C-F</sub> = 4.5 Hz), 95.7, 74.5, 73.91, 73.85, 73.8, 71.9, 71.2, 71.1, 70.9, 70.79, 70.78, 70.77, 70.74, 70.73, 70.69, 70.60, 70.59, 70.5, 70.32, 70.31, 69.2, 69.12, 69.08, 67.1, 66.9, 59.1, 58.6, 58.5, 57.10, 57.08, 57.06, 57.0, 56.8, 49.4, 43.4, 43.1, 41.1, 36.0, 35.0, 31.6, 26.5, 22.9, 17.6, 16.2; <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>): δ = –127.32––127.44 (m, 1F); LC-MS *m/z* calc. for C<sub>56</sub>H<sub>79</sub>FN<sub>7</sub>O<sub>17</sub>S [M+H]<sup>+</sup> 1172.5, found: 1173.1.

**(2*S*,4*R*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (72).**

Follow General Procedure H, using azide **62** and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisindoline-1,3-dione (**65**). Yield: 9 mg (47%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.97–8.92 (m, 1H), 8.67 (s, 1H), 7.47–7.42 (m, 1H), 7.41–7.39 (m, 1H), 7.36–7.31 (m, 4H), 7.15 (d, *J* = 8.7 Hz, 1H), 7.12–7.09 (m, 1H), 5.22–5.19 (m, 1H), 4.91–4.86 (m, 1H), 4.69 (t, *J* = 8.1 Hz, 1H), 4.63 (s, 2H), 4.59–4.48 (m, 3H), 4.35–4.30 (m, 1H), 4.07 (d, *J* = 11.3 Hz, 1H), 3.94–3.85 (m, 2H), 3.71 (t, *J* = 4.8 Hz, 2H), 3.68–3.50 (m, 17H), 3.44 (d, *J* = 5.2 Hz, 1H), 3.42 (d, *J* = 5.6 Hz, 1H), 3.39–3.25 (m, 9H), 2.87–2.66 (m, 3H), 2.50–2.45 (m, 4H), 2.14–2.08 (m, 2H), 0.95 (s, 9H), 0.92–0.92 ppm (m, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.60, 171.56, 171.55, 171.34, 171.31, 171.01, 170.99, 170.98, 170.6, 168.7, 167.58, 167.56, 167.09, 167.06, 153.92 (d, *J*<sub>C-F</sub> = 249.5 Hz), 150.4, 148.6, 142.79 (d, *J*<sub>C-F</sub> = 12.7 Hz), 138.4, 138.4, 131.74, 131.73, 130.96, 130.95, 130.1, 129.5, 129.5, 128.2, 118.65 (d, *J*<sub>C-F</sub> = 8.2 Hz), 110.34 (d, *J*<sub>C-F</sub> = 22.3 Hz), 106.04–105.91 (m), 96.6, 74.52, 74.48, 74.4, 73.8, 73.74, 73.69, 73.67, 71.3, 71.21, 71.16, 71.09, 71.06, 70.89, 70.87, 70.71, 70.68, 70.68, 70.6, 70.52, 70.48, 70.46, 70.3, 69.1, 69.02, 69.00, 66.9, 58.73, 58.71, 58.69, 58.67, 57.02, 57.00, 56.97, 56.8, 55.3, 49.4, 43.3, 43.1, 41.11, 41.09, 41.07, 36.2, 36.2, 36.1, 35.13, 35.11, 35.1, 31.6, 26.5, 22.8, 17.53, 17.51, 17.50, 16.2; <sup>19</sup>F{<sup>1</sup>H} NMR (471 MHz, CDCl<sub>3</sub>): δ = –127.39––127.44 (m, 1F); LC-MS *m/z* calc. for C<sub>54</sub>H<sub>75</sub>FN<sub>7</sub>O<sub>16</sub>S [M+H]<sup>+</sup> 1128.5, found: 1128.4.

**(2*S*,4*R*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,5,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (73).**

Follow General Procedure H, using azide **63** and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisindoline-1,3-dione (**65**). Yield: 6 mg (32%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.87–8.78 (m, 1H), 8.67 (s, 1H), 7.48–7.38 (m, 2H), 7.38–7.32 (m, 4H), 7.17–7.09 (m, 2H), 5.23–5.17 (m, 1H), 4.92–4.87 (m, 1H), 4.73 (s, 2H), 4.70 (t, *J* = 8.0 Hz, 1H), 4.61–4.47 (m, 3H), 4.37–4.31 (m, 1H), 4.10 (d, *J* = 9.8 Hz, 1H), 3.94–3.86 (m, 2H), 3.74–3.50 (m, 19H), 3.48–3.27 (m, 11H), 2.89–2.64 (m, 3H), 2.55–2.46 (m, 4H), 2.16–2.07 (m, 2H), 0.95 (s, 9H), 0.93–0.91 ppm (m, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.53, 171.48, 171.40, 171.39, 171.36, 171.0, 170.95, 170.93, 170.92, 170.7, 168.60, 168.59, 167.59, 167.58, 167.56, 167.56, 167.1, 153.93 (d, *J*<sub>C-F</sub> = 248.2 Hz), 150.4, 148.6, 142.80 (d, *J*<sub>C-F</sub> = 13.1 Hz), 138.39, 138.38, 138.37, 138.36, 131.75, 131.73, 130.99, 130.98, 130.13 (d, *J*<sub>C-F</sub> = 1.8 Hz), 129.57, 129.56, 129.56, 129.5, 128.2, 118.66 (d, *J*<sub>C-F</sub> = 8.9 Hz), 110.34 (d, *J*<sub>C-F</sub> = 23.0 Hz), 106.08–105.98 (m), 95.7, 74.54, 74.49, 74.4, 73.9, 73.8, 73.7, 73.7, 71.9, 71.12, 71.11, 71.09, 70.91, 70.88, 70.57, 70.56, 70.5, 70.4, 70.31, 70.30, 70.28, 69.14, 69.12, 69.11, 69.04, 69.02, 69.01, 67.04, 67.04, 66.9, 59.1, 58.69, 58.67, 58.6, 58.6, 57.08, 57.06, 57.05, 57.0, 56.8, 56.80, 56.79, 56.78, 49.43, 49.42, 43.33, 43.32, 43.31, 43.11, 43.10, 43.09, 41.12, 41.10, 41.08, 35.07, 35.06, 35.04, 35.02, 31.6, 26.5, 22.8, 17.54, 17.52, 17.50, 16.2; <sup>19</sup>F{<sup>1</sup>H} NMR (471 MHz, CDCl<sub>3</sub>): δ = –127.41––127.45 (m, 1F); LC-MS *m/z* calc. for C<sub>54</sub>H<sub>75</sub>FN<sub>7</sub>O<sub>16</sub>S [M+H]<sup>+</sup> 1128.5, found: 1128.4.

**(17S)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-11-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)methyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (74).**

Follow General Procedure E, using 1.0 eq. of (+)-JQ1-acid (**22**) and 1.2 eq. of di-MEM protected compound **64**. Yield: 40 mg (40%); Contains a mixture of two diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.67 (s, 1H), 7.42–7.38 (m, 3H), 7.36 (s, 4H), 7.32 (d, *J* = 8.5 Hz, 2H), 7.19 (d, *J* = 8.6 Hz, 1H), 4.72 (t, *J* = 8.0 Hz, 1H), 4.62–4.50 (m, 4H), 4.40–4.26 (m, 3H), 4.08 (d, *J* = 11.1 Hz, 1H), 3.99 (d, *J* = 15.4 Hz, 1H), 3.92 (d, *J* = 15.4 Hz, 1H), 3.74 (t, *J* = 4.7 Hz, 2H), 3.72–3.53 (m, 23H), 3.46–3.40 (m, 2H), 3.39–3.28 (m, 4H), 2.66 (s, 3H), 2.53–2.46 (m, 4H), 2.41 (s, 3H), 2.16 (dd, *J* = 8.1, 13.3 Hz, 1H), 1.69 (s, 3H), 0.98 (s, 3H), 0.96 ppm (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.7, 171.4, 171.1, 170.6, 164.0, 155.5, 150.4, 150.0, 148.6, 138.4, 136.9, 136.8, 132.4, 131.8, 131.0, 130.9, 130.6, 130.0, 129.6, 128.8, 128.3, 74.4, 74.1, 74.0, 73.8, 73.7, 72.8, 71.2, 71.10, 71.07, 71.0, 70.9, 70.7, 70.5, 70.2, 69.2, 64.2, 61.8, 58.7, 57.0, 56.9, 53.9, 43.4, 41.2, 36.9, 36.3, 35.3, 26.5, 17.7, 16.2, 14.5, 13.2, 11.9; LC-MS *m/z* calc. for C<sub>60</sub>H<sub>83</sub>ClN<sub>8</sub>O<sub>14</sub>S<sub>2</sub> [M+2H]<sup>2+</sup> 619.3, found: 619.7.

**(17S)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-11-((2-(2-(2-((methylsulfonyl)oxy)ethoxy)ethoxy)ethoxy)methyl)-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (75).**

Alcohol **74** (40 mg, 32.3 μmol) was dissolved in DCM (380 μL) before the addition of DIPEA (16.9 μL, 96.9 μmol) and cooling to 0°C. MsCl (2.5 μL, 32.3 μmol) was then added and the reaction was left to stir at 0°C for 20 min before stirring at r.t. for 1 h. LC-MS showed 1:1 ratio of starting material to product, with no change after an additional 1 h of stirring. The flask was cooled to 0°C and additional MsCl (1.3 μL, 16.2 μmol) was added. The flask was left to stir at 0°C for 20 min before stirring at r.t. for 30 min. Careful addition of MsCl is required due to the formation of di-mesyl product. The reaction was concentrated *in vacuo* and the residue purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient from 30% to 100% MeCN in 0.1% HCOOH in water over 11 min to afford compound **75** as a mixture of two diastereomers. Yield: 19 mg (44%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.67 (s, 1H), 7.41–7.36 (m, 3H), 7.35 (s, 4H), 7.32 (d, *J* = 8.6 Hz, 2H), 7.17–7.13 (m, 1H), 4.72 (t, *J* = 7.9 Hz, 1H), 4.62–4.50 (m, 4H), 4.40–4.26 (m, 5H), 4.06 (d, *J* = 11.2 Hz, 1H), 3.95 (d, *J* = 15.2 Hz, 1H), 3.90 (d, *J* = 15.3 Hz, 1H), 3.76–3.71 (m, 4H), 3.70–3.53 (m, 19H), 3.42 (d, *J* = 9.0 Hz, 1H), 3.40 (d, *J* = 9.3 Hz, 1H), 3.37–3.28 (m, 4H), 3.05 (s, 3H), 2.66 (s, 3H), 2.53–2.46 (m, 4H), 2.41 (s, 3H), 2.16 (dd, *J* = 8.6, 13.2 Hz, 1H), 1.68 (s, 3H), 0.99–0.96 (m, 3H), 0.95 ppm (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.6, 171.4, 171.1, 170.4, 164.0, 155.5, 150.4, 150.0, 148.6, 138.4, 137.0, 136.7, 132.3, 131.8, 131.04, 130.99, 130.6, 130.0, 129.6, 128.8, 128.3, 74.6, 74.0, 73.9, 73.8, 71.2, 71.1, 70.93, 70.85, 70.72, 70.69, 70.53, 70.51, 70.2, 69.4, 69.21, 69.16, 64.2, 58.7, 57.0, 56.8, 53.9, 43.3, 41.2, 37.8, 36.9, 36.3, 35.3, 26.5, 17.6, 16.1, 14.5, 13.2, 11.9; LC-MS *m/z* calc. for C<sub>61</sub>H<sub>85</sub>ClN<sub>8</sub>O<sub>16</sub>S<sub>3</sub> [M+2H]<sup>2+</sup> 658.3, found: 658.7.

***tert*-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperazine-1-carboxylate (76).**

2-(2,6-dioxopiperidin-3-yl)-4-fluoroisindoline-1,3-dione (**19**) (50 mg, 18.1  $\mu\text{mol}$ ) and 1-Boc-piperazine (37 mg, 20.0  $\mu\text{mol}$ ) were dissolved in DMSO (1.1 mL). DIPEA (126.7  $\mu\text{L}$ , 72.4  $\mu\text{mol}$ ) was then added and the reaction was stirred and heated to 90°C in a closed microwave vial for 16 h. The mixture was then purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient from 0% to 100% MeCN in 0.1% HCOOH in water over 8 min to afford compound **76** as a yellow/orange solid. Yield: 58 mg (73 %); Analytics were consistent with literature<sup>37</sup>; <sup>1</sup>H NMR (500 MHz, DMSO):  $\delta$  = 11.06 (s, 1H), 7.72 (dd,  $J$  = 7.4, 8.2 Hz, 1H), 7.39 (d,  $J$  = 7.1 Hz, 1H), 7.35 (d,  $J$  = 8.4 Hz, 1H), 5.10 (dd,  $J$  = 5.5, 12.8 Hz, 1H), 3.54–3.49 (m, 4H), 3.27–3.23 (m, 4H), 2.92–2.84 (m, 1H), 2.63–2.51 (m, 2H), 2.05–2.01 (m, 1H), 1.43 ppm (s, 9H); LC-MS  $m/z$  calc. for C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>6</sub> [M-(C(CH<sub>3</sub>)<sub>3</sub>)+H]<sup>+</sup> 386.1, found: 386.9.

***tert*-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)piperazine-1-carboxylate (77).**

2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisindoline-1,3-dione (**65**) (50 mg, 17.0  $\mu\text{mol}$ ) and 1-Boc-piperazine (35 mg, 18.7  $\mu\text{mol}$ ) were dissolved in DMSO (1.1 mL). DIPEA (118.5  $\mu\text{L}$ , 68.0  $\mu\text{mol}$ ) was then added and the reaction was stirred and heated to 90°C in a closed microwave vial for 16 h. The mixture was then purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient from 0% to 100% MeCN in 0.1% HCOOH in water over 8 min to afford compound **77** as a pale-yellow solid. Yield: 72 mg (91 %); Analytics were consistent with literature<sup>44</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.60 (br. s, 1H), 7.47 (d,  $J_{\text{H-F}}$  = 10.8 Hz, 1H), 7.37 (d,  $J_{\text{H-F}}$  = 7.3 Hz, 1H), 4.93 (dd,  $J$  = 5.6, 12.2 Hz, 1H), 3.59 (dd,  $J$  = 4.9, 4.9 Hz, 4H), 3.20 (dd,  $J$  = 4.8, 4.8 Hz, 4H), 2.89–2.67 (m, 3H), 2.13–2.07 (m, 1H), 1.47 ppm (s, 9H); <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>):  $\delta$  = -111.01 (dd,  $J_{\text{F-H}}$  = 7.4, 10.8 Hz, 1F); LC-MS  $m/z$  calc. for C<sub>18</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>6</sub> [M-(C(CH<sub>3</sub>)<sub>3</sub>)+H]<sup>+</sup> 404.1, found: 404.9.

**2-((allyloxy)methyl)-2-(hydroxymethyl)propane-1,3-diol (79).**

Pentaerythritol (**78**) (3.0 g, 22.0 mmol) was dissolved/suspended in DMF (44 mL) and cooled 0°C. 60% NaH in oil (1.32 g, 33.0 mmol) was then added and the reaction was left to stir at 0°C for 15 min. Allyl bromide (2.23 mL, 26.4 mmol) was added dropwise and the reaction was left to stir at r.t. for 16 h. The mixture was then filtered through celite and evaporated to dryness. The residue was purified by flash column chromatography (80 g silica column) using a linear gradient from 0% to 20% MeOH in DCM to afford **79** as a colourless oil. Yield: 1.364 g (35%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 5.93–5.83 (m, 1H), 5.26 (qd,  $J$  = 1.6, 17.2 Hz, 1H), 5.21 (qd,  $J$  = 1.3, 10.4 Hz, 1H), 3.99 (td,  $J$  = 1.4, 5.6 Hz, 2H), 3.74 (d,  $J$  = 5.6 Hz, 6H), 3.50 (s, 2H), 2.38 ppm (t,  $J$  = 5.6 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  = 134.3, 117.6, 72.8, 72.6, 65.2, 45.1.

**2-((allyloxy)methyl)-2-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)propane-1,3-diol (80).**

Follow General Procedure A, using 1.0 eq. triol **79**, 1.2 eq. of NaH and 1.0 eq. of mesylate 2-(2-(2-azidoethoxy)ethoxy)ethyl methanesulfonate (**6**). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 12 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 155 mg (39%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 5.94–5.82 (m, 1H), 5.25 (dd,  $J$  = 1.5, 17.2 Hz, 1H),



5.19 (dd,  $J = 1.2, 10.4$  Hz, 1H), 3.98 (d,  $J = 5.3$  Hz, 2H), 3.70–3.62 (m, 14H), 3.59 (s, 2H), 3.48 (s, 2H), 3.42–3.36 (m, 2H), 2.76 ppm (br. s, 2H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta = 134.5, 117.3, 72.7, 72.3, 70.88, 70.87, 70.7, 70.5, 70.2, 65.1, 50.9, 45.2$ .

**15-((allyloxy)methyl)-15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-2,4,7,10,13,17,20,23,26,28-decaoxanonacosane (81).**

Follow General Procedure A, using 1.0 eq. diol **80**, 4.0 eq. of NaH and 3.0 eq. of MOM mesylate **40**. Purified by reverse phase flash column chromatography (30 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1% HCOOH in water. Yield: 191 mg (62%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 5.93\text{--}5.83$  (m, 1H), 5.24 (dd,  $J = 1.6, 17.3$  Hz, 1H), 5.12 (d,  $J = 10.4$  Hz, 1H), 4.66 (s, 4H), 3.93 (d,  $J = 5.2$  Hz, 2H), 3.72–3.52 (m, 34H), 3.46–3.36 ppm (m, 16H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta = 135.5, 116.1, 96.7, 72.4, 71.2, 71.0, 70.84, 70.78, 70.72, 70.66, 70.6, 70.3, 70.2, 69.4, 67.0, 55.3, 50.9, 45.7$ .

**15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-(2,4,7,10,13-pentaoxatetradecan-14-yl)-2,4,7,10,13,17-hexaoxonadecan-19-al (82).**

Follow General Procedure B, using alkene **81**. Yield: 154 mg (81%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 9.73$  (s, 1H), 4.65 (s, 4H), 4.01 (s, 2H), 3.72–3.53 (m, 36H), 3.48–3.35 ppm (m, 14H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta = 202.4, 96.7, 71.2, 70.9, 70.82, 70.77, 70.72, 70.65, 70.6, 70.2, 70.0, 67.0, 55.3, 50.9, 45.8$ .

**15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-(2,4,7,10,13-pentaoxatetradecan-14-yl)-2,4,7,10,13,17-hexaoxonadecan-19-oic acid (83).**

Follow General Procedure C, using aldehyde **82**. Yield: 155 mg (quant.);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 4.65$  (s, 4H), 3.98 (s, 2H), 3.72–3.54 (m, 36H), 3.49–3.45 (m, 6H), 3.42–3.35 ppm (m, 8H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta = 173.8, 96.5, 72.3, 71.2, 71.1, 71.0, 70.9, 70.63, 70.60, 70.5, 70.41, 70.37, 70.3, 70.1, 70.0, 66.7, 55.2, 50.7, 45.1$ .

**(2S,4R)-1-((S)-15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21-(tert-butyl)-19-oxo-15-(2,4,7,10,13-pentaoxatetradecan-14-yl)-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (84).**

Follow General Procedure D, using carboxylic acid **83** and VH032-amine (**14**, synthesised through literature procedures<sup>21, 22</sup>). Yield: 51 mg (64%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.65$  (s, 1H), 7.41–7.28 (m, 5H), 7.13 (d,  $J = 8.8$  Hz, 1H), 4.68 (t,  $J = 7.5$  Hz, 1H), 4.62 (s, 4H), 4.58–4.48 (m, 3H), 4.32 (dd,  $J = 5.2, 15.0$  Hz, 1H), 4.00 (d,  $J = 11.1$  Hz, 1H), 3.93 (d,  $J = 15.3$  Hz, 1H), 3.88 (d,  $J = 15.0$  Hz, 1H), 3.68–3.45 (m, 37H), 3.42 (s, 6H), 3.38–3.32 (m, 8H), 2.54–2.44 (m, 4H), 2.29 (br. s, 1H), 2.09 (dd,  $J = 8.3, 13.0$  Hz, 1H), 0.93 ppm (s, 9H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta = 171.3, 170.9, 170.3, 150.3, 148.5, 138.3, 131.7, 131.0, 129.5, 128.2, 96.6, 71.2, 71.1, 71.03, 70.98, 70.8, 70.7, 70.6, 70.5, 70.4, 70.09, 70.07, 66.9, 58.6, 56.9, 56.7, 55.2, 50.8, 45.6, 43.3, 36.0, 35.2, 26.5, 16.1$ ; LC-MS  $m/z$  calc. for  $\text{C}_{51}\text{H}_{86}\text{ClN}_7\text{O}_{18}\text{S}$   $[\text{M}+\text{H}]^+$  1116.6, found: 1116.4.

**(2S,4R)-1-((21S)-21-(tert-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-19-oxo-15-(2,4,7,10,13-pentaoxatetradecan-14-yl)-**



**2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (85).**

Follow General Procedure H, using azide **84** and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1,3-dione (**65**). Purified by HPLC using a linear gradient of 5% to 95% MeCN in 0.1% HCOOH in water over 15 min gradient. Yield: 27 mg (55%); Contains a mixture of two diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.68 (s, 1H), 8.66–8.61 (m, 1H), 7.45–7.38 (m, 2H), 7.38–7.32 (m, 4H), 7.14–7.11 (m, 2H), 5.28–5.22 (m, 1H), 4.90 (dd, *J* = 5.2, 12.0 Hz, 1H), 4.71 (t, *J* = 7.4 Hz, 1H), 4.64 (s, 4H), 4.57 (dd, *J* = 6.6, 14.9 Hz, 1H), 4.53 (s, 1H), 4.49 (d, *J* = 8.8 Hz, 1H), 4.35 (dd, *J* = 5.1, 14.7 Hz, 1H), 4.08 (d, *J* = 11.3 Hz, 1H), 3.94 (d, *J* = 15.4 Hz, 1H), 3.88 (d, *J* = 15.3 Hz, 1H), 3.75 (t, *J* = 5.1 Hz, 2H), 3.70–3.35 (m, 49H), 2.90–2.66 (m, 3H), 2.56–2.48 (m, 4H), 2.16–2.10 (m, 2H), 1.81 (br. s, 1H), 0.94 ppm (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.5, 171.42, 171.36, 170.9, 170.6, 168.53, 168.49, 167.5, 167.04, 167.02, 153.96 (d, *J*<sub>C-F</sub> = 248.1 Hz), 150.4, 148.6, 142.84 (d, *J*<sub>C-F</sub> = 12.5 Hz), 138.37, 138.35, 131.7, 131.0, 130.16 (d, *J*<sub>C-F</sub> = 1.8 Hz), 129.60, 129.58, 128.3, 118.68 (d, *J*<sub>C-F</sub> = 8.9 Hz), 110.30 (d, *J*<sub>C-F</sub> = 21.3 Hz), 106.01–105.96 (m), 96.7, 71.13, 71.05, 71.0, 70.7, 70.6, 70.5, 70.4, 70.3, 70.0, 69.2, 69.1, 66.9, 58.6, 58.6, 57.02, 56.99, 56.8, 55.3, 49.4, 45.7, 43.3, 43.1, 43.0, 36.10, 36.06, 35.1, 31.6, 26.5, 22.9, 16.2; <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>): δ = –127.24––127.33 (m, 1F); LC-MS *m/z* calc. for C<sub>64</sub>H<sub>95</sub>FN<sub>7</sub>O<sub>22</sub>S [M+H]<sup>+</sup> 1364.6, found: 1365.0.

**11-(((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)methyl)-11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)methyl)-3,6,9,13,16,19-hexaoxahenicosane-1,21-diyl bis(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetate) (AB3124) (86).**

Follow General Procedure E, using compound **85** and 3.0 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient from 20% to 95% MeCN in 0.1% HCOOH in water over 15 min. Yield: 8.9 mg (22%); Contains a mixture of two diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.68 (s, 1H), 8.60 (s, 1H), 7.49–7.44 (m, 1H), 7.41–7.30 (m, 13H), 7.18 (d, *J* = 8.8 Hz, 1H), 7.10 (d, *J*<sub>H-F</sub> = 7.2 Hz, 1H), 5.35–5.29 (m, 1H), 4.89 (dd, *J* = 5.2, 12.0 Hz, 1H), 4.71 (t, *J* = 8.0 Hz, 1H), 4.60 (t, *J* = 7.0 Hz, 2H), 4.58–4.53 (m, 3H), 4.38 (dd, *J* = 5.4, 14.9 Hz, 1H), 4.35–4.24 (m, 4H), 4.04 (d, *J* = 11.1 Hz, 1H), 3.95 (d, *J* = 15.4 Hz, 1H), 3.90 (d, *J* = 15.2 Hz, 1H), 3.77–3.70 (m, 6H), 3.70–3.41 (m, 40H), 2.88–2.66 (m, 9H), 2.50 (s, 3H), 2.49–2.40 (m, 7H), 2.20 (dd, *J* = 7.8, 13.0 Hz, 1H), 2.14–2.07 (m, 1H), 1.68 (s, 6H), 0.96 ppm (s, 9H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ = 171.7, 171.4, 171.35, 171.28, 171.18, 171.15, 170.2, 168.51, 168.47, 167.5, 167.03, 167.01, 164.0, 162.8, 155.4, 153.94 (d, *J*<sub>C-F</sub> = 248.6 Hz), 150.4, 150.1, 148.5, 142.88 (d, *J*<sub>C-F</sub> = 12.8 Hz), 138.5, 136.9, 136.7, 132.3, 131.8, 131.02, 130.98, 130.9, 130.5, 130.16 (d, *J*<sub>C-F</sub> = 1.8 Hz), 130.0, 129.54, 129.53, 128.8, 128.2, 118.58 (d, *J*<sub>C-F</sub> = 8.9 Hz), 110.27 (d, *J*<sub>C-F</sub> = 21.9 Hz), 105.96 (d, *J*<sub>C-F</sub> = 5.5 Hz), 71.2, 71.1, 70.8, 70.7, 70.6, 70.5, 70.4, 70.2, 70.0, 69.2, 69.14, 69.09, 64.1, 58.9, 56.9, 56.8, 53.8, 49.4, 45.7, 36.9, 36.6, 35.6, 31.6, 26.5, 22.9, 16.2, 14.6, 13.2, 11.9; <sup>19</sup>F{<sup>1</sup>H} NMR (471 MHz, CDCl<sub>3</sub>): δ = –127.22\*, –127.26\* (1F); HRMS *m/z* calc. for C<sub>98</sub>H<sub>117</sub>Cl<sub>2</sub>FN<sub>15</sub>O<sub>22</sub>S<sub>3</sub> [M+H]<sup>+</sup> 2040.7015, found: 2040.6811.

**5,6-difluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (87).**

2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1,3-dione (**65**) (50 mg, 17.0  $\mu\text{mol}$ ) was dissolved in DMF (500  $\mu\text{L}$ ).  $\text{K}_2\text{CO}_3$  (47 mg, 34.0  $\mu\text{mol}$ ) was then added, and the flask was cooled to 0°C under  $\text{N}_2$ . Methyl iodide (29 mg, 20.4  $\mu\text{mol}$ ) was then added, and the reaction was stirred vigorously at r.t. for 5.5 h. The reaction was filtered with PTFE syringe filters before concentrating under vacuum. The residue was purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient over 9 min from 0% to 70% MeCN in 0.1% HCOOH in water to afford **87** as a white solid. Yield: 42 mg (80%);  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 7.69 (dd,  $J_{\text{H-H}} = 7.2$ ,  $J_{\text{H-F}} = 7.2$  Hz, 2H), 4.99–4.94 (m, 1H), 3.18 (s, 3H), 3.05–2.91 (m, 1H), 2.83–2.73 (m, 2H), 2.15–2.06 ppm (m, 1H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 171.0, 168.5, 165.5, 154.76 (dd,  $J_{\text{C-F}} = 15.6$ , 262.3 Hz), 128.71 (dd,  $J_{\text{C-F}} = 5.6$ , 5.6 Hz), 113.78 (dt,  $J_{\text{C-F}} = 10.1$ , 16.5 Hz), 50.6, 31.9, 27.4, 22.0;  $^{19}\text{F}$  NMR (471 MHz,  $\text{CDCl}_3$ ):  $\delta$  = -124.58 (dd,  $J_{\text{F-F}} = 7.3$ ,  $J_{\text{F-H}} = 7.3$ , 2F). LC-MS  $m/z$  calc. for  $\text{C}_{14}\text{H}_{11}\text{F}_2\text{N}_2\text{O}_4$   $[\text{M}+\text{H}]^+$  309.1, found: 309.0.

**(2S,4S)-1-((21S)-15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21-(tert-butyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (89).**

Follow General Procedure D, using carboxylic acid **53** and *cis*-Me-VH032-amine (**88**, synthesised according to literature procedures<sup>38</sup>). Yield: 50 mg (56%); Contains a mixture of two diastereomers;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 8.79 (s, 1H), 7.64 (d,  $J = 7.9$  Hz, 1H), 7.40 (d,  $J = 8.3$  Hz, 2H), 7.37 (d,  $J = 8.3$  Hz, 2H), 7.09 (d,  $J = 9.1$  Hz, 1H), 5.06 (dq,  $J = 7.1$ , 7.1 Hz, 1H), 4.72 (d,  $J = 9.0$  Hz, 1H), 4.62 (s, 2H), 4.53 (d,  $J = 9.2$  Hz, 1H), 4.46–4.42 (m, 1H), 3.97–3.89 (m, 3H), 3.79 (d,  $J = 11.1$  Hz, 1H), 3.68–3.52 (m, 22H), 3.43 (d,  $J = 9.0$  Hz, 1H), 3.39 (d,  $J = 8.9$  Hz, 1H), 3.38–3.29 (m, 9H), 2.54 (s, 3H), 2.31 (d,  $J = 14.0$  Hz, 1H), 2.13 (ddd,  $J = 5.0$ , 9.2, 14.2 Hz, 1H), 1.48 (d,  $J = 6.8$  Hz, 3H), 1.04 (s, 9H), 0.98 ppm (s, 3H);  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 171.9, 171.7, 169.9, 150.7, 147.9, 142.8, 132.0, 130.8, 129.7, 126.6, 96.6, 74.6, 73.9, 73.8, 71.12, 71.09, 71.07, 70.9, 70.8, 70.72, 70.68, 70.6, 70.55, 70.47, 70.1, 66.8, 59.9, 58.7, 56.4, 55.2, 50.7, 49.3, 41.1, 35.3, 34.8, 26.5, 22.0, 17.5, 15.8; LC-MS  $m/z$  calc. for  $\text{C}_{44}\text{H}_{70}\text{N}_7\text{O}_{13}\text{S}$   $[\text{M}-\text{H}]^-$  936.5, found: 936.3.

**(2S,4R)-1-((21S)-21-(tert-butyl)-15-((2-(2-(2-((6-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (90).**

Follow General Procedure H, using azide **60** and thalidomide derivative **87**. Yield: 13 mg (27%); Contains a mixture of four diastereomers;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 8.68 (s, 1H), 7.44 (d,  $J = 7.7$  Hz, 1H), 7.42–7.38 (m, 3H), 7.36 (d,  $J = 8.3$  Hz, 2H), 7.18 (d,  $J = 8.6$  Hz, 1H), 7.08 (d,  $J_{\text{H-F}} = 7.1$  Hz, 1H), 5.31–5.24 (m, 1H), 5.07 (dq,  $J = 7.0$ , 7.1 Hz, 1H), 4.93–4.88 (m, 1H), 4.73 (t,  $J = 7.6$  Hz, 1H), 4.64 (s, 2H), 4.54–4.48 (m, 2H), 4.10 (d,  $J = 11.7$  Hz, 1H), 3.95 (d,  $J = 15.9$  Hz, 1H), 3.92 (d,  $J = 16.2$  Hz, 1H), 3.75 (t,  $J = 5.0$  Hz, 2H), 3.70–3.53 (m, 21H), 3.46–3.38 (m, 4H), 3.38–3.31 (m, 7H), 3.19 (s, 3H), 3.01–2.92 (m, 1H), 2.82–2.70 (m, 2H), 2.56–2.47 (m, 4H), 2.12–2.04 (m, 2H), 1.47 (d,  $J = 6.9$  Hz, 3H), 1.05 (s, 9H), 0.98 ppm (s, 3H);  $^{13}\text{C}$  NMR

(126 MHz, CDCl<sub>3</sub>):  $\delta$  = 171.6, 171.3, 170.7, 169.8, 169.1, 167.7, 167.2, 162.8, 154.0 (d,  $J_{C-F}$  = 249.0 Hz), 150.5, 148.5, 143.3, 142.73 (d,  $J_{C-F}$  = 12.7 Hz), 131.7, 130.9, 130.2, 129.7, 126.6, 118.79 (d,  $J_{C-F}$  = 9.0 Hz), 110.24 (d,  $J_{C-F}$  = 22.7 Hz), 105.81 (d,  $J_{C-F}$  = 5.2 Hz), 96.6, 74.5, 73.9, 71.2, 71.1, 70.9, 70.7, 70.64, 70.57, 70.5, 70.2, 68.9, 66.9, 58.4, 57.1, 56.7, 55.3, 50.2, 49.0, 43.0, 41.1, 35.5, 35.1, 32.1, 27.4, 26.6, 22.4, 22.2, 17.6, 16.2; <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>):  $\delta$  = -127.29--127.35 (m, 1F); LC-MS m/z calc. for C<sub>58</sub>H<sub>83</sub>N<sub>7</sub>O<sub>17</sub>S [M+H]<sup>+</sup> 1200.6, found: 1200.4.

**(2*S*,4*S*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-((*S*)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (91).**

Follow General Procedure H, using azide **89** and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisindoline-1,3-dione (**65**). Yield: 11 mg (34%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.89–8.65 (m, 2H), 7.76–7.69 (m, 1H), 7.44–7.40 (m, 3H), 7.38 (d,  $J$  = 8.3 Hz, 2H), 7.14–7.09 (m, 2H), 5.62–5.57 (m, 1H), 5.26–5.20 (m, 1H), 5.08 (dq,  $J$  = 7.0, 7.1 Hz, 1H), 4.93–4.87 (m, 1H), 4.72 (d,  $J$  = 8.4 Hz, 1H), 4.64 (s, 2H), 4.58–4.53 (m, 1H), 4.49–4.43 (m, 1H), 3.97–3.90 (m, 3H), 3.86–3.81 (m, 1H), 3.77–3.74 (m, 2H), 3.70–3.51 (m, 20H), 3.48–3.25 (m, 11H), 2.91–2.66 (m, 3H), 2.53 (s, 3H), 2.30 (d,  $J$  = 14.3 Hz, 1H), 2.19–2.09 (m, 2H), 1.52–1.47 (m, 3H), 1.06 (s, 9H), 0.97–0.93 ppm (m, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  = 171.99, 171.94, 171.73, 171.71, 171.51, 171.45, 171.4, 170.1, 168.5, 168.4, 167.5, 167.0, 153.98 (d,  $J_{C-F}$  = 248.7 Hz), 150.5, 148.7, 142.85 (d,  $J_{C-F}$  = 12.4 Hz), 142.60, 142.57, 131.6, 131.3, 130.2, 129.8, 126.6, 118.75 (d,  $J_{C-F}$  = 8.6 Hz), 110.30 (d,  $J_{C-F}$  = 22.6 Hz), 105.97–105.91 (m), 96.7, 74.5, 73.9, 71.21, 71.19, 71.1, 71.0, 70.8, 70.74, 70.65, 70.6, 70.5, 69.1, 69.0, 66.9, 60.2, 60.1, 58.8, 56.5, 55.3, 49.4, 49.4, 43.0, 41.1, 35.3, 35.05, 35.01, 31.6, 26.5, 22.9, 22.0, 17.5, 16.2; <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>):  $\delta$  = -127.22--127.38 (m, 1F); LC-MS m/z calc. for C<sub>57</sub>H<sub>81</sub>FN<sub>7</sub>O<sub>17</sub>S [M+H]<sup>+</sup> 1186.5, found: 1186.4.

**(2*S*,4*S*)-1-((21*S*)-21-(*tert*-butyl)-15-((2-(2-(2-((6-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-*N*-((*S*)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (92).**

Follow General Procedure H, using azide **89** and thalidomide derivative **87**. Yield: 9.5 mg (30%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.68 (s, 1H), 7.62 (d,  $J$  = 7.8 Hz, 1H), 7.44–7.39 (m, 3H), 7.37 (d,  $J$  = 8.3 Hz, 2H), 7.12–7.07 (m, 2H), 5.45 (d,  $J$  = 8.9 Hz, 1H), 5.23 (dd,  $J$  = 4.8, 8.4 Hz, 1H), 5.08 (dq,  $J$  = 7.1, 7.2 Hz, 1H), 4.93–4.87 (m, 1H), 4.74 (d,  $J$  = 9.0 Hz, 1H), 4.64 (s, 2H), 4.56 (d,  $J$  = 9.2 Hz, 1H), 4.49–4.44 (m, 1H), 3.98–3.91 (m, 3H), 3.82 (d,  $J$  = 10.8 Hz, 1H), 3.75 (t,  $J$  = 4.9 Hz, 2H), 3.70–3.54 (m, 20H), 3.46–3.39 (m, 4H), 3.38–3.32 (m, 7H), 3.19 (s, 3H), 3.01–2.92 (m, 1H), 2.82–2.70 (m, 2H), 2.53 (s, 3H), 2.34 (d,  $J$  = 14.4 Hz, 1H), 2.17–2.06 (m, 2H), 1.50 (d,  $J$  = 6.8 Hz, 3H), 1.07 (s, 9H), 0.99 ppm (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  = 172.0, 171.7, 171.3, 170.0, 169.1, 167.7, 167.2, 154.01 (d,  $J_{C-F}$  = 248.1 Hz), 150.5, 148.7, 142.71 (d,  $J_{C-F}$  = 12.9 Hz), 142.5, 131.6, 131.3, 130.2, 118.89 (d,  $J_{C-F}$  = 8.9 Hz), 110.29 (d,  $J_{C-F}$  = 22.4 Hz), 105.79 (d,  $J_{C-F}$  = 4.9 Hz), 96.7, 74.6, 73.95, 73.91, 71.22, 71.16, 71.0, 70.8, 70.7, 70.61,

70.55, 68.9, 66.9, 60.0, 58.9, 56.5, 55.3, 50.2, 49.4, 43.0, 41.2, 35.4, 34.9, 32.1, 27.4, 26.5, 22.2, 22.0, 17.6, 16.2;  $^{19}\text{F}$  NMR (471 MHz,  $\text{CDCl}_3$ ):  $\delta = -127.38$ – $-127.42$  (m, 1F); LC-MS  $m/z$  calc. for  $\text{C}_{58}\text{H}_{83}\text{N}_7\text{O}_{17}\text{S}$   $[\text{M}+\text{H}]^+$  1200.6, found: 1200.8.

**(17S)-11-((2-(2-(2-((6-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-(((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetate (*neg*-AB3067) (93).**

Follow General Procedure E, using compound **90** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.2 mg (13%); Contains a mixture of four diastereomers;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.67$  (s, 1H), 7.44 (d,  $J = 7.9$  Hz, 1H), 7.42–7.34 (m, 7H), 7.32 (d,  $J = 8.6$  Hz, 2H), 7.18 (d,  $J = 8.4$  Hz, 1H), 7.08 (d,  $J_{\text{H-F}} = 7.0$  Hz, 1H), 5.30–5.25 (m, 1H), 5.08 (dq,  $J = 7.2, 7.2$  Hz, 1H), 4.90 (dd,  $J = 5.5, 12.5$  Hz, 1H), 4.74 (t,  $J = 7.9$  Hz, 1H), 4.60 (dd,  $J = 6.2, 7.9$  Hz, 1H), 4.55–4.49 (m, 2H), 4.36–4.26 (m, 2H), 4.11 (d,  $J = 11.3$  Hz, 1H), 3.98–3.90 (m, 2H), 3.77–3.73 (m, 4H), 3.68–3.56 (m, 19H), 3.47–3.40 (m, 4H), 3.39–3.31 (m, 4H), 3.19 (s, 3H), 2.98–2.93 (m, 1H), 2.82–2.70 (m, 2H), 2.66 (s, 3H), 2.55–2.48 (m, 4H), 2.41 (s, 3H), 2.12–2.06 (m, 2H), 1.68 (s, 3H), 1.48 (d,  $J = 7.0$  Hz, 3H), 1.06 (s, 9H), 1.00–0.98 ppm (m, 3H);  $^{19}\text{F}\{^1\text{H}\}$  NMR (471 MHz,  $\text{CDCl}_3$ ):  $\delta = -127.31^*$ ,  $-127.31^*$ ,  $-127.34^*$ ,  $-127.34^*$  (1F); HRMS  $m/z$  calc. for  $\text{C}_{75}\text{H}_{94}\text{ClFN}_{11}\text{O}_{17}\text{S}_2$   $[\text{M}+\text{H}]^+$  1538.5938, found: 1538.6122.

**(17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4S)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl 2-(((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetate (*cis*-AB3067) (94).**

Follow General Procedure E, using compound **91** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1% HCOOH in water. Yield: 1.2 mg (8%); Contains a mixture of four diastereomers;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.74$ – $8.55$  (m, 2H), 7.76–7.71 (m, 1H), 7.43–7.36 (m, 7H), 7.32 (d,  $J = 8.6$  Hz, 2H), 7.14–7.09 (m, 2H), 5.60–5.56 (m, 1H), 5.28–5.24 (m, 1H), 5.09 (dq,  $J = 7.1, 7.2$  Hz, 1H), 4.93–4.87 (m, 1H), 4.73 (d,  $J = 9.0$  Hz, 1H), 4.60 (dd,  $J = 6.1, 7.9$  Hz, 1H), 4.56 (t,  $J = 8.0$  Hz, 1H), 4.48–4.43 (m, 1H), 4.33–4.29 (m, 2H), 3.96–3.88 (m, 3H), 3.86–3.82 (m, 1H), 3.77–3.73 (m, 4H), 3.68–3.53 (m, 18H), 3.48–3.29 (m, 8H), 2.90–2.70 (m, 3H), 2.66 (s, 3H), 2.53 (s, 3H), 2.41 (s, 3H), 2.31 (d,  $J = 14.0$  Hz, 1H), 2.18–2.10 (m, 2H), 1.68 (s, 3H), 1.52–1.47 (m, 3H), 1.07 (s, 9H), 0.98–0.94 ppm (m, 3H);  $^{19}\text{F}\{^1\text{H}\}$  NMR (471 MHz,  $\text{CDCl}_3$ ):  $\delta = -127.24^*$ ,  $-127.28^*$ ,  $-127.32^*$ ,  $-127.35^*$  (1F); HRMS  $m/z$  calc. for  $\text{C}_{74}\text{H}_{92}\text{ClFN}_{11}\text{O}_{17}\text{S}_2$   $[\text{M}+\text{H}]^+$  1524.5781, found: 1524.7017.

**(17S)-11-((2-(2-(2-((6-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4S)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-**

**azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)acetate (neg-cis-AB3067) (95).**

Follow General Procedure E, using compound **92** and 1.5 eq of JQ1-acid (**22**). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1% HCOOH in water. Yield: 0.7 mg (9%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.68 (s, 1H), 7.65 (d, *J* = 8.1 Hz, 1H), 7.39 (q, *J* = 9.9 Hz, 7H), 7.32 (d, *J* = 8.7 Hz, 2H), 7.11 (d, *J* = 9.2 Hz, 1H), 7.08 (d, *J*<sub>H-F</sub> = 7.1 Hz, 1H), 5.48 (d, *J* = 9.1 Hz, 1H), 5.29–5.24 (m, 1H), 5.08 (dq, *J* = 7.2, 7.2 Hz, 1H), 4.90 (dd, *J* = 5.2, 12.3 Hz, 1H), 4.75 (d, *J* = 9.0 Hz, 1H), 4.60 (dd, *J* = 6.2, 7.9 Hz, 1H), 4.56 (d, *J* = 9.3 Hz, 1H), 4.48–4.43 (m, 1H), 4.35–4.27 (m, 2H), 3.98–3.92 (m, 3H), 3.82 (d, *J* = 10.9 Hz, 1H), 3.77–3.73 (m, 4H), 3.70–3.56 (m, 19H), 3.47–3.40 (m, 4H), 3.38–3.33 (m, 4H), 3.19 (s, 3H), 3.01–2.93 (m, 1H), 2.82–2.70 (m, 2H), 2.66 (s, 3H), 2.53 (s, 3H), 2.41 (s, 3H), 2.33 (d, *J* = 14.2 Hz, 1H), 2.17–2.07 (m, 2H), 1.68 (s, 3H), 1.50 (d, *J* = 6.9 Hz, 3H), 1.07 (s, 9H), 1.00 ppm (s, 3H); <sup>19</sup>F{<sup>1</sup>H} NMR (471 MHz, CDCl<sub>3</sub>): δ = -127.37\*, -127.37\*, -127.37\*, -127.37\* (1F); HRMS *m/z* calc. for C<sub>75</sub>H<sub>94</sub>ClFN<sub>11</sub>O<sub>17</sub>S<sub>2</sub> [M+H]<sup>+</sup> 1538.5938, found: 1538.6201.

**(17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-11,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16-azanonadecyl (2R)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl)butanoate (AB3145) (97).**

Follow General Procedure E, using compound **70** and 1.5 eq of ET-JQ1-OH (**96**, synthesised through literature procedures<sup>43</sup>). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.2 mg (16%); Contains a mixture of four diastereomers; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.67 (s, 1H), 8.53–8.48 (m, 1H), 7.48 (d, *J* = 7.8 Hz, 1H), 7.42–7.35 (m, 5H), 7.35–7.29 (m, 4H), 7.19 (d, *J* = 9.0 Hz, 1H), 7.12 (d, *J*<sub>H-F</sub> = 7.1 Hz, 1H), 5.31–5.26 (m, 1H), 5.08 (dq, *J* = 7.1, 7.2 Hz, 1H), 4.90 (dd, *J* = 5.3, 12.0 Hz, 1H), 4.73 (dd, *J* = 7.8, 7.8 Hz, 1H), 4.55–4.49 (m, 2H), 4.47–4.41 (m, 1H), 4.37–4.33 (m, 1H), 4.24 (d, *J* = 10.9 Hz, 1H), 4.12 (d, *J* = 11.1 Hz, 1H), 4.01–3.88 (m, 3H), 3.82–3.72 (m, 4H), 3.70–3.53 (m, 17H), 3.48–3.28 (m, 8H), 2.91–2.68 (m, 3H), 2.66 (s, 3H), 2.53–2.47 (m, 4H), 2.41 (s, 3H), 2.17–2.06 (m, 3H), 1.73–1.57 (m, 4H), 1.47 (dd, *J* = 2.4, 6.9 Hz, 3H), 1.06–0.99 (m, 12H), 0.98–0.94 ppm (m, 3H); <sup>19</sup>F{<sup>1</sup>H} NMR (471 MHz, CDCl<sub>3</sub>) δ = -127.23\*, -127.26\*, -127.26\*, -127.30\* (1F); HRMS *m/z* calc. for C<sub>76</sub>H<sub>96</sub>ClFN<sub>11</sub>O<sub>17</sub>S<sub>2</sub> [M+H]<sup>+</sup> 1552.6094, found: 1552.5944.

## Biology.

**CRISPR knock-in cell line generation for HiBiT-BRD2/3/4 in a HEK293 cell line stably expressing an 18 kDa LgBiT protein.** HEK293 HiBiT-BRD2 (LgBiT stable), HEK293 HiBiT-BRD3 (LgBiT stable), and HEK293 HiBiT-BRD4 (LgBiT stable) were created using CRISPR/Cas9 to insert at HiBiT tag at the N-terminal genomic loci of BRD2, BRD3, or BRD4 in a cell line stably expressing LgBiT protein as described previously.<sup>23</sup>



**Live kinetics HiBiT-BET degradation experiments.** For kinetic degradation experiments, HEK293 HiBiT-BRD2, 3, or 4 (LgBiT stable) cells and HEK293 HiBiT-BRD4 (LgBiT) CRBN KO and VHL KO cells were plated at 20,000 cells/well in DMEM +10% FBS in white 96-well tissue culture plates and allowed to adhere overnight. The next day, media was removed and 90  $\mu$ L of pre-warmed CO<sub>2</sub>-independent medium (Gibco) containing Endurazine (Promega) at a 1:100 dilution from stock was added. Plates were incubated at 37°C for 3 h to allow luminescence to equilibrate. A 3-fold dilution series of each PROTAC at 10x the desired final concentration was prepared (with the amount of DMSO in each treatment condition kept constant). After luminescence equilibration, a pre-read luminescence measurement was taken (prior to compound addition) to allow for baseline normalization to account for possible plating differences. Cells were then treated with 10  $\mu$ L of the prepared PROTAC dilution series (in triplicate or quadruplicate). Treated plates were placed in a GloMax Discover luminometer (Promega) pre-warmed to 37°C and luminescence measurements were obtained every 7 minutes for 24 h. Kinetic degradation plots were obtained by first normalizing time course luminescence readings in each well to the pre-read measurement, then to the average value of the DMSO only control at each timepoint. Data was analysed using GraphPad Prism (version 8) and excel. D<sub>max</sub> values were identified as the lowest luminescence reading in each well. Rate constant values were calculated using a one phase exponential decay ( $Y = (Y_0 - Plateau)e^{(\kappa * X)} + Plateau$ ) using Prism ( $Y_0$  constrained to 1). D<sub>max 50</sub> values were calculated by plotting D<sub>max</sub> as a function of concentration, then fitting plots using the following equation:  $Y = \frac{Bottom + (Top - Bottom)}{1 + (\frac{IC_{50}}{X})^{Hill\ slope}}$  to determine IC<sub>50</sub>.

**Generation of VHL and CRBN single and double knock-out RKO cell lines.** RKO WT, VHL KO, CRBN KO and CRBN/VHL dKO cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FCS and 1% penicillin-streptomycin. RKO CRBN KO and VHL KO were generated previously.<sup>45</sup> RKO CRBN/VHL dKO cells were generated by transiently expressing pSpCas9(BB)-2A-GFP (PX458) (Addgene 48138) loaded with a short guide RNA (sgRNA) targeting VHL (Fwd: CACCGGCGATTGCAGAAGATGACCT, Rev: AAACAGGTCATCTTCTGCAATCGCC) in RKO CRBN KO cells. Clones were single cell seeded and checked for VHL and CRBN double deletion via Western blot or PCR on genomic DNA (gDNA).

#### **Cell viability assays.**

Cells were seeded in 96-well plates at a cell density of 3,750 cells per well and treated for 3 days with DMSO or drug at ten 1/10 serial diluted concentrations. Starting concentration for all drugs was 10 $\mu$ M, and each treatment was performed in biological triplicates. Cell viability was assessed using the CellTiter-Glo assay (CellTiter-Glo Luminescent Cell Viability Assay, Promega G7573) according to manufacturer instructions. Luminescence signal was measured on a Multilabel Plate Reader Platform Victor X3 model 2030 (Perkin Elmer). Survival curves and EC<sub>50</sub> values were determined using GraphPad Prism v.10.0.3 by fitting a non-linear regression to the log<sub>10</sub>-transformed drug concentration and the relative viability after normalization of each data point to the mean luminescence of the lowest drug concentration.

#### **Western blot evaluation of heterotrivalent PROTACs 23 – 32 in HEK293 cells.**



**Cell Culture.** HEK293 cells were obtained from ATCC. HEK293 was cultured in DMEM supplemented with 10% (v/v) fetal bovine serum (FBS), 1% L-glutamate and 1% (v/v) penicillin/streptomycin (pen/strep) at 37°C, 5% CO<sub>2</sub>, and 95% humidity.

**Heterotrivalent PROTACs 23 – 32 dose-response degradation assays.** HEK293 cells were plated at a density of  $5 \times 10^5$  cells per well of a six well plate a day prior to initiation of the experiment. Compounds were dissolved to a 10 mM concentrated stock solution in DMSO from which the compounds were further diluted to a working concentration range of 1  $\mu$ M to 100 pM in DMEM and was subsequently added to cells at the initiation of the experiment. An additional vehicle control was added to cells alongside compound treatments. Cells were left to incubate with compound for 6 hours at 37°C, 5% CO<sub>2</sub>, and 95% humidity. Cells were then subsequently washed twice with PBS before being harvested in RIPA buffer supplemented with protease inhibitor cocktail and Benzonase® Nuclease before being store at -20°C.

**Western blotting analysis of heterotrivalent PROTACs 23 – 32 dose-response degradation assay.** Protein concentration was determined using the BCA assay. Samples were then prepared in LDS buffer containing 5% 1M DTT and subsequently loaded onto NuPAGE™ 4-12% Bis-Tris Midi gels, followed by the transfer of the proteins onto nitrocellulose membranes. The membranes were blocked for 1 hour prior to incubation with the primary antibodies using 5% Milk TBST. Membranes were incubated at 4°C in either BRD4(**Ab128874**), BRD3(**Ab50818**), BRD2(**Ab139690**), VHL(**CST#68547**) and CRBN(**CST#71810**) primary antibody overnight. Following overnight incubation, the membranes were incubated with complimentary IRDye® 800CW secondary antibody and a hFAB™ Rhodamine Anti-Tubulin Primary Antibody (loading control) for 1 h and then imaged with a Bio-Rad imager. All western blots were analysed for band intensities using Image Lab (Bio-Rad). The data extracted from these blots were then plotted and analysed using Prism (v. 10.2.2, GraphPad). Linear regression curve fitting was used to calculate pDC50 values. The standard deviation of the pDC50 was calculated for all compounds that had two independent repeats and the standard error of the mean calculated for all compounds that had three independent repeats. All western blotting figures were developed in Adobe illustrator.

**Live cell ternary complex formation assay.** NanoBRET ternary complex assays were performed using Promega kits for CRBN (ND2720) and VHL (ND2700) according to manufacturer's instructions. One day prior to the assay, HEK293 HiBiT-BRD4 (LgBiT Stable) were plated at a density of 800,000 cells/well in a 6-well plate. Cells were allowed to adhere for at least 4 hours. Transfection mixtures containing 100  $\mu$ L Opti-MEM, 6  $\mu$ L FuGENE HD, and either 2ug HaloTag-CRBN or HaloTag-VHL were prepared and allowed to incubate for 10 minutes at room temperature prior to addition to the cells. The next day, cells were trypsinized and resuspended in phenol red-free Opti-MEM Reduced Serum Medium supplemented with 4% FBS. Cells were counted and density was adjusted to 200,000 cells/mL. Cells were divided into two pools: one which received HaloTag NanoBRET 618 Ligand at a final concentration of 100 nM and one which received the same volume of DMSO. Cells were plated on white tissue-culture 96-well plates (100  $\mu$ L/well) and allowed to adhere overnight. The next day, media was aspirated from the cells and replaced with phenol red-free Opti-

MEM Reduced Serum medium supplemented with 4% FBS and a 1:100 dilution of Nano-Glo Vivazine substrate (Promega) and 10  $\mu$ M MG132. Luminescence was allowed to equilibrate at 37°C, 5% CO<sub>2</sub> for 1 hour. During this time, a dilution series of each PROTAC at 10x the desired final concentration was prepared (keeping DMSO constant in all concentrations). 10  $\mu$ L of this dilution series was added to the plate after luminescence equilibration, and kinetic measurements of donor emission at 460 nm and acceptor emission at 618 nm were collected every 3 min using a ClarioStar plate reader. milliBRET ratios were calculated as (Emission at 618 nm/Emission at 460 nm)  $\times$  1000. Donor-contributed background or bleedthrough was corrected for by subtracting milliBRET ratios from no ligand control cells from treated cells. Corrected milliBRET ratios were plotted as a function of time in GraphPad Prism.

**NanoBRET live vs lytic target engagement.** CRBN (N2910, Promega) and VHL (N2930, Promega) NanoBRET target engagement assays were performed according to manufacturer's instructions. Transfection complexes were prepared using 1 mL Opti-MEM, 30  $\mu$ L FuGENE HD, and either 9  $\mu$ g/mL DDB1 Expression Vector and 1  $\mu$ g/mL NanoLuc-CRBN fusion vector, or 9  $\mu$ g/mL Transfection Carrier DNA and 1  $\mu$ g/mL VHL-NanoLuc fusion vector. Transfection complexes were allowed to form for 20 minutes at room temperature, then were added to 20 mL of HEK293 cells at density of 200,000 cells/mL. Transfected HEK293 cells were plated in a T75 flask and allowed to express protein overnight. The next day, 85  $\mu$ L of transfected cells (at 200,000 cells/mL) were replated in white non-binding 96-well plates for live and lytic target engagement measurements. For live mode, a 100x solution of NanoBRET tracer was prepared using 100% DMSO (50  $\mu$ M for CRBN live-cell, 100  $\mu$ M for VHL live-cell). 100x tracer was used to prepare 20 $\times$  tracer using tracer dilution buffer. PROTACs or test compounds were prepared at 10x final concentrations in Opti-MEM. 5  $\mu$ L of the prepared tracer was then dispensed to each well and the plate was mixed on an orbital shaker at 300 RPM for 15 seconds. 10  $\mu$ L of each 10x PROTAC dilution was added to the cells and the plate was mixed again before being incubated at a 37°C, 5% CO<sub>2</sub> incubator for 2 or 5h (as indicated in each figure). After incubation, a 50  $\mu$ L of a 3X substrate solution (containing 30  $\mu$ L NanoBRET Nano-Glo Substrate, 10  $\mu$ L Extracellular NanoLuc inhibitor, and 4,960  $\mu$ L of Opti-MEM) was added to each well. Plates were incubated for 2-3 minutes at room temperature, then donor emission (450 nm) and acceptor emission (at 610 nm) values were read using a GloMax Discover. For lytic mode, the following changes were made. 100x tracer concentration for CRBN was 13  $\mu$ M, 100X tracer concentration for VHL was 25  $\mu$ M, 75  $\mu$ L of a 200,000 cell/mL solution was plated in white non-binding 96-well plates, and 10  $\mu$ L of a 10x digitonin solution was added immediately after the cells were treated with PROTACs. Plates were incubated in darkness for 5 minutes after digitonin addition to allow for permeabilization. 50  $\mu$ L of 3X substrate (30  $\mu$ L NanoBRET Nano-Glo substrate and 4,970  $\mu$ L Opti-MEM) was added to each well and plates were incubated for 1 minute at room temperature before being read on a GloMax Discover as above.

**Generation of CRBN and VHL knock-out in CRISPR'ed knock'ed in HiBiT-BRD2/3/4 HEK293 cells.** HiBiT-BRD4 (LgBiT stable) HEK293 cells (Promega) were used to generate both VHL KO HiBiT-BRD4 (LgBiT stable) and CRBN KO HiBiT-BRD4 (LgBiT stable) cell lines. For VHL, gRNAs targeting exon 1

(TCGAAGTTGAGCCATACGGG) and exon 2 (TCTCTCAATGTTGACGGACA) and for CRBN, gRNAs targeting exon 3 (CTCAAGAAGTCAGTATGGTG) and exon 6 (TATAAGGAATACAGCCAGCG) were purchased from IDT DNA. For each gRNA, tracrRNA:crRNA duplexes were formed by combining 10  $\mu$ L of 100  $\mu$ M Alt-R tracrDNA (IDT), 100  $\mu$ M Alt-R crRNA (IDT) and heating at 95C for 5 minutes, then were allowed to cool to room temp for 20 minutes. RNPs were then formed by combining 75 pmol Cas9 (IDT) with 2.4  $\mu$ L total of prepared tracrRNA:crRNA complex (1.2  $\mu$ L for each gRNA targeting each exon). Cells were then trypsinized and resuspended at 10,000,000 cells/mL in 1 mL of Mirus Ingenio electroporation solution. 3  $\mu$ L of 100  $\mu$ M electroporation enhancer (Mirus) was added, along with 3  $\mu$ L of RNP solution. Cells were electroporated in 2 mm cuvettes using a BioRad system (190V, 950  $\mu$ F, infinite resistance) and were then plated in a T75 flask in full growth medium to allow for recovery. After recovery from electroporation, knock-out pools were sorted for single cells in 96-well tissue culture treated plates. Clonal populations which expanded from single cells were then screened for loss of function of VHL by treating with MZ1, or loss of function of CRBN by treating with dBET6, using a HiBiT-BRD4 luminescent readout assay. Genomic DNA isolated from candidate clones was then PCR-amplified (Table of primers below), Gibson-assembled into a pF1A plasmid backbone, transformed into *E. coli.*, and then Sanger sequenced to confirm presence of indels in the targeted exons. CRBN exon 3 was found to carry a homozygous 5-nucleotide deletion 323bp downstream from the start codon, resulting at a premature stop codon in exon 3. CRBN exon 6 did not have any mutations. VHL exon 1 was found to have a 29bp deletion 270bp downstream from the start codon on one allele, and a 14bp deletion 265bp downstream from the start codon on the other allele. VHL exon 3 carried a 19 bp deletion on one allele, and a 1 bp insertion on the other allele, both occurring after the premature stop codon in exon 1.

CRBN Exon 3 F	TTAGTAAGGAGCGATCGCCCACTGTGCCCGGCTGTA
CRBN Exon 3 R	GCCTGCAGGTCGACT CTCACATTCTTACCCAACCTCTCC
CRBN Exon 6 F	TTAGTAAGGAGCGATCGCCACGTCATGGGATTATCTACAAA
CRBN Exon 6 R	GCCTGCAGGTCGACTAAGGCACTAGAACTGGAAAACT
VHL Exon 1 F	TTAGTAAGGAGCGATCGCAAGAGTACGGCCCTGAAGAAGAC
VHL Exon 1 R	GCCTGCAGGTCGACTCTCAGTTCCCCGTCTGCAAAATG
VHL Exon 2 F	TTAGTAAGGAGCGATCGCGTGGCTCTTTAACAACCTTTGCTT
VHL Exon 2 R	GCCTGCAGGTCGACTCAGGCAAAAATTGAGAACTGGGC

**NanoBRET ubiquitination assays.** NanoBRET ubiquitination experiments were conducted using Promega kit ND2690. HEK293 HiBiT-BRD4 parental, VHL KO, or CRBN KO cells (all stably expressing LgBiT) were plated in 6-well plates at 800,000 cells/well and allowed to adhere for 4-6 h prior to being transfected with 2  $\mu$ g of HaloTag-Ubiquitin Fusion Vector. Cells were allowed to express overnight, then were trypsinized and resuspended in Opti-MEM (reduced serum, no phenol red) 4% FBS at a concentration of 220,000 cells/mL. HaloTag NanoBRET 618 ligand was added at a final concentration of 100 nM to cells (with a portion of cells retained without ligand for use as no-acceptor controls for normalization). 90  $\mu$ L of cells were then

dispensed into each well of a white tissue culture 96-well plate and cells were allowed to adhere overnight. The next day, media was aspirated from cells and replaced with 90  $\mu\text{L}$  of a 1x solution of Opti-MEM 4% FBS containing a 1:100 dilution of Nano-Glo Vivazine substrate. Cells were incubated for 60 minutes at 37°C (5% CO<sub>2</sub>) and a dilution series of each PROTAC were prepared at 10x the desired final concentration (keeping the amount of DMSO in each concentration constant). 10  $\mu\text{L}$  of each 10x PROTAC was added to each well and the plate was immediately placed in a ClarioStar plate reader (pre-warmed to 37°C) where donor emission (460 nm) and acceptor emission (618 nm) was collected every 3 minutes for 4 h. NanoBRET ratios were calculated as described in the ternary complex assay.

**Mass Spectrometry Proteomics. S-Trap processing for quantitative proteomics.** S-Trap™ micro spin column digestion was performed according to the manufacturer's protocol. Briefly, HEK293 cells were treated with DMSO, 250 nM *neg-cis*-AB3067 (**95**) or 250 nM AB3067 (**27**) for 4 h; cells were harvested and washed with PBS and spun. Cell pellets were solubilized in 5% SDS, 50 mM triethylammonium bicarbonate, reduced with 100 mM DTT solution and alkylated with iodoacetamide to a final concentration of 40 mM. Aqueous phosphoric acid was added to a final concentration of 1.2%. Protein particulate was formed by adding S-Trap binding buffer [90% aqueous methanol, 100 mM TEAB (pH 7.1)]. The mixture was placed on S-Trap micro 1.7 ml columns and centrifuged at 4,000 g for 10 s. Columns were washed with 150  $\mu\text{L}$  of S-Trap binding buffer five times and centrifuged at 4,000 g for 10 s. Samples were digested with 2  $\mu\text{g}$  of trypsin (Promega) at 37°C for four h. Peptides were eluted with 40  $\mu\text{L}$  of 50 mM TEAB followed by 40  $\mu\text{L}$  of 0.2% aqueous formic acid, and peptides were finally vacuum dried. TMT15plex labelling of DMSO, 250 nM *neg-cis*-AB3067 (**95**) or 250 nM AB3067 (**27**) conditions were performed, with five biological replicates for each condition and peptide clean-up was performed according to the manufacturer's protocol. After checking the labelling efficiency, samples were combined, desalted, and dried under vacuum. TMT samples were fractionated using offline high-pH reverse-phase chromatography. Peptides were separated, concatenated to 22 fractions, dried, and peptides redissolved in 5% formic acid and analysed by LC-MS.

**Proteomics Quantification and Bioinformatics Analysis.** The raw mass spectrometric data were loaded into MaxQuant. Enzyme specificity was set to that of trypsin/P, allowing for cleavage of N-terminal to proline residues and between aspartic acid and proline residues. Other parameters used were as follows: (i) variable modifications—methionine oxidation, protein N-acetylation; (ii) fixed modifications, cysteine carbamidomethylation; (iii) database: Uniprot;-Human (iv) labels: 15-plex TMT (v) MS/MS tolerance: FTMS- 20ppm, (vi) minimum peptide length, 7; (vii) maximum missed cleavages, 2; and (viii) and (ix) PSM and Protein false discovery rate, 1%. Reporter ion intensities (corrected) results from MaxQuant were imported into excel for bioinformatic analysis. The normalized corrected reporter ion intensities for each label were used to calculate ratios, and all "Contaminant," "Reverse", and "Only identified by site" proteins were removed from the data. Proteins above or below two-fold change [ $\log_2(2) = 1$ ], and a nominal p-value less than 0.03 [ $-\log_{10}(0.03) = 1.5$ ] were considered as differentially expressed proteins. The final volcano plot was produced in GraphPad prism 10 version [10.2.2].

**BromoTag heterotrivalent PROTAC 97 in HEK293 cells. Cell Culture** HEK293 cells were obtained from ATCC. HEK293 was cultured in DMEM supplemented with 10% (v/v) fetal bovine serum (FBS), 1% L-glutamate and 1% (v/v) penicillin/streptomycin (pen/strep) at 37°C, 5% CO<sub>2</sub>, and 95% humidity.

**Development of eGFP-IRES-HiBiT-BromoTag-BRD4 HEK293 cell line.** To perform the single gRNA Cas9 CRISPR KI of BromoTag into BRD4 in HEK293. HEK293 cells were plated at a density of  $5 \times 10^5$  cells into individual wells of a six-well plate in 1 mL of DMEM and left overnight to adhere to the plate. The cells were subsequently transfected the following day using GeneJuice lipofectamine reagent simultaneously with a custom donor vector pMK-RQ containing 500bp BRD4 homology arms on either side of an eGFP-IRES-HiBiT-BromoTag and two individual pBABED vector harbouring U6-sgRNA and puromycin expression cassettes containing two BRD4 targeting gRNA sequences: GTGGGATCACTAGCATGTCTG and GACTAGCATGTCTGCGGAGAG. The construction of these plasmids was performed by Thomas Macartney of the MRC-PPU CRISPR services. The following day cells were washed with PBS before fresh DMEM media was applied cells were left to recover in DMEM for a further 4 days. Cells were subsequently FACS sorted for GFP expression and expanded from single cells. HEK293 clones were validated for eGFP-IRES-HiBiT-BromoTag-BRD4 integration via WB, junction PCR and sequencing.

**Dose-response degradation assay.** Dose-response degradation assay **97** of was performed on the genotype verified eGFP-IRES-HiBiT-BromoTag-BRD4 homozygous HEK293 cell lines. The cells were plated at a density of  $5 \times 10^5$  cells per well of a six well plate a day prior to initiation of the experiment. **97** was dissolved into a 10 mM concentrated stock solution in DMSO from which **97** was further diluted to a working concentration range of 10  $\mu$ M to 10 pM in DMEM and was subsequently added to cells. Additional controls including, vehicle, AGB1 (1  $\mu$ M) and *cis*-AGB1 (1  $\mu$ M) were similarly added to cells alongside **97** treatments. Cells were left to incubate with compound for 4 hours at 37°C, 5% CO<sub>2</sub>, and 95% humidity. Cells were then subsequently washed twice with PBS before being harvested in RIPA buffer supplemented with protease inhibitor cocktail and Benzonase® Nuclease before being store at -20°C.

**Western blotting analysis of dose-response degradation assay.** Total protein quantity was determined using the BCA protein assay. Protein concentration was determined using the BCA assay. Samples were then prepared in LDS buffer and subsequently loaded onto NuPAGE™ 4-12% Bis-Tris Midi gels, followed by the transfer of the proteins onto nitrocellulose membranes. The membranes were blocked for 1 hour prior to incubation with the primary antibodies using 5% Milk TBST. Membranes were incubated at 4°C in either BRD4(**Ab128874**), BRD3(**Ab50818**) or BRD2(**Ab139690**) primary antibody overnight. Following overnight incubation, the membranes were incubated with complimentary IRDye® 800CW secondary antibodies and a hFAB™ Rhodamine Anti-Tubulin Primary Antibody (loading control) for 1 h and then imaged with a Bio-Rad imager. All western blots were analysed for band intensities using Image Lab (Bio-Rad). The data extracted from these blots were then plotted and analysed using Prism (v. 10.2.2, GraphPad). All western blotting figures were developed in Adobe Illustrator.



## ASSOCIATED CONTENT

### Supporting information

The Supporting Information is available free of charge.

- Quantification of EC<sub>50</sub> values 95% CI from cellular proliferation and viability assays in RKO, KBM7 and K562 cells; raw kinetic traces for HiBiT-BET degradation of heteorivalent (**23** – **32**) and heterotetravalent (**86**) PROTACs; quantification of D<sub>max 50</sub> and λ<sub>max</sub> values with 95% CI from live cell HiBiT-BET degradation assay; uncropped western blots for BET, VHL and CRBN degradation by compounds **23** – **32**, **86** and **97** in HEK293 cells; live cell HiBiT-BET degradation for control compounds **93** – **95**; western blots and quantification for BromoTag-BRD4 degradation with **97** and AGB1 in BromoTag-BRD4 HEK294 cells; HPLC and HRMS traces for compounds **1**, **2**, **23** – **32**, **86**, **93** – **95** and **97**.

### Mass spectrometry data

The mass spectrometry raw data and MaxQuant search output tables has been deposited in ProteomeXchange, PRIDE database: <https://www.ebi.ac.uk/pride/archive/>.

## ACKNOWLEDGMENT

We thank Alejandro Correa-Saez, Aishani Garg, Selma Gulyrtlü and Mark Nakasone for discussions and contributions to the project, Alexandra Harris for discussions and resynthesizing compounds required for mass spec proteomics experiments, and Gajanan Sathe for technical support with data analysis of unbiased mass spectrometry proteomics. We also thank the excellent technical support of Dundee's Centre for Targeted Protein Degradation lab managers and senior chemistry and biology technicians. We thank Danette L. Daniels for discussions during the inception of the project. Research reported in this publication was supported by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement no. 875510 (EUbOPEN project). A.G.B. was funded by a PhD studentship from the Medical Research Scotland (MRS) (1170-2017). M.M.O was funded by a PhD fellowship from the Boehringer Ingelheim Fonds. C.C. was funded by a PhD studentship from the UK Medical Research Council (MRC) under the doctoral training programme in Quantitative and Inter-disciplinary approaches to biomedical science (QI Biomed) (MR/N0123735/1). CeMM and the Winter lab are supported by the Austrian Academy of Sciences. The Winter lab is further supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement 851478), as well as by funding from the Austrian Science Fund (FWF, projects P7909, P36746 and P5918723).

### Competing interests

The University of Dundee has filed a PCT patent application PCT/GB2024/051314 on May 24, 2024 covering the chemical structures and their use. A.C., A.G.B., and N. M. are inventors of this patent. A.C. is a scientific founder and shareholder of Amphista Therapeutics, a company that is developing targeted protein degradation



therapeutic platforms. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KaaG, Nurix Therapeutics, Ono Pharmaceutical and Tocris-Biotechne. G.E.W. is scientific founder and shareholder of Proxygen and Solgate. The Winter lab received research funding from Pfizer. C.M.B., E.A.C., M.U. and K.M.R. are or were employees of Promega Corporation. Promega Corporation is the commercial owner by assignment of patents of the HaloTag, NanoLuc, NanoBRET target engagement, and HiBiT technologies and their applications. Other authors declare no competing interests.

## 5.0. References

1. Békés, M.; Langley, D. R.; Crews, C. M., PROTAC targeted protein degraders: the past is prologue. *Nat Rev Drug Discov.* **2022**, *21* (3), 181-200.
2. Cowan, A. D.; Ciulli, A., Driving E3 ligase substrate specificity for targeted protein degradation: lessons from nature and the laboratory. *Annu Rev Biochem.* **2022**, *91*, 295-319.
3. Teng, M.; Gray, N. S., The rise of degrader drugs. *Cell Chem Biol.* **2023**, *30* (8), 864-878.
4. Dale, B.; Cheng, M.; Park, K.-S.; Kaniskan, H. Ü.; Xiong, Y.; Jin, J., Advancing targeted protein degradation for cancer therapy. *Nat Rev. Cancer* **2021**, *21* (10), 638-654.
5. Samarasinghe, K. T. G.; Crews, C. M., Targeted protein degradation: A promise for undruggable proteins. *Cell Chem Biol.* **2021**, *28* (7), 934-951.
6. Ishida, T.; Ciulli, A., E3 ligase ligands for PROTACs: how they were found and how to discover new ones. *SLAS Discov.* **2021**, *26* (4), 484-502.
7. Zoppi, V.; Hughes, S. J.; Maniaci, C.; Testa, A.; Gmaschitz, T.; Wieshofer, C.; Koegl, M.; Ricking, K. M.; Daniels, D. L.; Spallarossa, A.; Ciulli, A., Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7. *J Med Chem.* **2019**, *62* (2), 699-726.
8. Zeng, M.; Xiong, Y.; Safaee, N.; Nowak, R. P.; Donovan, K. A.; Yuan, C. J.; Nabet, B.; Gero, T. W.; Feru, F.; Li, L.; Gondi, S.; Ombelets, L. J.; Quan, C.; Jänne, P. A.; Kostic, M.; Scott, D. A.; Westover, K. D.; Fischer, E. S.; Gray, N. S., Exploring targeted degradation strategy for oncogenic KRASG12C. *Cell Chem Biol.* **2020**, *27* (1), 19-31.e6.
9. Wei, J.; Meng, F.; Park, K.-S.; Yim, H.; Velez, J.; Kumar, P.; Wang, L.; Xie, L.; Chen, H.; Shen, Y.; Teichman, E.; Li, D.; Wang, G. G.; Chen, X.; Kaniskan, H. Ü.; Jin, J., Harnessing the E3 ligase KEAP1 for targeted protein degradation. *J Am Chem Soc.* **2021**, *143* (37), 15073-15083.
10. Salerno, A.; Seghetti, F.; Caciolla, J.; Uliassi, E.; Testi, E.; Guardigni, M.; Roberti, M.; Milelli, A.; Bolognesi, M. L., Enriching proteolysis targeting chimeras with a second modality: when two are better than one. *J Med Chem.* **2022**, *65* (14), 9507-9530.
11. Imaide, S.; Ricking, K. M.; Makukhin, N.; Vetma, V.; Whitworth, C.; Hughes, S. J.; Trainor, N.; Mahan, S. D.; Murphy, N.; Cowan, A. D.; Chan, K.-H.; Craigon, C.; Testa, A.; Maniaci, C.; Urh, M.;

Daniels, D. L.; Ciulli, A., Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. *Nat Chem Biol.* **2021**, *17* (11), 1157-1167.

12. Zheng, M.; Huo, J.; Gu, X.; Wang, Y.; Wu, C.; Zhang, Q.; Wang, W.; Liu, Y.; Liu, Y.; Zhou, X.; Chen, L.; Zhou, Y.; Li, H., Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP. *J Med Chem.* **2021**, *64* (11), 7839-7852.

13. Ottis, P.; Palladino, C.; Thienger, P.; Britschgi, A.; Heichinger, C.; Berrera, M.; Julien-Laferrriere, A.; Roudnicky, F.; Kam-Thong, T.; Bischoff, J. R.; Martoglio, B.; Pettazzoni, P., Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway. *ACS Chem Biol.* **2019**, *14* (10), 2215-2223.

14. Zhang, L.; Riley-Gillis, B.; Vijay, P.; Shen, Y., Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes. *Mol Cancer Ther.* **2019**, *18* (7), 1302-1311.

15. Shirasaki, R.; Matthews, G. M.; Gandolfi, S.; de Matos Simoes, R.; Buckley, D. L.; Raja Vora, J.; Sievers, Q. L.; Brüggenthies, J. B.; Dashevsky, O.; Poarch, H.; Tang, H.; Bariteau, M. A.; Sheffer, M.; Hu, Y.; Downey-Kopyscinski, S. L.; Hengeveld, P. J.; Glassner, B. J.; Dhimolea, E.; Ott, C. J.; Zhang, T.; Kwiatkowski, N. P.; Laubach, J. P.; Schlossman, R. L.; Richardson, P. G.; Culhane, A. C.; Groen, R. W. J.; Fischer, E. S.; Vazquez, F.; Tsherniak, A.; Hahn, W. C.; Levy, J.; Auclair, D.; Licht, J. D.; Keats, J. J.; Boise, L. H.; Ebert, B. L.; Bradner, J. E.; Gray, N. S.; Mitsiades, C. S., Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins. *Cell Rep.* **2021**, *34* (1).

16. Zengerle, M.; Chan, K.-H.; Ciulli, A., Selective small molecule induced degradation of the BET bromodomain protein BRD4. *ACS Chem Biol.* **2015**, *10* (8), 1770-1777.

17. Bradner, J.; Buckley, D.; Winter, G. E. Methods to induce targeted protein degradation through bifunctional molecules. WO/2017/007612, 2017.

18. Girardini, M.; Maniaci, C.; Hughes, S. J.; Testa, A.; Ciulli, A., Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. *Bioorg Med Chem.* **2019**, *27* (12), 2466-2479.

19. Powell, C. E.; Du, G.; Bushman, J. W.; He, Z.; Zhang, T.; Fischer, E. S.; Gray, N. S., Selective degradation-inducing probes for studying cereblon (CRBN) biology. *RSC Med Chem.* **2021**, *12* (8), 1381-1390.

20. Steinebach, C.; Kehm, H.; Lindner, S.; Vu, L. P.; Köpff, S.; López Mármol, Á.; Weiler, C.; Wagner, K. G.; Reichenzeller, M.; Krönke, J.; Gütschow, M., PROTAC-mediated crosstalk between E3 ligases. *Chem Commun.* **2019**, *55* (12), 1821-1824.

21. Galdeano, C.; Gadd, M. S.; Soares, P.; Scaffidi, S.; Van Molle, I.; Birced, I.; Hewitt, S.; Dias, D. M.; Ciulli, A., Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. *J Med Chem.* **2014**, *57* (20), 8657-8663.

22. Steinebach, C.; Voell, S. A.; Vu, L. P.; Bricelj, A.; Sosič, I.; Schnakenburg, G.; Gütschow, M., A facile synthesis of ligands for the von Hippel–Lindau E3 ligase. *Synthesis* **2020**, *52* (17), 2521-2527.
23. Riching, K. M.; Mahan, S.; Corona, C. R.; McDougall, M.; Vasta, J. D.; Robers, M. B.; Urh, M.; Daniels, D. L., Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action. *ACS Chem Biol.* **2018**, *13* (9), 2758-2770.
24. Lopez-Girona, A.; Mendy, D.; Ito, T.; Miller, K.; Gandhi, A. K.; Kang, J.; Karasawa, S.; Carmel, G.; Jackson, P.; Abbasian, M.; Mahmoudi, A.; Cathers, B.; Rychak, E.; Gaidarova, S.; Chen, R.; Schafer, P. H.; Handa, H.; Daniel, T. O.; Evans, J. F.; Chopra, R., Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. *Leukemia* **2012**, *26* (11), 2326-2335.
25. Soares, P.; Gadd, M. S.; Frost, J.; Galdeano, C.; Ellis, L.; Epemolu, O.; Rocha, S.; Read, K. D.; Ciulli, A., Group-based optimization of potent and cell-Active inhibitors of the von Hippel–Lindau (VHL) E3 ubiquitin ligase: structure–activity relationships leading to the chemical probe (2S,4R)-1-((S)-2-(1-cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). *J Med Chem.* **2018**, *61* (2), 599-618.
26. Winter, G. E.; Mayer, A.; Buckley, D. L.; Erb, M. A.; Roderick, J. E.; Vittori, S.; Reyes, J. M.; di Iulio, J.; Souza, A.; Ott, C. J.; Roberts, J. M.; Zeid, R.; Scott, T. G.; Paulk, J.; Lachance, K.; Olson, C. M.; Dastjerdi, S.; Bauer, S.; Lin, C. Y.; Gray, N. S.; Kelliher, M. A.; Churchman, L. S.; Bradner, J. E., BET Bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. *Mol. Cell* **2017**, *67* (1), 5-18.e19.
27. Klein, V. G.; Bond, A. G.; Craigon, C.; Lokey, R. S.; Ciulli, A., Amide-to-ester substitution as a strategy for optimizing PROTAC permeability and cellular activity. *J Med Chem.* **2021**, *64* (24), 18082-18101.
28. Bond, A. G.; Craigon, C.; Chan, K.-H.; Testa, A.; Karapetsas, A.; Fasimoye, R.; Macartney, T.; Blow, J. J.; Alessi, D. R.; Ciulli, A., Development of BromoTag: A “bump-and-hole”–PROTAC system to induce potent, rapid, and selective degradation of tagged target proteins. *J Med Chem.* **2021**, *64* (20), 15477-15502.
29. Hu, J.; Hu, B.; Wang, M.; Xu, F.; Miao, B.; Yang, C.-Y.; Wang, M.; Liu, Z.; Hayes, D. F.; Chinnaswamy, K.; Delproposto, J.; Stuckey, J.; Wang, S., Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER). *J Med Chem.* **2019**, *62* (3), 1420-1442.
30. Buhimschi, A. D.; Armstrong, H. A.; Toure, M.; Jaime-Figueroa, S.; Chen, T. L.; Lehman, A. M.; Woyach, J. A.; Johnson, A. J.; Byrd, J. C.; Crews, C. M., Targeting the C481S Ibrutinib-resistance mutation in Bruton’s Tyrosine Kinase using PROTAC-mediated degradation. *Biochemistry* **2018**, *57* (26), 3564-3575.
31. Nowak, R. P.; DeAngelo, S. L.; Buckley, D.; He, Z.; Donovan, K. A.; An, J.; Safaei, N.; Jedrychowski, M. P.; Ponthier, C. M.; Ishoey, M.; Zhang, T.; Mancias, J. D.; Gray, N. S.; Bradner, J. E.;

- Fischer, E. S., Plasticity in binding confers selectivity in ligand-induced protein degradation. *Nat Chem Biol.* **2018**, *14* (7), 706-714.
32. Petrylak, D. P.; Gao, X.; Vogelzang, N. J.; Garfield, M. H.; Taylor, I.; Dougan Moore, M.; Peck, R. A.; Burris, H. A., First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI). *J Clin Oncol.* **2020**, *38* (15\_suppl), 3500-3500.
33. Lin, X.; Xiang, H.; Luo, G., Targeting estrogen receptor  $\alpha$  for degradation with PROTACs: A promising approach to overcome endocrine resistance. *Eur J Med Chem.* **2020**, *206*, 112689.
34. Burslem, G. M.; Ottis, P.; Jaime-Figueroa, S.; Morgan, A.; Cromm, P. M.; Toure, M.; Crews, C. M., Efficient synthesis of immunomodulatory drug analogues enables exploration of structure–degradation relationships. *ChemMedChem* **2018**, *13* (15), 1508-1512.
35. Degorce, S. L.; Tavana, O.; Banks, E.; Crafter, C.; Gingipalli, L.; Kouvcchinov, D.; Mao, Y.; Pacht, F.; Solanki, A.; Valge-Archer, V.; Yang, B.; Edmondson, S. D., Discovery of proteolysis-targeting chimera molecules that selectively degrade the IRAK3 pseudokinase. *J Med Chem.* **2020**, *63* (18), 10460-10473.
36. Zhou, Z.; Long, J.; Wang, Y.; Li, Y.; Zhang, X.; Tang, L.; Chang, Q.; Chen, Z.; Hu, G.; Hu, S.; Li, Q.; Peng, C.; Chen, X., Targeted degradation of CD147 proteins in melanoma. *Bioorganic Chemistry* **2020**, *105*, 104453.
37. Posternak, G.; Tang, X.; Maisonneuve, P.; Jin, T.; Lavoie, H.; Daou, S.; Orlicky, S.; Goulet de Rugy, T.; Caldwell, L.; Chan, K.; Aman, A.; Prakesch, M.; Poda, G.; Mader, P.; Wong, C.; Maier, S.; Kitaygorodsky, J.; Larsen, B.; Colwill, K.; Yin, Z.; Ceccarelli, D. F.; Batey, R. A.; Taipale, M.; Kurinov, I.; Uehling, D.; Wrana, J.; Durocher, D.; Gingras, A.-C.; Al-Awar, R.; Therrien, M.; Sicheri, F., Functional characterization of a PROTAC directed against BRAF mutant V600E. *Nat Chem Biol.* **2020**, *16* (11), 1170-1178.
38. Raina, K.; Lu, J.; Qian, Y.; Altieri, M.; Gordon, D.; Rossi, A. M. K.; Wang, J.; Chen, X.; Dong, H.; Siu, K.; Winkler, J. D.; Crew, A. P.; Crews, C. M.; Coleman, K. G., PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. *PNAS* **2016**, *113* (26), 7124-7129.
39. Rock, K. L.; Gramm, C.; Rothstein, L.; Clark, K.; Stein, R.; Dick, L.; Hwang, D.; Goldberg, A. L., Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell* **1994**, *78* (5), 761-771.
40. Riching, K. M.; Vasta, J. D.; Hughes, S. J.; Zoppi, V.; Maniaci, C.; Testa, A.; Urh, M.; Ciulli, A.; Daniels, D. L., Translating PROTAC chemical series optimization into functional outcomes underlying BRD7 and BRD9 protein degradation. *Curr Res Chem Biol.* **2021**, *1*, 100009.
41. Nabet, B.; Roberts, J. M.; Buckley, D. L.; Paulk, J.; Dastjerdi, S.; Yang, A.; Leggett, A. L.; Erb, M. A.; Lawlor, M. A.; Souza, A.; Scott, T. G.; Vittori, S.; Perry, J. A.; Qi, J.; Winter, G. E.; Wong, K.-K.; Gray, N. S.; Bradner, J. E., The dTAG system for immediate and target-specific protein degradation. *Nat Chem Biol.* **2018**, *14* (5), 431-441.

42. Ji, A.; Dao, D.; Chen, J.; MacLellan, W. R., EID-2, a novel member of the EID family of p300-binding proteins inhibits transactivation by MyoD. *Gene* **2003**, *318*, 35-43.
43. Bond, A. G.; Testa, A.; Ciulli, A., Stereoselective synthesis of allele-specific BET inhibitors. *Organic & Biomolecular Chemistry* **2020**, *18* (38), 7533-7539.
44. Crew, A. P.; Berlin, M.; Dong, H.; Ishchenko, A.; Cacace, A. M.; Chandler, J. T. Tau-protein targeting compounds and associated methods of use. WO/2021/011913, 2021.
45. Hanzl, A.; Casement, R.; Imrichova, H.; Hughes, S. J.; Barone, E.; Testa, A.; Bauer, S.; Wright, J.; Brand, M.; Ciulli, A.; Winter, G. E., Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders. *Nat Chem Biol.* **2023**, *19* (3), 323-333.

## TABLE OF CONTENT

